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ABSTRACT OF DISSERTATION 
DIETARY SELENIUM SUPPLEMENTATION:  
EFFECTS ON NEURODEGENERATION FOLLOWING TRAUMATIC BRAIN 
AND SPINAL CORD INJURY 
Traumatic brain and spinal cord injury continue to be substantial clinical problems 
with few available treatment strategies. Individuals who are at a greater risk for 
sustaining a central nervous system (CNS) injury, such as professional athletes and 
military personnel, may benefit from a prophylactic supplement that would intervene 
in the neurodegenerative pathways immediately following injury. The high demand 
for selenium within the central nervous system, as well as the synthesis of 
selenoproteins by neurons and astrocytes suggests a critical role of selenium within 
the brain and spinal cord. Studies were designed to test the efficacy of enriched 
dietary selenium status in providing neuroprotective benefits in rodent models of 
spinal cord and traumatic brain injury. Levels of selenium storage within the CNS are 
increased relative to the amount of selenium present in the diet, indicating that 
selenium compounds effectively cross the blood brain barrier.  
In a model of moderate severity spinal cord contusion injury, dietary selenium 
supplementation reduced the number of days until recovery of independent bladder 
function following injury. These benefits did not translate to improvements in 
locomotor function during open field testing or reduction in overall lesion volume in 
the injured animal groups. Examination of gene expression changes 24 hours after 
spinal cord injury revealed that dietary selenium enrichment increased expression of 
genes involved in DNA repair, mitochondrial respiration, and transcriptional 
regulation. By expanding the scope of these studies to include models of traumatic 
brain injury, these data show the importance of selenium in the cortex as well. In 
particular, when compared to diets deficient in selenium, higher levels of dietary 
selenium improve spatial memory performance and mitochondrial respiration. The 
results of this dietary study show modest improvements following both traumatic 
brain and spinal cord injury and suggest that while selenium enrichment may not have 
a profound effect on the secondary injury cascade immediately following injury, the 
presence of adequate dietary selenium is critical for mitochondrial respiration. 
Together the results of these studies suggest that dietary supplementation may play a 
subtle role in injury mechanisms within the CNS and warrant further investigation. 
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CHAPTER 1 
Introduction and Background 
 
1.1 Overview of Selenium 
 
1.1.1 Selenium supplementation 
Selenium in its elemental state is a non-metal element with the same valency as 
sulfur, allowing for it to be incorporated in place of sulfur in certain amino acids. 
Selenium is also an essential nutrient for human health and must be obtained through 
dietary sources. Natural intake occurs predominately through grains and meat1. 
Selenium is present in the soil in varying levels, dependent upon climate and specific 
soil composition.  Plants take up selenium directly from the soil as either the 
inorganic salt, selenite, or as selenate, a more readily incorporated form of selenium. 
Plant species incorporate soil selenium as the amino acids selenomethionine and 
selenocysteine, or as selenate. Following uptake and incorporation in plants, 
herbivores receive their necessary levels of selenium from plants grown in 
agricultural areas rich in selenium. Within mammalian tissues, elemental selenium is 
stored in the form of different selenoamino acids within specific selenoproteins. The 
approximately 25 characterized selenoproteins all possess different cellular 
localization specific to that particular selenium species2. 
 
In modern times, selenium deficiency is somewhat rare due to increased transport and 
consumption of foods from various regions. However, isolated cultures that 
predominately eat plant and animal species grown locally can be at risk for selenium 
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deficiency if the regional soil lacks adequate selenium levels. One of the first 
clinically documented cases of selenium deficiency occurred in the 1970s in an 
isolated, rural area of China with selenium deficient soil conditions. Keshan disease is 
characterized as a cardiomyopathy linked to deficient selenium dietary conditions, 
and initiated by a high viral load of the coxsackie virus (CVB3). Increasing dietary 
selenium levels raises immunity and reverses the clinical pathology3. Keshan disease 
is still prevalent in certain areas of China4. While most countries do not have high 
incidences of selenium deficiency, certain populations may be receiving a sub-
optimal nutritional dose. The minimum dietary intake required to prevent disease and 
maintain selenoprotein activity is estimated to be between 20-50µg/day, with 
supranutritional protective levels estimated to be around 120µg/day5. Deficient 
conditions are typically measured using plasma selenium concentrations, however 
some clinicians also use activity of certain selenoproteins as a more accurate measure 
of selenium status in humans6. During dietary deficient conditions, the brain and 
spinal cord prioritize the need for selenium7, suggesting a critical role within the 
central nervous system (CNS). Even though the current recommended dietary 
allowance (RDA) is 55µg/day for adults8, a reference dose (RfD) that allows for a 
larger intake still within safe ranges indicates total safe selenium consumption as high 
as 350µg/day9. Some studies suggest that selenium deficiency may contribute to 
disease susceptibility. Deficient conditions result in difficulty in processing viral load, 
specifically by regulating expression of cytokines and chemokines with influenza 
infection10, while supplementation with selenium decreased overall HIV viral load11.  
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Toxicity, or selenosis, is characterized by brittle nails and hair loss, but may also 
result in skin lesions, nausea, fatigue, and a distinct garlic-like odor on the breath12. 
The tolerable upper intake level (UL) set by the Food and Nutrition Board of the 
Institute of Medicine for selenium consumption in adults is 400µg/day8. However, 
toxicity is largely dependent upon the form of selenium. Some residents in a region of 
high selenium soil content in South Dakota were reported to consume up to 
700µg/day from locally raised livestock high in selenium with no adverse 
consequences13. A commonly known form of selenium, selenium disulfide in anti-
dandruff shampoos, utilizes cytotoxic properties as an anti-fungal agent topically to 
control the scalp issues. However, taken orally, selenium disulfide has an average 
lethal dose (LD50) lower than that of the selenium present in multivitamins14. Natural 
forms of selenium, such as selenomethonine and selenocysteine, show a significantly 
smaller level of toxic potential when compared to inorganic selenium salts, such as 
sodium selenite or selenate15. Selenized yeast, which incorporates inorganic selenium 
as selenomethionine and selenocysteine, also has higher bioavailability and decreased 
toxicity issues. The brand of selenized yeast utilized in these studies, Sel-Plex®, has a 
lower level of both acute and subchronic toxicity in mouse, rat, and canine models 
when compared to inorganic sodium selenite16. Specifically, the LD50 of acute 
administration of Sel-Plex is ≥2500mg/kg in rats and the overall no observed adverse 
effect level (NOAEL) is 30mg/kg/day whereas similar levels of inorganic sodium 
selenite resulted in occasional mortality and clinical chemical changes. The 
predominate form of selenium used to supplement infant formulas, as well as 
mutlivitamins on the market, are typically either sodium selenite or sodium selenate. 
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Thus, it is critically important to consider the average lethal dose and the tolerable 
upper intake level of selenium formulations before utilizing them in clinical studies.   
 
Selenized yeast has also come to the forefront of supplementation studies as an 
effective method for delivering high levels of bioavailable selenomethionine. Yeast is 
grown in the presence of selenium-enriched media. Selenized yeast incorporates 
inorganic selenium (selenite) from supplemented media into the cell wall of the yeast 
and converts it into the seleno amino acids, selenomethionine and selenocysteine17. 
Along with selenomethionine and selenocysteine, selenized yeast has a unique 
chemical profile of other selenoproteins and selenometabolites. Selenized yeast is 
composed of approximately 70-90% L(+)selenomethionine, 10% selenocysteine, and 
a small percentage each of selenocystathionine, γ-glutamyl-Se methylselenocysteine, 
and potentially other predicted selenospecies (Figure 1.1)18, 19.  
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Figure 1.1: Chemical structures of selenium compounds. Different components of 
both selenized yeast (A) and inorganic selenium compounds (B). Selenized yeast is 
composed of a unique chemical profile of different selenium containing compounds 
including the amino acids selenocysteine and selenomethionine, as well as various 
derivatives such as selenocystathionine, and γ-glutamyl-Se methylselenocysteine. 
Inorganic selenium compounds are typically supplemented into multi-vitamins or 
livestock diets in the form of sodium selenite or selenate. 
 
 
 
 
 
 
A 
B 
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1.1.2 Selenium metabolism 
Once selenium sources reach the digestive system, transport systems for seleno-
amino acids utilize Na+ dependent transport, much like is utilized for other amino 
acid absorption20. Selenite diffuses directly through the endothelial membrane of the 
small intestine. These differences in absorption may explain the critical differences 
observed in toxicity between these two formats. Selenoprotein P (SelP) is the primary 
transporter for selenium in the plasma for delivery to tissues throughout the body21. 
Once selenium reaches the target tissue, it can either be converted into selenide, the 
precursor for selenoprotein biosynthesis or, in the case of selenomethionine, 
incorporated in place of methionine in normal body proteins (Figure 1.2). The transfer 
RNA for methionine (tRNAMet) cannot distinguish between methionine and 
selenomethionine. This allows for selenomethionine to be stored in high levels in 
tissues and thus readily available for conversion back into selenide for selenoprotein 
synthesis as needed. In particular, the brain stores large amounts of selenomethionine, 
emphasizing the importance of selenium within the CNS22.  
 
When selenium is needed from tissue stores, selenomethionine is converted into the 
intermediate selenocystathione, and then into selenocysteine. Selenocysteine, either 
from conversion of selenomethionine or from dietary sources, is converted into 
selenide by selenocysteine β-lyase or bacterial methionase in the intestine23. Selenide 
is then made into selenophosphate and through the selenocysteine synthetase can be 
attached to the selenocysteyl-tRNA (tRNASec) for selenoprotein biosynthesis. The 
SECIS must be present upstream (within the 3’ UTR) of the of the UGA codon for 
translation to occur. Mutations present in the SECIS are detrimental for incorporation 
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of selenium into selenoproteins. The SECIS binding protein (SBP2) has been found 
through different cross-linking studies to be critical for selenoprotein synthesis, in 
addition to the selenocysteyl-tRNA and the SECIS24. By binding to the SECIS, SBP2 
prevents the translational machinery from reading the UGA as a stop codon and 
translation of Sec can proceed. 
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Figure 1.2: Selenium metabolism. Selenium is typically obtained from dietary 
sources in one of three formats, selenomethionine, selenocysteine, or the inorganic 
selenite (can also be in the form of selenate).  Selenomethionine can be easily 
incorporated into bodily tissues in place of methionine, as tRNA(Met) does not 
distinguish readily between methionine and selenomethionine. This serves a store for 
selenium in tissues in cases of deficiency. Selenomethionine can also be converted to 
selenocysteine or broken down by γ-lyase into methyl-selenol (CH3SeH), which can 
then be converted into selenide. Selenocysteine is converted into selenide by the 
enzyme selenocysteine β-lyase. Selenite is converted into the intermediate 
selenoglutathione by thioredoxin reductase and then into selenide. Selenide (H2Se) is 
the precursor for all selenoprotein synthesis. Adapted from Schrauzer GN19. 
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1.1.3 Selenoproteins 
Selenoprotein biosynthesis requires dietary intake of selenium. Certain 
selenoproteins, such as selenoprotein P (SelP), transport selenium in the plasma to 
tissues for protein synthesis. Once converted to the precursor compound selenide, 
protein synthesis can then begin. The mRNA sequence of a selenoprotein utilizes a 
UGA codon, which normally functions as a stop codon, and also requires a 
selenocysteine (Sec) insertion sequence (SECIS). This insertion sequence is a stem-
loop structure that is coded in the 3’ untranslated region upstream of the coding 
mRNA25. Synthesis also requires the presence of a special tRNA, tRNA-Sec. In the 
amino acid cysteine, the sulphur atom is replaced by selenium. The selenocysteine 
residue functions as the crucial component in oxido-reductase activity in 
selenoprotein enzymes26. Based on genome searches using both the UGA codon and 
the upstream SECIS, approximately 25 selenoproteins have been identified2. 
Selenoproteins function as antioxidant enzymes, in redox signaling, thyroid hormone 
metabolism, transport and storage of Se, and putative protein folding27. While some 
groups of selenoproteins have well characterized functions, many need further study 
and these may play a role in cellular response to oxidative stress. 
 
One of the predominant selenoprotein families critical for human health are the 
glutathione peroxidase (GPx) enzymes. Of the 7 characterized GPx enzymes, 5 are 
selenium dependent27. Glutathione peroxidase enzymes have potent antioxidant 
capability by catalyzing the reduction of hydroperoxides. GPx1, considered to be the 
classic glutathione enzyme, is found in the cytosol of cells, and has been shown to be 
protective against oxidative stress28. The other seleno-specific glutathione enzymes 
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include GPx2 (intestinal GPx), GPx3 (highly expressed in plasma), GPx4 
(ubiquitously expressed and critical for sperm formation), and GPx6 (olfactory 
specific)29. As discussed, selenium is an essential component of several antioxidant 
enzymes and the glutathione peroxidase family enzymes are critical components of 
the human antioxidant response.  
 
The group of thioredoxin reductases (TrxR) also plays a major role in the antioxidant 
defense system in human health. These enzymes can affect cell survival and apoptosis 
by scavenging reactive oxygen species 1. The thioredoxin system acts on lipid 
hydroperoxides, a damaging by-product that is formed following brain and spinal 
cord injury. TrxRs play a crucial role in redox signaling by regulating thioredoxin, a 
central molecule in the redox pathway. 
 
Selenoprotein P is another selenoprotein of importance in human health. SelP has up 
to 10 SeCys residues, allowing it to bind multiple selenium molecules at a time. Thus, 
SelP is the predominate transporter of selenium to peripheral tissues, including the 
central nervous system, and thus is highly expressed in the plasma21. Due to the high 
levels in plasma, SelP protein levels have been used frequently as a biomarker for 
selenium status30. SelP has dual functions and also has antioxidant properties, 
providing protection in the plasma from oxidation and nitration31. SelP knockout mice 
exhibit neurological deficits including axonal degeneration, impaired spatial learning, 
and altered hippocampal synaptic function32, 33. Additionally, SelP expressed in 
astrocytes is a unique membrane bound protein, distinct from the glycosylated and 
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secreted forms of SelP recognized in the plasma and extracellularly in other tissues34. 
This membrane bound SelP helps to protect astrocytes from oxidative damage, even 
selectively retaining selenium levels in cases of deficiency.  
 
Selenoprotein S (SelS) has been identified as an important protein in protein folding 
and is localized within the endoplasmic reticulum35. SelS is also associated with 
inflammatory response. When examined in models of TBI, SelS was upregulated in 
astrocytes in response to injury. Prior to injury, expression of SelS protein is noted in 
naïve neurons, but not in astrocytes. This increase in SelS after injury suggests a 
potential protective role of this selenoprotein in response to induction of harmful 
inflammation that occurs after CNS injury36.  
 
Additionally, selenoprotein O (SelO) has been recently characterized as another 
selenoprotein that plays a role in redox signaling37. However, this particular protein is 
unique in that it appears to localize specifically to mitochondria. SelO expression was 
preserved under selenium deficient conditions, suggesting that this protein is critical 
for cellular function and must be maintained even in deficient conditions37, 38. The 
implications of a selenoprotein that functions as a mitochondrial specific redox 
regulator are particularly interesting in models of CNS trauma. Mitochondrial 
dysfunction generally precedes cellular death following injury and is thus an 
important target for investigation. 
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Table 1.1: Currently identified selenoproteins. Many selenoproteins have been 
identified and the function of these proteins has been identified and largely has been 
identified with antioxidant mechanisms and redox signaling in the cell. However, the 
function of several selenoproteins remains to be elucidated. Additional putative 
selenoproteins have been identified but are not yet characterized. 
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1.1.4 Selenium and modulation of gene expression 
Selenium acts as a micronutrient that is an essential component for multiple different 
selenoproteins. In addition to being incorporated as altered amino acids into the active 
site of antioxidant enzymes, different levels of dietary selenium also have an effect on 
overall gene expression39-42. Changes in mRNA expression can be tissue specific, 
with suboptimal conditions decreasing expression levels of selenoproteins in different 
tissues, driven by post-transcriptional modifications. Regulation allowing translation 
of tRNA(Sec), and thus synthesis of selenoproteins, instead of reading the UGA 
sequence as a stop-codon is dependent upon the SECIS, located in an intron 
immediately upstream of the Sec codon43. Mutations within the SECIS will result in 
the Sec mRNA (UGA) being read as a termination codon instead of the Sec amino 
acid44. 
 
Selenium may also play a role in transcriptional regulation. In particular, the 
selenoproteins in the Trx family control cell signaling pathways via transcription 
factors45. TrxR enzymes are also part of the oxidoreductase family and can reduce 
oxidized Trx, selenite, and lipid hydroperoxides27. 
 
Several studies have examined the effect of different forms of selenium on overall 
gene expression. Studies examining specific selenoglycoproteins in tumor 
progression, showed that selenized yeast induced changes in gene expression in NF-
κB and associated pathways, implying a larger role of selenium in transcriptional 
regulation46. Barger et al. also showed differential effects specific to the form of 
selenium supplementation in mouse models39. Selenium supplementation, regardless 
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of form, reduced the mRNA expression of Gadd45b, and reduced protein levels 
specifically in animals receiving selenized yeast. Expression of Gadd45b is associated 
with the onset of DNA damage and thus decreased expression is evidence of a 
protective response. Treatment with selenium, concurrent with the addition of lead, an 
environmental toxin, altered specific expression patterns40. Gene regulatory pattern 
analysis showed specific effects with organic selenium (selenized yeast and 
selenomethionine) in pathways associated with DNA repair, particularly those 
involved with base excision repair. These changes in gene expression also carried 
over to afford protection of cells from DNA damage after supplementation with 
organic forms of selenium. 
 
1.1.5 Selenium and immune system function 
Selenium is a critical component for healthy immune function. However, the exact 
mechanism is currently unknown. It is hypothesized that the antioxidant activities 
exert protective effects over immune function as well as in response to certain 
injuries47. Increasing levels of dietary selenium, when compared to selenium 
deficiency, help to improve the two components of adaptive immunity, humoral and 
cell-mediated immunity48. A study examining adults with selenium deficiency (below 
1.2µmol/L) showed impaired immune function in response to an injection of a live-
attenuated poliovirus. Selenium supplementation, in the form of sodium selenite, 
restored plasma selenium levels, cytosolic GPx activity, and increased production of 
cytokines49. The increase in selenium levels improved overall viral handling in these 
subjects. Different sources of selenium also improve the overall response against 
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certain forms of cancer. In particular, selenized yeast was used in a large scale clinical 
trial examining cancer prevention (Nutritional Prevention of Cancer Study Group) 
and has been shown to improve outcomes in carcinoma patients50.  Selenium may 
function as an antioxidant through protection of DNA51 or through cell cycle 
mediation52. Studies have also established the interaction of selenium with neutrophil 
function. Selenium deficiency leads to decreased GPx1 activity in neutrophils53.  
 
1.1.6 Selenium and the central nervous system 
The well-studied antioxidant and immune functions of selenoproteins establish a 
crucial role in the central nervous system. While many studies have examined the 
therapeutic efficacy of selenium as preventative against cancer, other sources have 
laid the groundwork for the importance of selenium in central nervous system tissues. 
Several studies have emphasized the importance of antioxidants in the brain and 
spinal cord, particularly following neurotrauma54. Additionally, ebselen, a selenized 
yeast supplement provides neuroprotective effects in rodent cerebral artery occlusion 
and Alzheimer’s Disease models55-57. Yeo et al. showed selenium provided 
neuroprotection in vitro from reactive oxygen species (ROS) induced damage in both 
traumatic brain and spinal cord injury58, 59. However, these studies used an injection 
of sodium selenite directly onto the epicenter of injury, immediately following injury. 
Sodium selenite, as discussed previously, has a high risk of toxicity. The form of 
selenium used, as well as the method of drug delivery, makes translation of these 
findings to the clinical setting unreasonable.  
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Selenium levels are also associated with various neurodegenerative pathologies. 
Patients with Alzheimer’s disease (AD) have consistently lower selenium levels in 
the temporal lobe60. Additionally, supplementation with selenized yeast reduces 
overall amyloid plaque deposition and DNA/RNA oxidative damage in a mouse 
model of AD34. In neurons located in the substantia nigra in patients diagnosed with 
Parkinson’s disease, expression of SelP is reduced61. SelP plays dual roles in 
transporting selenium to the CNS (and other tissues) and as an integral membrane 
protein in astrocytes36, 62, suggesting a critical role for SelP in neuronal function. 
Additionally, recent studies have shown that selenium is protective against neuronal 
DNA damage in a rodent model of induced Parkinson’s disease63. Other 
selenoproteins, such as GPx4, also protect the CNS from oxidative damage. Increased 
expression of GPx4 protects cortical neuronal cultures from cell toxicity induced by 
oxidative injury64. 
 
While the brain only contains approximately 2% of the total body selenium storage, 
in cases of selenium deficiency, the central nervous system prioritizes selenium 
retention over other tissues in the body7. Selenium levels are affected by ApoER2 
expression. The major selenium transport protein, SelP, binds to ApoER2. In an 
ApoER2 knock-out model, mice without this transport protein exhibit lower brain and 
testicle selenium levels65. Once mice were kept on a selenium deficient diet, severe 
neurological dysfunction and death resulted. These studies further emphasize the 
importance of appropriate selenium levels for optimal function of the CNS.  
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1.2 Traumatic Brain Injury and Spinal Cord Injury 
 
1.2.1 Overview of Traumatic Brain Injury 
Traumatic brain injury (TBI) continues to be a prevalent clinical problem, with young 
adult males as the most vulnerable population due to their active lifestyle and a higher 
prevalence of military service66. Due to the diverse types of TBI presentations, 
confounding patient symptoms, and a complex secondary injury cascade, there have 
not been any successful pharmacological interventions for TBI to date. Attempts to 
target individual components of the multifactorial secondary injury cascade have 
resulted in only modest improvements in experimental animal studies and lack of 
significant results in clinical trials67. It is increasingly recognized that a treatment to 
intervene in the progression of the secondary injury cascade will need to have a broad 
spectrum approach.  
 
In response to the initial mechanical injury of a TBI, the secondary injury cascade is 
activated in the following first hours and days. While it is difficult to prevent the 
initial injury, the molecular events that eventually lead to neuronal death provide a 
viable target for pharmacologic intervention. Mechanisms involved in the secondary 
injury cascade following TBI include hypoxia, Ca2+ dysregulation, mitochondrial 
dysfunction, free radical production, lipid peroxidation, and eventual cell death.  
Many studies have examined antioxidants and free radical scavengers as potential 
pharmacologic interventions68.  Oxidative damage following injury has a significant 
effect on mitochondrial respiration.  
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As the location of the electron transport chain and the site for the manufacture of the 
main form of energy, ATP, mitochondria are considered the powerhouse of the cell. 
Over 90% of cellular ATP is synthesized in the electron transport chain (ETC). 
Damage to CNS mitochondria leads to a host of cellular problems, including a halt in 
ATP production, calcium dysregulation, and an increase in ROS production that 
ultimately leads to neuronal cell death. In the secondary injury cascade, degradation 
of the cellular membrane results in an influx of intracellular calcium. This calcium is 
typically buffered by mitochondria, which function as a calcium sink for neurons. 
However, an overload of calcium within the mitochondria leads to cellular membrane 
break down and the opening of mitochondrial permeability transition pore (MPTP)69. 
These events will eventually result in neuronal cell death. To further understand the 
interaction between injury and mitochondrial respiration, methods have been 
developed to examine the different components of the ETC. Endogenous and 
exogenous substrates are added directly to isolated mitochondria and the resulting 
consumption of oxygen in the system is measured. In normal conditions, the ETC 
utilizes a proton electrochemical gradient to drive the phosphorylation of ADP into 
ATP. Electrons are passed down the different complexes of the ETC, beginning with 
either complex I or complex II, and then subsequently transferred to complex III and 
finally complex IV. Complex IV will ultimately pass the electrons to oxygen, thus 
consuming oxygen in the system and allowing for a measurable readout of ETC 
function (Figure 1.4)70, 71. The electrochemical gradient is created by the flux of 
protons out of the mitochondrial matrix and into the intermembrane space. Energy 
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release from electron transfer between complexes of the ETC creates the necessary 
drive to move protons against their concentration gradient.  
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Figure 1.3: Electron transport chain. A representative diagram outlining the 
movement of electrons, oxygen consumption, and ultimately phosphorylation of ADP 
into ATP in the electron transport chain (ETC). Electrons are passed between the 
different complexes of the ETC and eventually transferred to oxygen by complex IV. 
Electrons can be passed into the ETC through either complex I or complex II. Each 
transfer of electrons to the subsequent complex releases energy that is used to drive 
protons against their concentration gradient and into the intermembrane space. The 
movement of protons across the mitochondrial matrix membrane creates the 
electrochemical gradient critical for ATP production. Protons eventually pass back 
into the mitochondrial matrix through the ATP synthase (F0/F1), driving the 
phosphorylation of ADP into ATP. Assays designed to measure the efficiency of 
mitochondrial respiration utilize endogenous and exogenous substrates added to 
isolated mitochondria to manipulate different complexes of the ETC. With this data, 
pathologies in specific steps within the ETC can be studied directly. Adapted from 
Sullivan et al, 200772. 
 
 
 
 
 
 
 
 
 
 
 
 21 
1.2.2 Overview of Spinal Cord Injury 
Spinal cord injury (SCI) is a prevalent clinical problem, with approximately 270,000 
patients living with SCI in the United States alone73. A neuroprotective intervention 
that functions as a pretreatment paradigm may prove especially interesting for high 
risk groups of people. The primary mechanical injury results in either a contusion, 
complete transection of the spinal cord, or a compression injury. The severity of the 
primary injury, along with the spinal level of the injury, determines the clinical 
outcome for the patient. The financial and psychological costs are extreme for 
patients surviving with spinal cord injury. Much like the secondary effects described 
in traumatic brain injury, a similar cascade of neurodegeneration begins after the 
primary mechanical injury. Many of the molecular events associated with the 
secondary injury cascade, in particular free radical production, are common pathways 
between traumatic brain and spinal cord injury. Despite differences and difficulties 
with each injury paradigm, the similar aspects of the secondary injury cascade are of 
particular interest for pharmaceutical intervention.  
 
1.2.3 Antioxidants and neurotrauma 
The initial mechanical trauma in traumatic brain and spinal cord injury is followed by 
a wave of neurodegenerative events that eventually lead to pathological dysfunction. 
In particular, oxidative stress is a key contributor to neurodegeneration following 
injury. Antioxidants have frequently been a target of efforts to use pharmaceutical 
intervention as a treatment strategy for neurotrauma54. Antioxidant therapies can 
function to sequester reactive oxygen and nitrogen species or inhibit their production. 
Traditional endogenous antioxidants play an important role in regulating free radicals 
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after injury. Antioxidant enzymes, including superoxide dismutase (SOD), catalyze 
the conversion of oxygen radicals into hydrogen peroxide (H2O2). Glutathione 
peroxidase (GPx), a well-characterized family of selenoproteins, then converts 
harmful hydrogen peroxides into non-harmful by products. Some of the pathological 
outcomes of oxidative damage include mitochondrial dysfunction74, neuronal death, 
and damage of synaptic proteins in the hippocampus75.  
 
Because of the high level of polyunsaturated fatty acids (PUFA) in the CNS, neurons 
are highly susceptible to damaging to lipid peroxidation. As free radicals attack these 
PUFAs, cellular membrane integrity is disrupted and will eventually lead to cytotoxic 
effects. Lipid peroxidation results in production of the two aldehydic compounds, 
acrolein and 4-hydroxynonenal. Levels of 4HNE, and thus evidence of lipid 
peroxidation, have been shown to peak at 24 hours following spinal cord injury76. 4-
HNE is evident as early as 1 hour after traumatic brain injury with sustained levels as 
far as 96 hours post injury77. Antioxidant therapies have shown success in pre-clinical 
trials and limited efficacy in clinical trials54. The development of reactive oxygen 
species and resulting damage following injury, suggest that modulation of the 
antioxidant system may prove a valuable target for neuroprotection following 
traumatic brain and spinal cord injury.  
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1.2.4 Nutriceuticals in the treatment of neurotrauma 
The use of dietary supplementation in the treatment or prevention of 
neurodegenerative disorders has been investigated in a limited fashion in previous 
studies. The Institute of Medicine published a report detailing the importance of 
proper nutrition in traumatic brain injured patients78. While energy requirements are 
critical following injury, levels of micronutrients are also important. In particular, this 
review of nutritional status in TBI patients emphasizes the value of supplementation 
with creatine, N-3 fatty acids, flavonoids, progesterone and vitamin D. In a rodent 
model of traumatic brain injury, creatine was shown to protect against tissue damage 
and deficits in mitochondrial membrane potential in injured animals79. In a weight-
drop model of traumatic brain injury, N-acetylcysteine (NAC) when combined with 
selenium treatment increased protective cytokine levels as well as decreased harmful 
lipid peroxidation80. In a patulin induced brain damage model, selenium 
supplementation was also shown to be neuroprotective by reducing protein carbonyl 
levels, reactive oxygen species generation, and by increasing both the activity and 
expression of several GPx proteins81.  
 
Following brain injury, selenoproteins may play a role in providing critical selenium 
to neurons and astrocytes at the blood brain barrier. As discussed, Burk et al. showed 
that a knockout of apolipoprotein E receptor-2 (ApoE2) results in dysfunction of 
selenoprotein levels in the brain65. Further studies show that both SelP and 
apolipoprotein E receptor-2 mediate selenium uptake at the blood brain barrier, 
especially in conditions of selenium deficiency62. Another selenoprotein, 
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selenoprotein S (SelS) is secreted from astrocytes and expression of SelS is greatly 
increased in reactive astrocytes after brain injury36. Overexpression of SelS influences 
the inflammatory markers in astrocytes. Additionally, Yeo et. al, also established 
through several studies that sodium selenite injections are neuroprotective in both 
traumatic brain and spinal cord injury58, 59. However, these studies present limitations, 
including the risk of toxicity in treatments with inorganic formulations of selenium.  
 
These various studies lay the foundation for the importance of examining the 
neuroprotective effects of dietary selenium in models of traumatic brain and spinal 
cord injury. While a few studies have investigated the potential protective properties 
of selenium as an important component of antioxidant systems and as a regulator of 
gene expression, no work has been done to date with dietary organic selenium 
supplementation in neurotrauma models. Due to the vast spectrum of 
neurodegenerative events that occur as a part of the secondary injury cascade, 
traumatic brain and spinal cord injury have proven very difficult diseases to target 
with pharmacological intervention. While unconventional in the field, a dietary 
pretreatment with selenium may be able to provide multiple benefits in the event of 
an injury. Selenized yeast should increase tissue storage of selenomethionine, 
allowing for a readily available source of selenium for selenoprotein synthesis 
following injury. It also may be able to modulate gene expression patterns, as those 
involved with DNA repair40, transcriptional regulation39, and inflammation41 thus 
providing neuroprotection following injury. While the functions of many identified 
selenoproteins remains unknown, the critical need for selenium and beneficial effects 
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with supplementation support further investigation into its effects within the CNS 
following injury.   
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CHAPTER 2 
Dietary supplementation with organoselenium following spinal cord injury 
2.1 Introduction 
Spinal cord injury (SCI) is a prevalent clinical problem, with approximately 273,000 
patients living with SCI in the United States alone73. Young adults represent a 
particularly vulnerable population due to their active lifestyle and a higher prevalence 
of military service. A prophylactic supplement to help protect in the event of acute 
neurotrauma may be particularly beneficial to this high risk group. 
We investigated selenium supplementation as a prophylactic treatment for reducing 
damage and improving functional outcomes following spinal cord injury.  Selenium is 
essential for the formation of selenoproteins throughout the body, particularly in the 
CNS. However, different forms of selenium are associated with varying toxicity 
levels82. Organic selenium supplements have much lower levels of toxicity and fewer 
of the pathogenic effects that are commonly associated with high levels of inorganic 
selenium in the body83, 84, 85, 86. The diets utilized in this study were formulated with 
selenized yeast to provide an organic form of selenium supplementation. The 
selenium is present in the form of two amino acids, selenomethionine and 
selenocysteine, as well as a variety of other seleno-compounds giving this supplement 
a unique chemical fingerprint18. Selenomethionine can be incorporated in place of 
methionine in tissues, allowing for storage of selenium in the event of a dietary 
deficiency. 
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The brain and spinal cord prioritize the retention of selenium when dietary levels are 
deficient87, utilizing the selenium transporter in the body, selenoprotein P (SelP), to 
supply physiological selenium to the brain88, 89.  Selenoproteins are well characterized 
for their role in redox regulation2, 90, 91 and anti-inflammatory pathways92, 93.  In 
particular, several antioxidant enzymes, including glutathione peroxidases and 
thioredoxin reductases, are selenoproteins which require the presence of 
selenocysteine for protein production. Reactive oxygen species initiate lipid 
hydrolysis, breakdown of cellular membranes, mitochondrial dysfunction, and thus 
perpetuate the damaging secondary injury cascade.94 Increasing levels of selenium 
available in tissues prior to injury may prepare the CNS to quickly synthesize 
selenoproteins to mitigate this series of damaging events.  
 
The objective of this study was to examine the effect of supplementation with 
selenized yeast on functional and pathological endpoints following SCI. Dietary 
selenium supplementation increased selenium tissue storage in the CNS, with no 
aberrant weight gain or other adverse physiological changes between treatment 
groups.  This increase in selenium levels did not translate to a visible improvement in 
locomotion or lesion volume in the injured tissue, but resulted in more rapid recovery 
of autonomous bladder expression.   
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2.2 Methods 
 
2.2.1 Animal care and diet 
Female Sprague-Dawley rats were obtained from Harlan at weaning and placed 
immediately on either a control diet or on a selenium enriched diet (Se-yeast, Sel-
Plex, Alltech, Nicholasville, KY). The control diet of normal rat chow contained 
standard dietary levels of selenium (0.3ppm selenium, approximately 4.5µg per day) 
and a yeast additive to account for any variation that may be seen due to the selenized 
yeast in the other diet. Caloric content was appropriately adjusted in diet composition 
after the addition of the supplements. The selenium enriched diet also used a standard 
rat chow as the diet base and incorporated a selenized yeast preparation (1.3ppm total 
selenium, approximately 19.5µg per day) in which the yeast is grown in the presence 
of selenium.  The selenium, in the form of selenized yeast (Sel-Plex®), is 
supplemented at levels well below tested toxicity levels.  Animals were fed their 
respective diets (n=20 per diet) ad libitum for 4 months.  Throughout the trial, 
animals were weighed weekly, and immediately prior to receiving the injury, to 
monitor health statuses of the rats as well as to check for any significant differences 
in body weight of the animals at the time of injury.  Animals were housed and 
handled within regulation, as a part of an approved protocol with University of 
Kentucky Institute of Animal Care and Use Committee (IACUC). 
 
2.2.2 Spinal cord injury and post-surgical care 
Following 4 months of dietary supplementation, rats were subjected to a moderate 
contusive SCI. Contusive SCI surgeries were performed as previously described95. In 
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brief, rats were anesthetized with an intraperitoneal injection of ketamine (80mg/kg) 
and xylazine (10mg/kg).  The spinal cord was exposed via a T10 laminectomy.  The 
rats received a moderate (150kdyn) contusive thoracic SCI using the Infinite 
Horizons SCI injury device (Precision Systems and Instrumentation).  Sham animals 
received only anesthetics and the laminectomy procedure.  Following injury (n=12) or 
sham surgery (n=8), the musculature and skin are closed with sutures and wound 
clips, respectively. As part of routine post-surgical care, bladders were manually 
expressed twice daily using the Credé maneuver96 until the animal recovered 
autonomous bladder control.  Bladder function following injury was recorded as 
either non-functional (full bladder) or functional (empty to half-full bladder) prior to 
manual voiding by the investigator97. The number of days until each animal exhibited 
autonomous bladder functional recovery was recorded.  The rats also received 
injections of Buprenorphine (0.05 mg/kg) twice daily to manage pain and Baytril (5-
10mg/kg) twice daily during this time to prevent development of post-surgical 
infection. Animals were maintained on their respective diets until the time of 
euthanasia.  
 
2.2.3 Spinal cord and cortical selenium levels 
A separate cohort of animals was also maintained on the two different diets for 4 
months under the conditions as described above.  Animals were fed ad libitum for 4 
months (n=5 per dietary group).  Immediately following the feeding regimen animals 
received the moderate contusive spinal cord injury described above.  24 hours post 
injury, fresh tissue from spinal cord sections both rostral and caudal to the injury site 
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and cortical samples were removed and flash frozen in liquid nitrogen.  Selenium 
levels were then analyzed by liquid chromatography-mass spectroscopy (LC-MS). 
Values rostral and caudal to the injury site were averaged for each animal. One value 
was removed from spinal cord dataset due to being an extreme outlier (greater than 3 
standard deviations from the mean). 
 
2.2.4 Behavioral assessment 
At three days following SCI, two investigators blinded to treatment groups assessed 
open field locomotor functional recovery using the Basso, Beattie, and Bresnahan 
(BBB) locomotor rating scale98. Locomotor testing was then repeated once weekly for 
6 weeks following injury. At 3 days following injury there is a substantial injury 
effect. With a moderate injury (1.50kdyn) animals lose motor control of their 
hindlimbs. Over 6 weeks, rats typically demonstrate a gradual improvement in 
locomotion that typically plateaus around a score of 13, indicating that animals have 
frequent to consistent weight support in plantar stepping and frequent coordination.   
When discrepancy occurred between observers, the lower score was assigned to the 
animal’s performance.  
 
2.2.5 Tissue histology 
Following the final behavioral testing, animals received a thoracotomy followed by 
transcardial perfusions.  Animals were given an intraperitoneal injection of a fatal 
overdose of sodium pentobarbital and then perfused with ice-cold phosphate buffered 
saline (PBS), followed by fixation with a 4% paraformaldehyde/PBS solution.  Spinal 
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cord tissues were kept at 4°C in a 4% paraformaldehyde solution for 4 hours and then 
transferred to a 30% sucrose solution overnight at 4°C for cryopreservation.  The 
fixed tissues were transferred into OCT medium for cryosectioning at -25°C.  
Transverse spinal cord sections (20µm thick) were collected every 100µm and 
mounted onto slides.  Sections were stained according to a modified protocol utilizing 
eriochrome cyanine RC and cresyl violet stained myelin and differentiated between 
white and gray matter99, 100.  Lesion volume and tissue sparing were measured and 
calculated for sections extending 0.7mm on either side of the injury epicenter.  Lesion 
and healthy tissue were measured using Scion Imaging analysis software (Scion 
Corporation, Frederick, MD).  Utilizing the Cavalieri method101, the total volume of 
tissue in the lesion or in spared tissue was calculated.  The investigator was blinded to 
treatment groups until all parameters had been measured and calculated. 
 
2.2.6 Statistical Analysis 
Data represented in each figure are shown as mean±standard deviation. Using 
GraphPad Prism 6.0, differences in weekly weight gain were evaluated by repeated 
measures, one-way ANOVA encompassing the 16 week feeding period.  
Additionally, to ensure that there were no significant differences between the two diet 
groups immediately before surgery, Student’s t-test (significance at p<0.05) was used 
to compare final weights.  Differences in behavioral assessment between treatment 
groups were assessed by repeated measures, one-way ANOVA with significance 
assigned at p<0.05.  Tissue selenium content, separately in spinal cord and cortex, 
was compared using Student’s t-test between control and selenium enriched diets 
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(p<0.05). Bladder functional recovery between animals on the control and selenium 
enriched diets was assessed using a Student’s t-test (significance at p<0.05). 
Differences between injury and control in lesion volume were calculated using a two-
way ANOVA (significance at p<0.05).  
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2.3 Results 
2.3.1 Weekly Weights  
To ascertain the effect of the selenium-enriched and control diets on body weight 
throughout the course of the study, animals were weighed weekly as described above 
(n=25 for each diet). Weight gain showed no significant differences between rats 
maintained on the control (+yeast) rat chow and the yeast-selenium enriched diet 
(Figure 2.1).   
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Figure 2.1: Dietary selenium enrichment does not affect overall weight gain.  
Rats were weighed weekly. No differences in body weight were seen between 
selenium enriched rats and rats maintained on control diet. 
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2.3.2 Selenium levels in the central nervous system 
Data from liquid chromatography mass spectroscopy (LC-MS) showed that dietary 
enrichment with selenium increased tissue storage of selenium. In the cortex, 
selenium levels increased by approximately 2-fold between the control diet and 
selenium enriched diet (p<0.0001) (Figure 2.2A). Supplementation also increased 
selenium levels in the spinal cord (p<0.0001) (Figure 2.2B).  
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Figure 2.2: Dietary selenium enrichment increases selenium tissue storage. CNS 
selenium levels were analyzed by LC-MS. These results indicate that supplemented 
selenium is able to cross the blood-brain barrier and is available for incorporation into 
cortical (A) and spinal cord (B) tissue.  Values are mean±SEM, p<0.001. 
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2.3.3 Bladder function 
Animals (n=12 per diet) maintained on selenium enriched diets regained bladder 
function by 3±0.4 days after injury as compared to rats on a control diet, at 5±0.5 
days (mean±SD p<0.05) (Figure 2.3).  Animals that received sham surgeries did not 
lose autonomous bladder control and thus did not require manual emptying by the 
investigator. 
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Figure 2.3: Dietary selenium supplementation improves the time to recovery of 
bladder function. Rats receiving selenium supplementation recovered bladder 
function in an average of 3 days±0.4 as compared to rats on a control diet, which 
recovered bladder function in 5 days±0.5.  Recovery of bladder expression is an 
additional functional marker for improvement.  Values are mean±SEM, p<0.05. 
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2.3.4 Locomotor functional recovery 
Sham animals in both dietary groups showed no loss of function following sham 
surgery.  Injured animals in both groups had a complete loss of hindlimb locomotor 
function immediately following surgery, confirming that the contusion injury was 
effective.  Three days after injury, all rats exhibited slight motor recovery, as evident 
from the BBB scores, which reflect slight movement of two joints and extensive 
movement of the third joint.  Over the course of the 6 week behavioral testing, all 
injured animals showed a steady improvement in locomotor function, plateauing 
around the second week with overall function that included consistent stepping, 
occasional to frequent coordination, and occasional correct paw placement.  In the 
injured animals, there was no significant difference in locomotor functional recovery, 
over time or during the final behavioral testing, between those fed the control diet and 
animals fed the selenium-enriched diet (Figure 2.4).   
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Figure 2.4: Dietary selenium supplementation does not improve locomotor 
functional recovery.  Recovery was evaluated weekly after injury using the BBB 
scale.  No difference in improvement was seen between the two diets in the injured 
rats. Sham animals showed no change in performance after laminectomy.  Values are 
mean±SEM. 
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2.3.5 Tissue lesion volume measurements 
Following the final behavioral testing, spinal cord tissue from each animal was fixed 
and cryopreserved. Staining for myelin and neuronal cell bodies showed no 
significant difference between the two injured groups in total lesion volume, or in the 
total amount of gray matter and white matter sparing after injury (Figure 2.5). Sham 
injured animals showed no tissue lesion. 
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Figure 2.5: Dietary selenium supplementation does not reduce lesion volume 
following SCI. Spinal cords sections (20µm) were stained for cell bodies and myelin.  
Total lesion volume (A) and total tissue sparing (B) revealed a significant injury 
effect (**p<0.01) between sham and injured.  No significant difference in lesion 
volume or tissue sparing was seen between the control injured and the selenium 
injured group. Additionally, there were no significant differences between grey matter 
sparing and white matter sparing. 
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2.4 Discussion 
Dietary selenium supplementation may be particularly beneficial for CNS disorders, 
as the CNS maintains a high priority for selenium storage in deficient conditions87, 102- 
104. This has been examined previously for metastatic brain tumors105, Alzheimer’s 
Disease106, ischemia107, and Parkinson’s Disease108. One previous study examined the 
effects of selenium on SCI109, although the experimental conditions differed 
markedly. Yeo and colleagues injected sodium selenite (10-50ng/kg) mixed with 
matrigel directly into the lesion site immediately following a dorsal hemisection 
injury. This study observed a reduction in apoptotic cell death, decreased GFAP 
positive cells, and a dramatic improvement in locomotor function in selenium over 
vehicle treated rats.  
Pre-injury dietary supplementation in this study showed increased CNS tissue levels 
of selenium, implicating increased bioavailability of seleno-amino acids for the 
production of selenoproteins. However, the increased selenium levels did not result in 
improved pathological outcomes and only minimal improvement in functional 
outcomes. Additionally, these effects were not evident through histological analysis 
of tissue sparing. In behavioral tasks, the rats receiving a selenium enriched diet did 
not exhibit significant improved locomotor function post-injury as compared to 
animals whose diet consisted of normal rat chow.  
Rats in the selenium enriched diet group were able to regain autonomous control of 
bladder expression following spinal cord contusion injury more quickly than rats 
maintained on the control diet. Initiation of autonomous micturition has been 
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examined as a marker for recovery of sensory-motor function in previous spinal cord 
contusion studies110, 111. Neurological control of bladder function is controlled 
through splanchnic parasympathetic nerves (located in the sacral spinal cord S2-S4), 
pudendal nerves (also in the sacral spinal cord S2-S4), and thoracic sympathetic 
nerves (cell bodies originating at T10-L2 spinal cord levels). Sympathetic innervation 
of the bladder plays a crucial role in closing the internal urethral sphincter and of 
blood vessels in the detrusor muscle of the bladder. Although histological 
examination did not show an overall improvement in total lesion volume, it is 
possible that sympathetic neurons present at the site of injury (thoracic level T10) 
were protected with selenium treatment. Additionally, because selenoproteins are 
found highly expressed in astrocytes, the supporting glial cells may have protected 
neuronal cell bodies in the epicenter of injury. In rat contusion (incomplete injury) 
models of SCI, rats spontaneously recover voluntary bladder control in the days to 
weeks following injury. Human patients with incomplete SCI do not exhibit recovery 
of voluntary bladder control. Disruptions in bladder and bowel function are very 
important clinical pathologies to SCI patients, however, disconnect between clinical 
outcomes and those found in experimental models may limit the translation of bladder 
functional recovery in preclinical models to patient application.  
Overall, the results do not support our hypothesis that selenium supplementation 
would result in improved outcomes following SCI. However, the studies that have 
also observed bladder functional recovery without associated improvement in 
locomotor behavioral tasks suggest that these improvements in bladder function may 
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be important markers for functional recovery112, 113. Shunmugavel et al. suggest the 
crucial importance of inflammatory pathways in mediating bladder dysfunction 
following SCI114. The involvement of selenium in modulating the inflammatory 
response92, 93 may be responsible for the improvement in recovery of bladder function 
observed in the present study.  
Current studies are examining effects of selenium-enriched and selenium-deficient 
diets on levels of selenoproteins and related enzyme activities in both naïve and 
traumatic brain injured animals. The antioxidant natures of many of the 
selenoproteins in the CNS, along with the results from this study suggest, that while 
selenium’s effects may be modest in this SCI model, examining various levels of 
selenium to attenuate neurodegenerative pathways warrants further research. 
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CHAPTER 3 
Dietary selenium supplementation alters gene expression following spinal cord 
injury 
3.1 Introduction 
The initial contusion of the spinal cord brought on by a mechanical injury, triggers a 
host of neurodegenerative molecular events, commonly referred to as the secondary 
injury cascade. While it is difficult to anticipate or prevent the contusion itself, the 
subsequent cellular and molecular changes are common targets for pharmaceutical 
intervention. The secondary injury cascade is characterized by lipid peroxidation115, 
cytotoxic influx of calcium, mitochondrial dysfunction116, production of reactive 
oxygen species, and inflammatory response. These events ultimately result in 
neuronal cell death and the clinical pathologies associated with spinal cord injury 
(SCI). In addition to these early markers of injury, spinal cord trauma also results in 
extensive changes in the gene expression profile as early as 4 hours and continuing 
through at least 24 hours post injury117-119. Gene ontologies associated with spinal 
cord injury include inflammatory cytokines, transcriptions factors, regulation of 
immune response, and response to oxidative stress120. These changes in gene 
expression help to complete the understanding of the secondary injury cascade and 
how changes in mRNA are triggered in response to injury. 
With the limited success thus far with clinical treatments targeting spinal cord 
pathology following injury, innovative approaches that target the secondary injury 
cascade may be beneficial for future patients with SCI. As an essential component of 
several antioxidant enzymes and other selenoproteins in the body, increased dietary 
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selenium represents a potential strategy to combat neurodegeneration following SCI. 
Low tissue selenium levels or changes in selenoprotein levels are also associated with 
other diseases of the central nervous system (CNS) including Alzheimer’s Disease34,
60 and Parkinson’s disease61.  
In addition to altering selenoprotein levels, selenium also impacts gene expression 
patterns, making it an interesting target for modulating gene expression in spinal cord 
injury models. Selenized yeast decreases expression of Gadd45b, a gene known to 
increase in response to DNA damage, as well as several gene ontology groupings 
associated with mitochondrial damage39. These shifts in DNA repair pathways are 
supported further by McKelvey et al40 in which organic formulations of dietary 
selenium, including selenized yeast and selenomethionine, induce gene expression 
shifts in pathways associated with DNA damage. These gene expression changes also 
translated to protection against lead-induced DNA damage in cell culture. 
Additionally, specific selenoglycoproteins, extracted from selenized yeast, impact 
transcriptional regulation through modulating expression of nuclear factor-κβ (NF-
κβ)46. 
While gene expression changes following spinal cord injury are well documented and 
studies have shown differential pathway shifts with formulations of selenium, the 
impact of selenium on mRNA expression patterns following spinal cord injury has yet 
to be investigated. Neuroprotective effects have been proposed for selenium in 
different neurodegenerative diseases but gene expression changes may provide more 
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of an indication through which selenium is providing neuroprotection in vivo. It is 
expected that the injury will cause vast changes in gene expression. Additionally, 
these studies tested the hypothesis that dietary selenium would drive additional 
changes in gene expression and potentially modulate expression of genes associated 
with pathologies of the secondary injury cascade. 
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3.2 Methods 
3.2.1 Diet supplementation  
Selenized yeast (Sel-Plex®, Alltech, Nicholasville, KY) was added to rat chow at a 
concentration of 1ppm selenium. Normal rat chow contains 0.3ppm of selenium, 
giving the selenium enriched diet a final concentration of 1.3ppm selenium (19.5µg). 
The control diet containing 0.3ppm of selenium (4.5µg) was representative of normal 
dietary levels. Yeast was also added to the control diet to account for any differences 
that may be seen due to the addition of yeast in the selenium enriched diet. Diets were 
formulated to contain otherwise similar caloric and nutritional content (Harlan 
Laboratories). Female Sprague-Dawley rats were obtained at weaning (21 days) and 
placed on either the control or selenium enriched diets (n=10 per diet). Animals were 
fed ad libitum for 16 weeks prior to receiving spinal cord injury. Throughout the 
study, weights and health status were monitored to check for any adverse 
consequences due to dietary differences. The animals were maintained on their 
respective diets until the terminal data collection. 
3.2.2 Spinal Cord Contusion Injury and Post-Surgical Care 
Rats received either a moderate (150kdyn) contusive thoracic spinal cord injury via 
the Infinite Horizons (IH) SCI injury device (Precision Systems & Instrumentation) 
or a sham laminectomy after 16 weeks on their respective diets (n=5 injured, n=5 
sham within each diet). Female rats received an intraperotineal injection of 
ketamine/xylazine (80mg/kg and 10mg/kg, respectively). Once significant depth of 
anesthesia was confirmed an incision was performed at approximately T10 (thoracic 
spinal cord level). The exact location of T10 spinal cord level was determined and a 
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laminectomy removed the overlying vertebra. The animal was secured using clips on 
either side of the vertebral column. IH impactor was set to 150kdyn force injury and 
was allowed to impact the exposed spinal cord tissue. Animals were sutured and 
allowed to recovery on warming pads. Buprenorphine (0.05mg/kg) was administered 
for control of pain every 12 hours following surgery. Loss of bladder control is a 
typical symptom following a contusion injury of this severity. Bladders were 
manually expressed 2-3 times daily until rats recovered the ability to express their 
bladder autonomously. Additionally, animals were given baytril (5-10mg/kg) to help 
prevent urinary tract infection twice daily following surgery until the recovery of 
bladder function and urine is clear. The rats also received injections of Buprenorphine 
(0.05 mg/kg) twice daily to manage pain. Animals were maintained on their 
respective diets until the time of euthanasia at 24 hours post injury. 
3.2.3 Sample Preparation and RNA Isolation   
A 7mm section of spinal cord tissue directly surrounding and including the injury 
epicenter was dissected at 24 hours post injury. Samples were flash frozen in liquid 
nitrogen to preserve RNA quality. Due to the high quantity of lipids within the spinal 
cord white matter, total RNA was isolated using RNeasy Lipid Tissue Mini Kit 
(Qiagen). Approximately 50mg of tissue was homogenized and processed according 
to the recommended protocol, including the optional DNase digestion. Final samples 
were eluted from columns with 30µL of RNase-free water. RNA quantity and quality 
were determined using the Nanodrop spectrophotometer and Bioanalyzer (Agilent), 
respectively. All samples used for microarray analysis had an RNA integrity number 
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(RIN) of at least 8, as is recommended for the sample purity necessary for 
reproducible results with the Affymetrix platform.  
3.2.4 Affymetrix Gene Array  
Affymetrix reagents and protocol were utilized (3’ IVT Expression kit) for all steps. 
RNA samples (200ng) were thawed on ice and assembled with other reagents to 
synthesize 1-strand cDNA. Second strand cDNA synthesis created aRNA which was 
purified using magnetic beads. aRNA was then labeled with a biotinylated probe and 
15µg of aRNA was added to fragmentation buffer. Samples were hybridized over 
night to a species-specific microarray chip (Rat 230 2.0 array, Affymetrix). This array 
chip represents over 30,000 transcripts from the rat genome. Affymetrix fluorescent 
scanner measures fluorescence emitted from hybridized RNA and translates this 
information into raw signal intensity. Software within the scanner assigns each signal 
intensity reading a numerical value, allowing for quantitative evaluation of gene 
expression levels. 
3.2.5 Statistical Analysis and Template Design  
The original data set included a total of 31,097 genes. From this list, the initial 
filtering process removed genes based on presence/absence calls, redundant gene 
symbols, and a lack of gene annotation. A gene is considered absent from a chip if an 
insufficient amount of signal intensity is detected. Expression values for a particular 
gene were removed from the entire data set if there are more than 17 “absent” calls 
out of all 20 microarray gene chips, regardless of injury/diet group. Among those 
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genes with redundant gene symbols, the expression data with the strongest expression 
across all groups was selected. Additionally, genes that do not have any annotation 
data were eliminated. While potentially interesting, with no annotation data available, 
little can be learned from these genes at the current time. This pre-statistical filtering 
generated a list of 14,907 genes.  
Using 2-way ANOVA, a list of genes that met p≤0.017 (Bonferroni correction for 3 
tests) was generated. This list included a total of 9,533 statistically significant gene 
expression changes. To analyze such an extensive list, templates of potential gene 
expression patterns were designed. Additionally, due to the concern that the extensive 
changes resulting from the injury effect may mask potentially subtle changes due to 
diet, templates pulled out gene expression changes due only to injury, exposing the 
dietary changes. Genes from the statistically filtered list were assigned to one of 8 
constructed templates based on their expression patterns in all 4 treatment groups. 
These templates represent overall directions that expression could take between 
different groups. Genes in each of these groups were analyzed using DAVID 
Bioinformatics Resource (http://david.abcc.ncifcrf.gov/) to generate functional 
annotations of gene lists. Affymetrix probe set IDs within each template were loaded 
into the Functional Annotation tool, utilizing the statistically filtered list (9,533 
genes) as the background for this search. Gene ontologies were selected based on the 
number of potential genes in that pathway, relative to the probe sets from that 
particular template with the pre-determined p≤0.05. The resulting gene ontologies 
were compiled and duplicate pathways combined to simplify analysis. Due to the 
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stringency of the α at each stage of statistical analysis, the final gene pathways are 
unlikely to be due to the large amount of multiple testing that occurs with 31,000 data 
points. 
54 
3.3 Results 
3.3.1 Significant gene selection and template design 
Analysis of gene array data began with probe sets representing 31,097 genes (Figure 
3.1). Genes were selected for further analysis based on presence or absence of signal 
intensity in all 20 microarray chips. Genes were eliminated from further analysis if no 
annotation data was available or data represented a duplicate gene annotation. This 
initial screening yielded a list of 14,907 genes. From this list, genes were further 
filtered based on statistical significance. Two-way ANOVA with Bonferroni post-hoc 
correction indicated a p-value cut off of 0.017. Using p≤0.017, expression of 9,533 
genes significantly changed in the current study. 
Templates were designed based on possible directional changes in gene expression 
across the four groups (Figure 3.2). Template based analysis provides the unique 
benefit for this study of allowing for the separation of certain patterns of expressional 
changes. In the case of this study, and has been established by previous works, spinal 
cord injury creates a massive change in mRNA expression levels117-119. The injury has 
a large fold change, potentially overwhelming expression changes due to diet. 
Template analysis allows us to detect more subtle gene expression changes, especially 
those due to dietary influences. All possible changes in gene expression have been 
considered, however, some templates are of more interest to the current investigation 
than others. An algorithm assigned each gene based on its pattern of expression to a 
template. The first two templates (Figure 3.2 A, B) represent the overall changes 
either up or down regulated following injury alone. Of the total filtered list, 4301 
genes were placed into the template in which all the genes were down regulated 
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following injury. 4812 genes were assigned to the up regulated template following 
injury. Two other templates that are of particular interest are those genes that are 
increased in the selenium injured group, suggesting a potential protective role of the 
dietary enrichment (Figure 3.2 I, 111 genes) and those genes that are restored to sham 
levels in the selenium supplemented group (figure 3.2 J, 78 genes).  
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Figure 3.1: Total genes represented in microarray analyses in SCI animals. Each 
gene chip begins with 31,097 genes represented. Filtering for presence/absence of 
signal across all chips. 2-way ANOVA run for remaining genes to generate p-value 
for diet, injury, and interaction. Bonferroni multiple comparison correction brought 
significant p-value to ≤0.017 and a total of 9,533 genes. 
 
Total
31,097
Filtered
14,907
P	  ≤	  0.017*
9,533
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Figure 3.2: Templates representing expression patterns from microarray 
analysis. A) Gene expression changes representative of genes that are down regulated 
following spinal cord injury, regardless of diet (4301 genes). B) Gene expression 
changes representative of gene that are up regulated following injury, regardless of 
diet (4812 genes). C) Genes that are upregulated with selenium supplementation, 
regardless of injury (16 genes). D) Genes that are down regulated with selenium 
supplementation, regardless of injury (30 genes). E) Genes that are upregulated only 
in control injured animals (55 genes). F) Genes that are upregulated only in selenium 
sham animals (95 genes). G) Genes that run in opposition (7 genes). H) Genes that 
group into pattern analysis of opposition (28 genes). I) Genes upregulated in animals 
that were selenium supplemented with SCI (111 genes). J) Genes in this list are 
representative of 78 total genes that are down regulated in injured animals maintained 
on the control diet. Selenium enrichment in injured animals restores expression levels 
of these genes to sham levels. 
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3.3.2 Gene changes with injury  
SCI causes a large change in gene expression with the majority of the genes that were 
a part of the final filtered list sorted into one of the two injury based templates (Figure 
3.3 A, B). Figure 3.3 assigns a color relative to the amount of gene expression 
change. Blue indicates down regulation of gene expression and red indicates up 
regulation of gene expression changes. Each animal is represented by one column, 
each row is representative of one gene. This heat map clearly shows the strong shift in 
expression that is created by injury. Each heat map is coupled with its respective 
template for reference.  
When examining the lists for assignment into specific functional annotations, the p-
value cut-off was adjusted slightly for these gene lists. DAVID Bioinformatics 
Database only allows submission of a probe set list of 3000 genes. Therefore, the 
stringency was increased to p≤0.0001 to generate a list of appropriate size for 
analysis. This database characterized the genes into an extensive list of functional 
ontologies (Table 3.1). Genes that are down regulated post-injury in the current study 
include those involved with synaptic transmission, mitochondrial respiration and 
membrane integrity, ATP production, and ion transport. Genes that are up regulated 
post-injury include those associated with translational machinery and mRNA 
processing, cell cycle, nuclear transport, and lymphocyte mediated immunity.  
59 
Figure 3.3: Representative heat maps and related templates for gene expression 
changes associated with injury. In the heat maps shown, expression values indicated 
by a red color are up regulated and expression values indicated by a blue color are 
down regulated. These images clearly show the relative gene expression changes as a 
result of injury. 
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Table 3.1 Gene ontologies from genes down regulated post-injury 
Down regulated post-injury 
synaptic transmission 
neuron projection/cytoskeleton 
mitochondrial inner membrane 
integral to membrane 
mitochondrial part (matrix) 
ion transport 
adult behavior (locomotor) 
ATPase activity, coupled to transmembrane movement of substances 
mitochondrial respiratory chain 
neurotransmitter transport 
regulation of neuron differentiation (neurogenesis) 
NAD or NADH binding (cofactor binding) 
cellular component maintenance 
peroxisome 
ion binding 
sulfur metabolic process (glutathione metabolic process) 
calmodulin binding 
cellular chemical homeostasis (regulation of membrane potential) 
glutamate signaling pathway 
acetyl-CoA metabolic process (cellular respiration) 
cation-transporting ATPase activity 
regulation of catecholamine secretion 
(negative) regulation of adenylate cyclase activity 
homophilic cell adhesion 
carbohydrate catabolic process 
vesicle-mediated transport 
hydrogen ion transporting ATP synthase activity, rotational mechanism 
carboxylic acid transport (amino acid transport) 
Ras guanyl-nucleotide exchange factor activity 
microtubule motor activity 
cyclic nucleotide metabolic process 
activation of protein kinase A activity 
phosphoinositide metabolic process 
regulation of action potential 
phosphoric diester hydrolase activity (lipase activity) 
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Table 3.2: Gene ontologies from genes up regulated post-injury 
Up regulated post-injury 
translational elongation 
nuclear lumen 
intracellular non-membrane-bounded organelle 
RNA/mRNA processing 
ribonucleoprotein complex biogenesis 
positive regulation of I-kappaB kinase/NF-kappaB cascade 
nuclear pore 
proteasome complex 
chromosome 
ribosomal small subunit biogenesis 
macromolecular complex assembly 
DNA metabolic process 
nucleotide binding 
lymphocyte mediated immunity 
helicase activity 
positive regulation of transcription factor activity 
mitotic cell cycle 
regulation of endopeptidase activity 
positive regulation of programmed cell death 
chaperonin-containing T-complex 
nucleotide-excision repair 
positive regulation of cell migration 
vasculature development 
response to amino acid stimulus 
nuclear-transcribed mRNA catabolic process 
nuclear transport 
'de novo' protein folding 
erythrocyte homeostasis 
peptidyl-asparagine modification 
actin cytoskeleton 
positive regulation of tumor necrosis factor production 
regulation of RNA stability 
positive regulation of myeloid cell differentiation 
negative regulation of protein kinase activity 
tissue remodeling 
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Table 3.2 (continued) 
hydrolase activity, hydrolyzing N-glycosyl compounds 
transition metal ion transmembrane transporter activity 
biopolymer methylation 
epithelial to mesenchymal transition 
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3.3.3 Genes up regulated in injured animals that were maintained on a selenium 
enriched diet 
A total of 111 genes were differentially up regulated in injured animals that were 
maintained on the selenium diet. A heat map of these gene changes clearly shows that 
the animals in the selenium injured group had increased gene expression as compared 
to those on the control diet (Figure 3.4). Animals in the control injured group 
exhibited a moderate amount of increase in expression as compared to sham levels. 
Animal 2 in the control injured group exhibited a marked decrease in expression in 
the genes that filtered into this template. However, since the remainder of this 
sample’s expression profile follows the patterns of the other templates, this data set 
could not be eliminated without bias. 
The complete gene list of genes that filtered into this particular template is shown in 
Table 3.3. There are many interesting genes that are filtered into this particular 
template, including those associated with mitochondrial function, protein turnover, 
transcriptional regulation, and cell differentiation.  
This complete list of genes was uploaded to DAVID Bioinformatics Software to 
assess any patterns in genes that were present. Only one functional annotation was 
returned as statistically significant (p≤0.05). Genes upregulated within the selenium 
injured group were associated with pathways of DNA repair and included genes such 
as polymerase (DNA directed) beta (Polb) and poly (ADP-ribose) polymerase 1 
(Parp1).  
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Figure 3.4: Heat map representing genes up regulated in the selenium injured 
group. A representative heat map from the template in which genes in animals from 
the selenium-enriched, injured group show increased expression. In this heat map, 
blue color for a gene indicates decreased expression and red indicates increased 
expression. Each column represents an animal in the study and each row represents a 
gene within this template grouping. 
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Table 3.3: Representative list of genes increased with selenium following injury. 
A functional annotation search on DAVID Bioinformatics Software indicated that 
there is a statistically significant alteration in expression in pathways involved with 
DNA repair. A complete list of the 111 genes that filtered into the increased 
expression in selenium-enriched template is also included (Appendix B). 
Injury in diet (+), p<0.017, total of 111 genes 
Gene Description Gene Ontology Information 
Svil Supervillin Regulation of actin filaments 
Tgfb3 transforming growth factor, beta 3 Cell differentiation 
Anxa3 annexin A3 Cell growth and signal transduction 
Hspa12b heat shock protein 12B Cellular chaperone 
Gtf2h4 
general transcription factor II H, 
polypeptide 4 DNA repair 
Recql RecQ protein-like (DNA helicase Q1-like) DNA repair/function 
Polb polymerase (DNA directed), beta DNA repair/function 
Parp1 poly (ADP-ribose) polymerase 1 DNA repair/function 
Casp12 caspase 12 Inflammatory caspase 
Mrpl12 mitochondrial ribosomal protein L12 Mitochondrial function 
Acbd6 
acyl-Coenzyme A binding domain 
containing 6 Mitochondrial function 
Tfb1m transcription factor B1, mitochondrial Mitochondrial transcription 
Snx33 sorting nexin 33 Protein sorting/targeting 
Psmc4 
proteasome (prosome, macropain) 26S 
subunit, ATPase, 4 Protein turnover 
Ubap2 ubiquitin-associated protein 2 Protein turnover 
Ubfd1 ubiquitin family domain containing 1 Protein turnover 
Btbd12 BTB (POZ) domain containing 12 Protein turnover (substrate for ubiquitin) 
Duoxa1 dual oxidase maturation factor 1 Redox regulator 
Atf6b activating transcription factor 6 beta Transcription 
Foxj2 forkhead box J2 Transcriptional activator 
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3.3.4 Genes down regulated in injured animals maintained on the control diet.  
The template designed to examine changes in which genes are down regulated with 
injury but restored to sham levels with selenium enrichment resulted in a total of 78 
genes sorted into this pathway. The heat map (Figure 3.5) shows a visual 
representation of the expression patterns of genes in this template. The animals in the 
injured, selenium-enriched group have expression patterns for these genes that are 
close to sham levels. 
A total of 78 genes filtered into this template (Table 3.3) and include genes with 
functions associated with transcriptional regulation, mitochondrial proteins, and NF-
κβ activation signaling. This gene list was uploaded to DAVID Bioinformatics 
Software for analysis of functional annotation. Analysis resulted in two significantly 
(p≤0.05) altered functional annotations, including regulation of transcription and cell 
cycle arrest.  
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Figure 3.5: Heat map representing genes down regulated in injury and restored 
to sham levels with selenium supplementation. The heat map presents a visual 
representation of changes in gene expression in which blue indicates down regulated 
gene expression and red indicates up regulated gene expression. 
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Table 3.4: Representative list of genes down regulated in injury and restored to 
sham levels with selenium supplementation. Analysis of this list in DAVID 
Bioinformatics Software indicated 2 significant functional annotations for these 
genes, including transcriptional regulation and cell cycle arrest. A complete list of the 
78 genes that filtered into the increased expression in selenium-enriched template is 
also included (Appendix C). 
Injury in control (-), p<0.017, total of 78 genes 
Gene Description Gene Ontology Information 
Aven apoptosis, caspase activation inhibitor Anti-apoptotic 
Solh small optic lobes homolog (Drosophila) Calpain 15 
Dmtf1 cyclin D binding myb-like transcription factor 1 cell cycle regulation 
Mkks McKusick-Kaufman syndrome developmental dysfunction 
Trmt12 
tRNA methyltransferase 12 homolog (S. 
cerevisiae) epigenetic regulation 
N6amt2 
N-6 adenine-specific DNA methyltransferase 2 
(putative) epigenetic regulation 
Mmp15 matrix metallopeptidase 15 extracellular matrix 
Mrpl50 mitochondrial ribosomal protein L50 
Formation of mitochondrial 
proteins 
Mrpl48 mitochondrial ribosomal protein L48 
Formation of mitochondrial 
proteins 
Tomm40b 
translocase of outer mitochondrial membrane 40 
homolog B (yeast) mitochondrial translocation 
Sharpin SHANK-associated RH domain interactor NFK-b activation - signaling 
Efha1 EF-hand domain family, member A1 transcription 
Zswim3 zinc finger, SWIM-type containing 3 transcription 
Zfp422 zinc finger protein 422 transcription 
Zdhhc8 zinc finger, DHHC-type containing 8 transcription 
Zfp444 zinc finger protein 444 transcription 
Zfp322a Zinc finger protein 322a transcription 
Zzef1 zinc finger, ZZ-type with EF hand domain 1 transcription 
Zhx2 Zinc fingers and homeoboxes 2 transcription 
Zfhx3 zinc finger homeobox 3 transcription 
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3.4 Discussion 
SCI affects approximately 273,000121 patients every year and creates millions of 
dollars worth of health care costs. With relatively few effective treatments, a new 
neuroprotective strategy is needed. Transcriptional changes with selenium 
supplementation following injury explored some pathways that may be able to 
provide a small amount of neuroprotection following spinal cord injury.  
Mechanical trauma to the CNS induces a sequence of molecular events known as the 
secondary injury cascade. Eventually, these neurodegenerative events result in 
neuronal cell death and pathologies associated with SCI. In addition, SCI produces a 
robust change in gene expression beginning as early as 4 hours post-injury and 
continuing into the days and weeks following the initial injury117-120.  
The gene ontologies represented in the templates for increased/decreased gene 
expression following SCI closely match gene ontologies observed in other studies 
looking at transcriptional changes after SCI. In particular, Aimone et al., showed 
significant changes in synaptic vesicle transport119 in relation to disruption in synaptic 
plasticity. The current study supports this finding through functional pathways down 
regulated after injury including synaptic transmission, neurotransmitter transport, and 
vesicle-mediated transport (Table 3.1).  
The similarities between the current study and other published studies support the 
methods used for performing the contusion SCI as well as the analysis of gene array 
data. However, the gene expression changes induced by injury alone were not the 
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main focus of this study. The importance of selenium for an optimally functioning 
CNS and previous publications that show the role selenium plays in modulating gene 
expression support the original hypothesis of this study that selenium will drive gene 
expression changes associated with the secondary injury cascade.  
Template design as utilized in this analysis of microarray data provides both great 
benefit and a potential caveat. In the case of this study, when one particular 
overwhelming shift in gene expression is expected, more subtle changes in expression 
can be lost in the analysis. Even a moderate SCI produces pronounced changes in 
gene expression, with high fold changes, while the more subtle effects of diet are 
difficult to determine. These templates filter out all genes that are changed 
predominately by injury. This leaves smaller groups of genes that may show a subtle 
shift in gene expression, but represent significant changes due to dietary treatment in 
this injury model and may have been otherwise difficult to detect with traditional 
pathway analysis. This design, does however, limit the scope of the analysis of genes 
that are expected with selenium supplementation. Changes in selenoproteins, such as 
glutathione peroxidase for example, are expected to increase with selenium 
supplementation. These genes are predominately changed with injury and thus are 
included in the injury alone templates. Despite the caveats, this method provides an 
unbiased analysis of genes with subtle expressional pattern shifts, which is critical 
when evaluating such a large data set. 
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The two templates discussed in detail here are those genes with expression patterns 
that are upregulated in selenium enriched animals following injury and those that are 
down regulated in control injured animals, but brought back to sham levels with 
selenium treatment. Several genes associated with mitochondrial function upregulated 
with selenium dietary enrichment following SCI. These genes are particularly 
interesting in a model of CNS trauma due to the critical importance of mitochondria 
following injury. Mitochondrial dysfunction occurs as the result of membrane 
damage and calcium dysregulation in the cell and is an important trigger for apoptotic 
pathways following SCI. An increase in synthesis of mRNA for these mitochondrial 
proteins may provide neuroprotection following CNS trauma. Additionally, genes 
associated with transcriptional changes, NFK-b regulation, cell cycle regulation and 
mitochondrial proteins are down regulated following injury, but restored to sham 
levels with selenium supplementation. The changes in mitochondrial genes support 
the genes up regulated with selenium supplementation and the improvement in 
transcriptional regulation suggests a potential role in selenium restoring normal 
protein production following injury. 
Further studies are needed to determine the exact mechanism through which 
selenoproteins are modulating expression of these different pathways. Changes in 
mRNA levels of these genes provide only a small picture of the cellular changes that 
this particular form of selenium is creating within the CNS. Selenium has been shown 
to activate the transcriptional regulator, NF-κβ46, as well as modulate histone 
acetylation in controlling inflammatory gene expression41. These targeted changes of 
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transcriptional machinery may provide a clue as to how different seleno compounds 
are regulating shifts in gene expression patterns. 
Another important caveat to consider when examining gene expression data in spinal 
cord injury models is the well characterized response to injury that involves an influx 
of cells into the site of primary injury122. In future experiments, performing cell-
sorting with samples to specifically choose neuronal or glial specific cells, may 
provide interesting information and allow for distinction of gene expression changes 
from invading macrophages or leukocytes.  
73 
CHAPTER 4 
Long term dietary selenium supplementation may provide neuroprotective 
benefits for mitochondrial respiration 
4.1 Introduction 
The neurological devastation brought on by traumatic brain injury (TBI) is costly 
both financially and in terms of quality of life for the estimated 3.17 million patients 
with long term disabilities associated with TBI every day123. Certain groups of 
individuals run a higher risk for sustaining a traumatic brain injury. In particular, with 
recent military involvement in conflicts in Iraq [Operation Iraqi Freedom (OIF)] and 
Afghanistan [Operation Enduring Freedom (OEF)], soldiers are increasingly 
returning from deployment with combat injuries classified as TBIs66. The prevalence 
of mild traumatic brain injuries among athletes in contact sports has also become a 
focus of growing concern, with as many as 3.8 million sports concussions occurring 
each year124. This substantial incidence of TBIs, particularly in high-risk groups, 
emphasizes the importance of developing novel therapies to combat the 
neurodegeneration and pathologies following TBI. In the hours and days after a 
mechanical injury to the CNS, a host of secondary molecular events occur, which, if 
unchecked will lead to neuronal cell death. This secondary injury cascade includes 
molecular problems such as calcium dysregulation, mitochondrial dysfunction, 
oxidative damage, lipid peroxidation, and excitoxicity. As an essential dietary 
nutrient, critical for the function of several antioxidant enzymes, dietary selenium 
enrichment may serve as an effective pretreatment to minimize CNS damage in the 
event of trauma.  
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Selenium modulates neurodegeneration in many other disorders of the CNS, making 
it an interesting therapeutic target for TBI. Increased dietary selenium levels reduced 
RNA and DNA oxidative damage in an Alzheimer’s Disease model34 and decreased 
DNA damage and movement disorders in mouse models of Parkinson’s Disease63. A 
form of selenium yeast, ebselen, has also proven neuroprotective following ischemic 
stroke in rodents56. Selenium functions as a co-factor for several antioxidant 
selenoproteins, including glutathione peroxidase. Additionally, other selenoprotein 
families have important immune modulating and antioxidant effects49, thereby 
providing potential for these neuroprotective effects to extend into neurotrauma as 
well. 
Selenium was enriched at different levels in rat diets prior to injury to examine a 
potential neuroprotective role for dietary selenium. In the present study, dietary 
selenium enrichment was present in the form of selenized yeast. The formulation of 
selenium is critical when considering increasing selenium levels in both animal 
models and in translation to human clinical trials. Inorganic forms of selenium, such 
as sodium selenite and selenium sulfides, common in most over the counter 
multivitamins and anti-dandruff shampoos, respectively, can cause toxicity in high 
concentrations14. Selenium was incorporated into the diets in the form of selenized 
yeast (Sel-Plex®, Alltech, Nicholasville, KY), which like other organic forms of 
selenium, has a lower risk of toxicity issues than the inorganic salt forms15, 16. 
Selenized yeast has been used previously in studies examining the cancer 
preventative properties of selenium50, as well as in rodent ischemic stroke models55. 
75 
In this formulation, yeast is grown in the presence of elemental selenium and results 
in the presence of several different selenium species. When analyzed by mass 
spectrometry selenized yeast contains approximately 20% selenomethionine125, 20% 
selenocystine and Se-methylselenocysteine, and 40-50% of other unique selenium 
compounds126. By adding selenium in the form of seleno-amino acids, selenium can 
be stored easily in tissues as selenomethionine (in place of methionine) and provide a 
readily available source of selenium for the formation of selenoproteins. The unique 
selenium compounds specific to selenized yeast may be crucial to defining the 
neuroprotective benefits over other formulations of selenium18. 
In the secondary neurodegenerative cascade of events that follow the initial 
mechanical trauma, mitochondrial dysfunction is one of the primary pathologies that 
precipitates neuronal death127. As the primary site for ATP production in the neuron, 
mitochondrial damage results in a loss of critical energy production as well as failure 
to buffer intracellular calcium levels. A dysregulation of calcium buffering within the 
neuron can inhibit ATP synthesis, lead to the release of the apoptotic signaling factor, 
cytochrome c, increase production of reactive oxygen species (ROS), and eventually 
lead to cell death128, 129. Through work with isolated mitochondria, endogenous (and 
exogenous) substrates can be added directly to cortical mitochondrial to mimic 
various states of electron transport chain (ETC) respiration (Figure 4.1). These assays 
measure oxygen consumption rate (OCR) and can provide information about overall 
mitochondrial health following injury. The Seahorse Bioscience system measures 
oxygen levels within a closed chamber was modified to allow for multiple sample 
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testing in one plate (Seahorse Bioscience®). Because they are crucial for energy 
production and dysfunction can trigger cell death, mitochondria are a particularly 
attractive target for intervention after traumatic brain injury.  
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Figure 4.1: Representative trace of oxygen consumption in isolated 
mitochondria. Oxygen consumption is measured in response to various endogenous 
and exogenous substrates (Seahorse Bioscience). Isolated mitochondria are kept in a 
chamber with a controlled level of oxygen. Oxygen consumed is representative of the 
efficiency of the electron transport chain (ETC). Adding the substrates pyruvate and 
malate, along with ADP, allow the ETC to consume oxygen through the production 
of ATP from ADP (III or State III respiration). Oligomycin is then added to 
artificially stop the ATPase, thus effectively halting ATP production, the ETC, and 
oxygen consumption (IV or State IV respiration). Following that, the protonophore, 
FCCP, is added (V-C I or State V-complex I respiration) which allows for free 
passage of H+ ions across the membrane and thus maximally driven respiration. 
Finally, rotenone, a Complex I inhibitor, and succinate, the endogenous substrate for 
respiration through Complex II, are added to test respiratory capacity through 
Complex II of the ETC (V-C II or State V-complex II driven respiration). Changes in 
rates of oxygen consumption in response to these different substrates correlate 
directly to problems with these specific components of the ETC, pinpointing the 
location of mitochondrial damage following injury. 
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The detrimental impact of the secondary injury cascade typically results in neuronal 
death. Ultimately, this neuronal death leads to pathological functional changes. 
Improving these functional deficits is crucial in the lives of patients living with TBI 
and thus is also an important parameter to investigate. Different animal models of 
TBI have been linked to spatial memory deficits130, 131. As this is also a common 
clinical symptom, the Morris Water Maze task was developed and used in a wide 
variety of studies to test cognitive problems in various rodent models132. In addition, 
memory deficits have been linked to development of cortical lesion, particularly in 
the controlled cortical impact (CCI) injury model. 
This study examines the potential for increased dietary selenium to protect various 
states of mitochondrial respiration in the injured cortex, prevent neuronal cell death, 
and ultimately improve memory deficits following TBI. 
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4.2 Methods  
4.2.1 Animal care and diet 
Male Sprague-Dawley rats were purchased from Harlan and placed immediately on 
one of four diets. Selenized yeast was formulated within the rat diet for a final 
concentration of either 1.3ppm selenium (approximately 19.5µg/day) or 2.3ppm 
selenium (approximately 34.5µg/day). Normal rat chow containing 0.3ppm of 
selenium (4.5µg/day) was utilized as the control diet. The control diet is comparable 
to a normal rat chow with a yeast additive to account for any differences caused by 
the yeast in the selenium compound. The selenium enriched diets are labeled as 1ppm 
(SP1) or 2ppm (SP2) of additional selenium in the form of selenium yeast. Yeast was 
grown in the presence of selenium; allowing selenium to be taken up into the cell 
walls of the yeast and incorporated as the amino acids selenocysteine and 
selenomethionine, as well as other small seleno-compounds. The selenium deficient 
diet is formulated using a torula yeast base. Because selenium is present in most plant 
sources, normal plant-based rodent diets will contain a small amount of selenium. By 
using torula yeast as a base for the diet, this controls the growing environment and 
ensures the diet will be completely deficient in selenium. Animals were fed ad libitum 
for 2, 4, 8, or 16 weeks, depending on the length of feeding required for each 
experiment. Diets were formulated by Harlan and selenized yeast, in the two different 
concentrations, was supplied to Harlan as Sel-Plex® (Alltech, Nicholasville, KY). 
4.2.2 Selenium tissue levels 
Diets were fed ad libitum to male Sprague-Dawley rats for either 2 weeks, 4 weeks, 8 
weeks, and 16 weeks prior to tissue collection. Naïve cortex samples were collected 
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for tissue analysis. Prior to sampling, animals were transcardially perfused with 
approximately 250mL of phosphate buffered saline to eliminate selenium 
contamination from blood in the tissues. Selenium levels were analyzed (Alltech) by 
liquid chromatography-mass spectrometry (LC-MS) in samples taken from the left 
cortex (n=6 per diet). Animal weights and caloric content consumed were also 
monitored for significant changes due to the different dietary formats.  
4.2.3 Controlled cortical impact injury 
After being maintained on their respective diets for 16 weeks, rats received a 
moderate (1.75mm depth) unilateral, controlled cortical impact (CCI) injury133 or a 
sham craniotomy. In the second major cohort of animals tested, the dosage period 
was shortened to 4 weeks of dietary supplementation (or deficiency) and animals 
received a severe (2.2mm depth) unilateral, CCI or a sham craniotomy. Animals were 
first anesthetized with 3% continuous isoflurane, followed by shaving the scalp, and 
securing the animal in a stereotaxic frame. After sterilizing the scalp, an incision was 
made over the site of the intended craniotomy. A 6mm craniotomy was created using 
a hand trephine, lateral to the central suture, centered between lambda and bregma, 
and positioned directly over the left parietal cortex. The injury was performed with a 
pneumatically controlled impactor with an intended depth of either 1.75mm or 2.2mm 
(depending on the experimental paramaters), a dwell time of 500msec, and a velocity 
of 3.5m/s as previously described129 (Precision Systems and Instrumentation, Fairfax 
Station, VA). Immediately following the injury, the craniotomy was covered, the 
scalp sutured, and the scalp injected with bupivicaine/epinephrine to minimize 
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discomfort due to the incision. Sham controls received a craniotomy, anesthesia, and 
bupivacaine/epinephrine solution without the cortical contusion injury. 
4.2.4 Behavioral assessment of functional deficit  
Spatial memory after injury was assessed using the Morris Water Maze task. The 
Morris Water Maze (MWM)132 was developed as an open field behavioral task 
designed to test spatial and working memory in rodent models. Since its development, 
the MWM is a widely utilized and highly cited method to determine cognitive deficits 
in the trauma field. This task is an open-field swimming task in which a sunken 
platform is placed in a particular quadrant of the testing pool. To discover the location 
of the platform, animals must rely on spatial memory and visual cues on the walls 
surrounding the pool. Testing in the water maze began at 10 days post-injury. This 
lapse of time after injury is necessary for sufficient recovery following surgery. 
Animals underwent 4 trials each day for 4 consecutive days. During each trial, 
animals had 60 seconds to find a sunken platform. If the platform was not discovered, 
rats were led to the platform. The fifth day consisted of a probe test in which the 
platform was removed and the number of times the animal crossed the location of the 
(now) missing platform were recorded. Both time and distance (path length) to the 
platform were recorded as functional measures of spatial memory over the testing 
days and the number of times to cross the platform location during the probe trial.  
4.2.5 Mitochondrial respiration 
Mitochondria were isolated from a separate cohort of animals using a differential 
preparation method at 24 hours after injury, with slight alterations from Patel et al72,
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134. Animals were euthanized with CO2 inhalation and the brain was rapidly removed. 
Following a brief rinse of the surface of the cortex with ice cold isolation buffer (1 
mM EGTA, 215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, pH 7.2 
adjusted with KOH), a cortical punch was taken from the area immediately 
surrounding the injury epicenter in the ipsilateral cortex. A cortical punch was also 
taken from either the sham cortex or the contralateral cortex. The sham or 
contralateral cortices were utilized to control for any plate-to-plate differences within 
the assay. The tissue was homogenized in 1mL of cold isolation buffer using a downs 
homogenizer. Isolation buffer was added to samples to a total of 2mL and spun at 
1300 x g for 3 minutes at 4°C. Supernatant was transferred to new tubes and filled to 
2mL with isolation buffer. The pellet was resuspended in 500µL of isolation buffer 
and spun again at 1300 x g for 3 minutes at 4°C. The resulting supernatant was 
transferred to a new tube and filled to 2mL with isolation buffer. The two sets of 
supernatants from the two different spins were then spun at 13,000 x g for 10 
minutes. The supernatant was discarded and the resultant pellet was resuspended in 
400µL of isolation buffer. Samples were then placed in a cell disruption nitrogen 
bomb to release mitochondria contained within synaptosomes at 1200 psi for 10 
minutes. Total mitochondria were then spun at 10,000 x g for 10 minutes. The 
resulting pellet was resuspended in 100µL of isolation buffer without EGTA (as listed 
above without EGTA added).  
Mitochondrial viability was assayed by measuring respiration rates using the 
Seahorse XF Extracellular Flux Analyzer (Seahorse Bioscience). Each plate contains 
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24 wells, allowing for up to 8 samples to be run in either duplicate or triplicate on 
each plate. To control for plate-to-plate variation in signal by the Seahorse 
Bioscience, each sample was normalized to the sham control within the same plate. A 
total of 15µg of isolated mitochondria was added to each well in the plate. Any 
preparations that resulted in a respiratory control ratio (RCR) of <5 for the 
contralateral or sham samples were not included in further analysis. The RCR is the 
ratio of State III/State IV oxygen consumption rates.  
4.2.6 Immunohistochemistry 
Animal cohorts that were used in behavioral testing were euthanized after the final 
behavioral assessment at 15 days post injury. Animals were injected with an overdose 
of sodium pentobarbital (150mg/kg, i.p.). Once an appropriate depth of anesthesia 
was determined based on a non-response with toe-pinch, a thoracotomy was 
performed. Animals were transcardially perfused with ice-cold 1X phosphate-
buffered saline (PBS) (approximately 200mL), followed by cold 4% 
paraformaldehyde (approximately 250mL). Following perfusion, whole brain was 
removed and placed into a post-fixative solution of 4% PFA for 24 hours at 4°C. 
Then brains were transferred to 30% sucrose for 3 days for cryoprotection. Brains 
were sectioned using a sliding microtome in 50µm sections in the coronal plane. 
Sections were kept in a series of 10, ensuring that each set of sections was 
representative of tissue at 500µm apart. Sections were stored in a cryoprotective 
solution (30% ethylene glycol, 30% sucrose in 1X PBS) until staining. Sections were 
mounted to slides (Fisher SuperFrost Plus, Fisher Scientific) and dehydrated first with 
chloroform + 95% ethanol (EtOH). Sections were then rehydrated using increasing 
84 
dilutions of EtOH with water. Slides were then stained with cresyl violet stain and 
serially dehydrated with increasing concentrations of EtOH, followed by Citrisolv. 
Slides were cover slipped with Permount (Fisher Scientific) and allowed to dry 
overnight prior to imaging. Spared tissue was evaluated as a percentage of the healthy 
tissue on the contralateral side.   
Tissue sections analyzed for the presence of gluial fibrillary acidic protein (GFAP), a 
marker of astrocytic activation, were transferred from cryoprotectant solution into 
TBS. Free floating sections were blocked for 1 hour with 1% normal horse serum at 
room temperature and then incubated in the primary antibody for GFAP (Mouse anti-
GFAP, 1:50,000, Millipore) overnight at room temperature. After washes in Tris-
buffered saline (TBS), anti-GFAP was bound to the secondary antibody conjugated to 
biotin (1:5000 Jackson Immunoresearch) for 1 hour at room temperature. Slices were 
treated with peroxidase conjugated streptavidin (1:1000, Jackson Immunoresearch) 
and then detected using 3,3’-diaminobenzidine (DAB, Jackson Immunoresearch) for 
5 minutes. Slides were allowed to dry overnight and then dehydrated with increasing 
concentrations of EtOH, then xylene, and cover slipped with Permount (Fisher 
Scientific). 
4.2.7 Glutathione peroxidase activity 
Glutathione peroxidase (GPx) enzyme activity was determined using a glutathione 
peroxidase assay kit (Cayman Chemical). In naïve animals, the left cortex was 
homogenized in 1mL of ice-cold buffer (50mM Tris-HCL, pH 7.5, 5mM EDTA, 
1mM DTT). In injured animals, a portion of the ipsilateral and contralateral cortex 
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homogenized for mitochondrial analysis was set aside for GPx activity. These 
samples were further homogenized with the homogenization buffer buffer containing 
(1mM DTT). The samples were then centrifuged at 10,000 x g for 15 minutes at 4°C. 
Samples were loaded onto a 96-well plate along with other buffers provided with the 
kit. The assay was activated with cumene hydroperoxide and immediately read for 
absorbance at 340nm every minute for 5 total minutes. The assay measures the 
oxidation of NADPH to NADP+, which results in a decrease in absorbance at 340nm. 
Each sample was run in duplicate or triplicate on the plate. The overall rate of change 
in absorbance values were calculated using the following equation (A indicates 
absorbance): 
∆𝐴/min =   
𝐴 𝑇𝑖𝑚𝑒  2 − 𝐴(𝑇𝑖𝑚𝑒  1)
𝑇𝑖𝑚𝑒  2 𝑚𝑖𝑛. − 𝑇𝑖𝑚𝑒  1  (𝑚𝑖𝑛. )
The change in absorbance was averaged across all wells for each sample. The rate of 
change (ΔA/min) for the background wells was then subtracted from values for the 
samples. The following formula was used to calculate the GPx activity:  
𝐺𝑃𝑥  𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =   
∆𝐴/𝑚𝑖𝑛
0.00373𝜇𝑀!! 𝑥
0.19𝑚𝐿
0.02𝑚𝐿 𝑥  𝑠𝑎𝑚𝑝𝑙𝑒  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 =
𝑛𝑚𝑜𝑙
𝑚𝑖𝑛 /𝑚𝐿 
The constant (0.00373µM-1) is the NADPH extinction coefficient and was applied to 
all samples according to the above formula. After the GPx activity was calculated for 
each sample, the activity was also adjusted for protein concentration of the sample.  
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4.2.8 Statistics 
Data presented in each figure are shown as mean±standard error of the mean (SEM). 
For all experiments, significance was set as α=0.05. Using GraphPad Prism 6.0, 
differences between mitochondrial respiration data were calculated using either a 
Student’s t-test (Figure 4.1) or a one-way ANOVA (Figure 4.6) depending on the 
number of variables being tested. Each state of mitochondrial respiration was 
analyzed separately as each is a separate measure, using distinct substrates. Data 
generated from MWM behavioral testing was evaluated using either a 2-way, 
repeated measures ANOVA when examining the time and distance to the platform 
over the 4 training days or a 2-way ANOVA when analyzing the significance in the 
4th day of training and probe test data (Figure 4.2 and Figure 4.8). Differences in 
cortical tissue sparing and GFAP between control and SP1 animals were calculated 
using a Student’s t-test (Figure 4.3). Tissue selenium content was analyzed using a 
repeated measure, one-way ANOVA for the time course supplementation data, or a 
one-way ANOVA for the selenium levels for each diet after 4 weeks of 
supplementation (Figure 4.4). A one-way ANOVA was used to analyze differences 
between overall caloric content and final weight gain of animals maintained on the 4 
different diets, with multiple comparisons to the selenium deficient diet (Figure 4.5). 
Significance of data on GPx activity was calculated using either a one-way ANOVA 
for naïve animals and for samples taken from injured isolated mitochondrial 
preparations (Figure 4.7A, B). No statistical analysis was performed on data for GPx 
activity in the injured cortex as the sample size was too small to accurately run 
statistics (Figure 4.7C, D). 
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4.3 Results 
4.3.1 Mitochondrial respiration (16 weeks of dietary supplementation) 
When examining mitochondrial respiration 24 hours post-injury, those animals on the 
selenium enriched diet showed improvement in the different states of respiration 
tested. When the endogenous substrates, pyruvate/malate and ADP, were added to 
isolated injured mitochondria a significant improvement in OCR in mitochondria 
isolated from animals maintained on the selenium enriched diet (Figure 4.2A). 
Mitochondrial samples were then manipulated with oligomycin and FCCP. These 
substrates mimic maximal mitochondrial respiration, State V complex I driven 
respiration. When normalized to sham controls, animals maintained on the selenium 
enriched diet showed significant increase in oxygen consumption as compared to 
control animals (Figure 4.2B). Substrates rotenone and succinate were then added to 
the samples. Rotenone acts to inhibit complex I in the electron transport chain, 
allowing succinate to supply complex II (mitochondrial respiration as State V, 
complex II). Mitochondria isolated from animals maintained on the selenium 
supplementation showed improved State V, complex II respiration following injury 
when compared to control animals (Figure 4.2C). 
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Figure 4.2:  Mitochondrial respiration following injury in animals maintained on 
different dietary levels of selenium. Animals were fed diets for 16 weeks (n=4 for 
all injured/sham). OCR is expressed as a percentage of sham levels within the same 
plate to account for plate-to-plate variability. A) Dietary enrichment with selenium 
(SP1) improved State III mitochondrial respiration following the addition of ADP and 
pyruvate/malate. B) Increased selenium improved State V-complex I driven 
mitochondrial respiration following the addition of FCCP. C) Animals with increased 
selenium exhibited improved mitochondrial respiration through complex II in State 
V-complex II respiration after the addition of rotenone and succinate. Error bars 
represent SEM, *p≤0.05 
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4.3.2 Spatial memory following injury (16 weeks of dietary supplementation) 
Behavioral training began 10 days following injury and included 4 days of training 
followed by a probe test on the 5th day. Both the time and distance to the sunken 
platform were recorded as a measure of spatial memory and learning within the 
Morris Water Maze (MWM) task. Sham animals showed no difference in spatial 
memory between different dietary levels of selenium. Injured animals on the selenium 
enriched diet (SP1) showed an overall trend over the four days towards shorter time 
and distance to platform discovery when compared to the control diet injured group 
(Figure 4.3A and 4.3B). When examining the final day of training (Day 4), the 
selenium enriched group had a significantly shorter distance to platform discovery 
(Figure 4.3D). While the time to the platform was not significantly shorter between 
injured animals on the selenium diet and control diet injured animals, the data shows 
a trend toward improvement in the selenium enriched group (Figure 4.3C). On the 
fifth day of MWM testing, the platform was removed as part of the probe test. The 
total number of times the animal crossed the original location of the platform was 
recorded as a final measure of spatial memory. The data presented represents the total 
number of platform crossings within the first 15 and 30 seconds after being placed in 
the pool. Probe data indicates a trend towards improvement after injury in animals 
supplemented with selenium after both 15 and 30 seconds but does not reach 
statistical significance (Figure 4.3E and 4.3F).  
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Figure 4.3: Selenium improves performance in behavioral testing after injury. 
Overall performance on MWM task during four training days and final probe test 
(n=7 control injured group, n=8 SP1 injured group, n=6 sham groups). One animal in 
control injured group was euthanized due to complications from surgery. A, B) Sham 
animals showed no difference in the time or distance to the platform over the four 
training days. In injured animals, those supplemented with selenium exhibited an 
overall improvement in the time and distance to discovery of the platform over the 
four training days. C) On day 4, the time to the platform discovery appeared to 
improve in injured animals supplemented with selenium, however did not reach 
significance. D) On day 4, the distance to the platform was improved in injured 
animals with the enriched selenium diet when compared to injured animals on the 
control diet. Sham animals did not show any differences between dietary groups. E, 
F) During the probe test, animals on the selenium enriched diet found the location of
the platform similar to sham animals within 15 and 30 seconds of being placed in the 
testing pool. However, due to variability, this did not reach statistical significance. 
Error bars represent SEM, *p≤0.05. 
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4.3.3 Tissue histology 
Brain tissue collected from animals that were utilized for MWM testing was 
examined for overall lesion volume and astrocyte activation following injury. At 15 
days after the initial CCI injury, cell death begins to occur and typically a lesion 
results in the area of the impact. In this data, selenium enrichment did not provide any 
protection from cell loss leading to a lesion in the cortex (Figure 4.4A). Additionally, 
astrocyte activation following injury is not significantly different between the animals 
maintained on the two different diets (Figure 4.4B). 
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Figure 4.4: Selenium does not improve cortical tissue sparing or astrocyte 
activation following injury. Overall cortical tissue sparing and astrocyte activation 
shown in coronal sections (50µm) in the injured cortex. A) Animals maintained on 
the selenium enriched diet (SP1) did not show any improvement in cortical tissue 
sparing. Additionally, the moderate injury (1.75mm impact depth) did not result in a 
large amount of lesion in the cortex. B) Astrocyte activation, as measured by GFAP 
staining, did not show any significant differences between the two dietary groups. 
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4.3.4 Different time periods and supplementation dosages 
Due to the promising results seen after 16 weeks of selenium enrichment, the time 
course and dietary dosage were examined to determine the shortest length of 
supplementation time necessary for protective effects. Shortening the 
supplementation time frame helped to simplify the time constraints for laboratory 
experiments and may potentially be beneficial for translation of this supplement in the 
clinical setting. LC-MS analysis showed that selenium levels increased significantly 
in the CNS as early as 2 weeks following dietary enrichment (Figure 4.5A and 4.5B). 
For further experiments, the 4 week supplementation time period was selected. To 
expand the scope of our studies, we added two additional dietary dosage levels for 4 
week dietary supplementation (selenium deficient and increased selenium, SP2). The 
selenium deficient diet decreased overall tissue storage of selenium in the cerebral 
cortex and the SP2 diet further increased cortical selenium levels (Figure 4.5C).  
The diets were adjusted so that caloric content was similar among the different diets. 
However, upon close examination of the nutritional content, the selenium deficient 
diet contained a large difference in different micronutrient content. In order to 
formulate the diet into pellets, a large amount of corn oil was added to the torula yeast 
based diet. Additionally, high levels of choline are present in this diet (Appendix H). 
While the caloric content consumed by the animals was relatively equal, the 
differences in micronutrients within the diet as well as the large amount of corn oil 
confound any potential conclusions that can be drawn from this data. 
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The slightly different composition of the selenium deficient diet may be of concern 
when considering specific components, but the overall weight gain and calories 
consumed by animals on these diets showed no significant differences (Figure 4.6A 
and 4.6B).  
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Figure 4.5: Selenium tissue levels are altered relative to time of dietary 
supplementation and level of selenium in the diet. A) Cerebral cortex levels at 
different time points of supplementation in naïve animals. (n=5) As early as 2 weeks 
of supplementation with increased selenium (SP1), tissue selenium levels were 
increased in cortex. This level continued to increase over 16 weeks of 
supplementation. B) Spinal cord selenium levels at different time points of 
supplementation in naïve animals. (n=5) Selenium tissue levels were increased at 2 
weeks and continued to increase over 16 weeks of supplementation with SP1 diet. C) 
The time point of 4 weeks of supplementation was selected for further dietary 
supplementation studies. (n=6) Studies were widened to include additional dietary 
levels of selenium, including a diet deficient in selenium and one increased level of 
selenium. Tissue levels of selenium were altered relative to the amount of selenium 
present in the diet. The tissue levels in animals on the control, SP1, and SP2 diets 
were increased relative to those maintained on the selenium deficient diet. Error bars 
represent SEM, *p≤0.05, **p≤0.001 
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Figure 4.6: Dietary composition did not significantly alter the caloric intake, but 
did change weight gain. A) Average number of kcal consumed per cage, per week (2 
animals housed in each cage). (n=3 cages, calories representative of calories for 2 
animals) The different diets did not have a significant effect on the total number of 
calories the animals consumed. B) Final weight of animals prior to surgery (n=6). The 
weights of animals in the selenium deficient diet group were significantly different 
from animals in the control, SP1, and SP2 groups. However, because the weight 
difference was less than 20% of animals in the other group, the difference was not a 
concern for animal care and surgical techniques. Error bars represent SEM, *p≤0.05 
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4.3.5 Mitochondrial respiration (4 weeks of supplementation) 
To examine the effects of the 4 different levels of dietary selenium over 4 weeks of 
supplementation on mitochondrial function, following injury we utilized a more 
severe injury (2.2mm impact depth). Due to modest mitochondrial protective effects 
seen at a less severe injury (1.75mm) in previous experiments, the injury severity was 
increased in these studies and similar parameters were tested in an effort to 
demonstrate a more robust effect of selenium treatment. At 24 hours following injury, 
cortical mitochondria isolated from the area immediately surrounding the injury 
(ipsilateral) showed damaged mitochondrial respiration in comparison to the 
contralateral side. In these experiments the contralateral cortical mitochondria was 
used as an in-plate control. The ipsilateral mitochondria, when expressed as a 
percentage of the contralateral side did not replicate the protective effects of selenium 
enrichment seen previously from the 16 week supplementation time period (Figure 
7A, B, C). While it is clear that the selenium deficient diet exacerbated the injury 
effect, the additional levels of selenium did not provide additional protection from 
injury. The increased detriment to respiration in animals on the selenium deficient 
diet does, however, emphasize the importance of selenium in the CNS following 
injury. Interestingly, this effect persisted throughout the three different states of 
respiration tested (Figures 7A, 6B, 6C).  
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Figure 4.7: Mitochondrial respiration in injured cortex following 4 weeks of 
dietary supplementation. OCR is expressed as a percentage of the contralateral 
cortex samples within the same plate to account for plate-to-plate variability. (n=7 for 
all injured/sham) A) Selenium enrichment did not improve mitochondrial respiration 
through State III driven respiration (A), State V-Complex I driven respiration (B), or 
State V-complex II driven respiration (C). There is a clear trend exhibiting 
exacerbation of the injury effect in animals maintained on the selenium deficient diet. 
However, this was not statistically significant (α=0.05). Error bars represent SEM. 
O
xy
ge
n 
co
ns
um
pt
io
n 
(p
m
ol
es
/m
in
)
%
 o
f c
on
tra
la
te
ra
l s
id
e
Se
De
f
Co
nt
ro
l D
iet SP
1
SP
2
0.0
0.2
0.4
0.6
0.8
1.0
SeDef
Control Diet
SP1
SP2
A
State III
O
xy
ge
n 
co
ns
um
pt
io
n 
(p
m
ol
es
/m
in
)
%
 o
f c
on
tra
la
te
ra
l s
id
e
Se
De
f
Co
nt
ro
l
SP
1
SP
2
0.0
0.2
0.4
0.6
0.8
1.0
SeDef
Control
SP1
SP2
B
State V complex I
O
xy
ge
n 
co
ns
um
pt
io
n 
(p
m
ol
es
/m
in
)
%
 o
f c
on
tra
la
te
ra
l s
id
e
Se
De
f
Co
nt
ro
l
SP
1
SP
2
0.0
0.2
0.4
0.6
0.8
1.0
SeDef
Control
SP1
SP2
C
State V complex II
99 
4.3.6 GPx activity with different levels of selenium supplementation 
After being maintained on 4 different levels of selenium supplementation for 4 
weeks, naïve cortex samples showed no significant changes in glutathione peroxidase 
(GPx) activity (Figure 4.8A). Animals receiving the selenium deficient diet, exhibited 
a slight decrease in GPx activity, but deficient conditions were not sufficient to 
impact overall GPx activity.  
Following severe (2.2mm impact depth) TBI, GPx activity in crude mitochondrial 
preparations had very little difference in activity levels between the dietary groups 
(Figure 4.8B). The dietary source was not enough to drive a change in GPx activity or 
potentially the sample utilized for these studies did not represent total cellular GPx 
activity and thus is not conclusive of the effect on overall GPx activity within the 
injured cortex. 
In a small cohort of animals, we also tested GPx activity following injury in isolated 
cortical samples from both the ipsilateral injured cortex as well as the contralateral 
cortex. Due to limitations of available diet, the number of animals included in this 
experiment was not large enough to run statistical analysis. These animals did 
however demonstrate a trend towards a rise in GPx activity following injury (Figure 
4.8C). Additionally, when examining only the ipsilateral cortex, it is clear that the 
first level of enriched dietary selenium (SP1) increases GPx activity at the highest 
level in comparison to other dietary levels of selenium (Figure 4.8D).  
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Figure 4.8: Glutathione peroxidase activity in both naïve and traumatic brain 
injured animals. A) Naïve animals showed no changes in overall GPx activity 
despite 4 weeks of differing dietary levels of selenium (n=6). B) Samples from 
isolated crude mitochondria following injury showed no changes relative to dietary 
selenium content. (n=5) C) All 4 dietary sources show a distinct injury effect. There 
is an increase in GPx activity in the ipsilateral cortex at 24 hours after TBI. Ipsilateral 
(ipsi) and contralateral (contra) cortical tissue levels are shown for each dietary 
group. (n=2) D) Within the cerebral cortex data (C), the ipsilateral cerebral cortex 
showed an increase specifically with the first level of enriched selenium dietary level 
(SP1). Due to a small number of animals within each group, no statistics were run on 
this data. (n=2)  
Naïve
G
P
x 
ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Se
De
f
Co
nt
ro
l
SP
1
SP
2
0
50
100
150
SeDef
Control
SP1
SP2
A Injured mitochondria
G
P
x 
ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Se
De
f
Co
nt
ro
l
SP
1
SP
2
0
20
40
60
SeDef
Control
SP1
SP2
B
G
P
x 
ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Se
De
f -
 Ip
si
Se
De
f -
 C
on
tra
Co
nt
ro
l -
 Ip
si
Co
nt
ro
l -
 C
on
tra
SP
1 -
 Ip
si
SP
1 -
 C
on
tra
SP
2 -
 Ip
si
SP
2 -
 C
on
tra
0
100
200
300
400
500
SeDef - Ipsi
SeDef - Contra
Control - Ipsi
Control - Contra
SP1 - Ipsi
SP1 - Contra
SP2 - Ipsi
SP2 - Contra
C Cerebral cortex
Ipsilateral cerebral cortex
G
P
x 
ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
Se
De
f
Co
nt
ro
l
SP
1
SP
2
0
100
200
300
400
500
SeDef
Control
SP1
SP2
D
101 
4.3.7 Spatial memory following injury (4 weeks of supplementation) 
Due to a lack of effect in comparison to the SP1 diet in mitochondrial and GPx data, 
the highest level of selenium enrichment (SP2) was eliminated from the behavioral 
studies. After 4 weeks of dietary supplementation and a severe CCI injury, animals 
showed an injury effect during testing in the Morris Water Maze task (Figure 4.9A, 
B). The selenium deficient and SP1 groups exhibited the expected injury effect in the 
time and distance to platform discovery. The confounding results in these behavioral 
studies are that the control sham group performed poorly in the 4 days of MWM 
training and testing. Additionally, these animals showed the lowest number of 
platform crossings out of all sham animals during probe testing (Figure 4.9E, F). The 
previously observed improvements in time and distance to platform discovery in 
animals maintained on the selenium enriched diet were not replicated in this current 
study (Figure 4.9C, D). While an injury effect is apparent between the selenium 
deficient and SP1 groups, any significant improvements in spatial memory between 
injured animals on these diets were not apparent. 
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Figure 4.9: Selenium supplementation over 4 weeks does not improve spatial 
memory following injury. Overall performance on Morris Water Maze task is shown 
following TBI and 4 weeks of dietary supplementation (n=10 all injury groups, n=5 
selenium deficient sham, n=6 control and SP1 shams). One animal in the selenium 
deficient sham group was euthanized due to complications from surgery. A, B) Sham 
animals showed an overall improvement in comparison to injured animals. The sham 
animals maintained on the control diet were an exception, however, and did not show 
improvements over the 4 days of training in the time or distance to platform 
discovery. C, D) On day 4, the time and distance to platform discovery showed a 
significant injury effect but no differences due to diet within the injured group. 
Control sham animals did significantly worse in locating the sunken platform on day 
4. E, F) Number of times animals crossed the platform location within 15 and 30
seconds with probe testing showed an injury effect but no significant differences due 
to diet. Error bars represent SEM. 
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4.4 Discussion 
Selenoproteins play a critical role in several different pathways essential for human 
health. Of the approximately 25 selenoproteins that have been currently identified, 
these proteins have roles in immune function47, antioxidant systems2, and selenium 
transport to tissues21. The CNS prioritizes storage of selenium in deficient conditions, 
underlining the importance of maintaining selenium levels in the brain and spinal 
cord7. These findings, along with many studies that have emphasized the role of 
selenium in neurological diseases such as AD, Parkinson’s disease, and spinal cord 
injury, support our original hypothesis that enriching dietary selenium levels prior to 
injury will protect mitochondria and improve pathological outcomes following TBI, 
while a deficiency in dietary selenium would exacerbate observed injury effects. 
Animals that were fed the selenium enriched diet (SP1) for a long supplementation 
period of 16 weeks showed modest improvements in both mitochondrial respiration 
and spatial memory deficits. The improvements in mitochondrial respiration, in 
particular, are suggestive of neuroprotection provided by enriched level of selenium 
in the diet. These effects were carried over and also seen in the spatial memory tasks 
at a longer time point after injury. The data indicate that long term dietary selenium 
enrichment may provide neuroprotection in neurodegenerative models.  
To examine the length of time necessary to achieve these neuroprotective benefits, 
the time course studies examined selenium tissue storage over four different lengths 
of supplementation. Selenium levels within the CNS were increased as early as after 2 
weeks of dietary supplementation. The 4-week time period was chosen for future 
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studies. This represents a supplementation period that will simplify future laboratory 
experiments and also shorten the necessary time frame for supplementation in human 
clinical application. Additionally, to further expand the scope examined in these 
studies, two other doses of selenium levels were added. The selenium deficient diet 
and 2ppm selenium diet (SP2), when added to the control and 1ppm selenium diet 
(SP1) provide data on the physiologic response from a variety of dietary doses of 
selenium.  
Animals supplemented with the four different levels of dietary selenium for four 
weeks prior to receiving a CCI injury, unfortunately did not repeat the mitochondrial 
protective effect that was previously observed over the longer (16 week) 
supplementation time frame. While there is a clear trend for the exacerbation of the 
injury effect for animals deficient in selenium, the other groups tested did not show 
any improvements in mitochondrial respiration. These data suggest little 
neuroprotection occurs with short term selenium supplementation and no additional 
protective mechanisms are noted between supplemented animals and those with 
sufficient dietary selenium levels present.  
Due to the critical nature of selenium in the formation of the selenoprotein, 
glutathione peroxidase, we hypothesized that dietary selenium enrichment would 
increase the activity of glutathione peroxidase, particularly following injury. Naïve 
animals on different levels of dietary selenium, including deficient conditions, did not 
show any changes in overall GPx activity. After injury, no changes in GPx activity 
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were observed in isolated mitochondrial preparation. While this preparation was a 
crude mitochondrial sample and may have contained a small amount of other cellular 
fractions, these samples may not have contained enough cytoplasmic GPx to properly 
ascertain how GPx activity was changed in these circumstances. A small cohort of 
animals showed that following TBI, GPx activity is increased in the ipsilateral cortex. 
GPx activity was the highest in animals receiving the SP1 diet, suggesting that this 
dose of dietary selenium improved the function of the antioxidant enzyme, GPx. 
However, due to the small size of this group of animals, further testing is required to 
make definitive conclusions about this data. 
While tissue storage levels were increased significantly in the CNS, the lack of 
mitochondrial protection and behavioral outcomes following four weeks of 
supplementation suggests that this time frame may not be long enough to create the 
physiological changes necessary for neuroprotection. If selenium is modulating gene 
expression, down stream effects may take longer to occur, despite the increase in 
tissue selenium. It is also possible that the method used to measure selenium levels 
(LC-MS), while incredibly precise, may not be sufficient to determine physiological 
activity of selenium in these tissues. Further studies examining the exact speciation of 
selenoproteins in the supplemented central nervous system tissues may be needed to 
ascertain the exact mechanism through which selenized yeast is affecting 
mitochondrial respiration.  
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CHAPTER 5 
Discussion and Concluding Remarks 
Identification of improved treatments for CNS trauma continues to be a clinical issue 
of great significance. With approximately 270,000 people sustaining a spinal cord 
injury (SCI)121 and 3.17 million with a traumatic brain injury (TBI)66 each year in the 
United States, understanding more about the pathology of this disease is critical for 
millions of patients in this country and worldwide. Certain groups of people are at 
higher risk for neurological injuries. With a rise in TBIs among soldiers returning 
from recent conflicts in Iraq and Afghanistan and growing concern surrounding sports 
related concussions, pretreatment strategies in the form of a safe, dietary supplement, 
such as selenium, could be of particular interest for these groups. 
The action of selenium in several antioxidant enzymes, as well as its established role 
in preventing neurodegeneration in other CNS disorders, led to the hypothesis that 
prophylactic dietary selenium treatment would attenuate molecular degeneration and 
provide overall neuroprotection in the event of an injury. The results from the studies 
described herein have only shown modest improvement in the different neurotrauma 
models investigated. Further studies are still warranted to ascertain whether selenium 
is a viable pretreatment for CNS trauma.  
5.1 Pretreatment with Selenium in Spinal Cord Injury 
Following 16 weeks of prophylactic treatment with selenized yeast and a moderate 
contusive SCI, selenized yeast did significantly improve the number of days to 
recovery of bladder function. However, treatment was unable to preserve locomotor 
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deficits or rescue the overall lesion volume normally observed after this injury model. 
Any neuroprotective effects that selenium may have imparted through gene 
expression changes or through alteration of selenoprotein status was not strong 
enough to prevent degradation of spinal locomotor associated neurons, but may have 
prevented cell death in those spinal cord cell bodies or supporting glia responsible for 
innervation of bladder function. 
When expanded to consider the effect of selenium on transcriptional regulation, 
selenized yeast differentially altered gene expression patterns 24 hours after moderate 
contusive SCI. Analysis methods for dealing with the large quantity of data produced 
by microarray gene expression can vary greatly from study to study. The template 
analysis described here recapitulated similar gene pathways changed with injury that 
have been previously published supporting the validity of our analysis method. 
Expression patterns in which selenium supplementation increased gene expression as 
compared to control injured groups, included genes involved with mitochondrial 
respiration/function and protein turnover were significantly up regulated following 
injury. Additionally, expression patterns of genes that returned to sham levels with 
selenium supplementation included genes associated with transcriptional regulation, 
as well as cell cycle control. These two particular expression patterns support a 
potential neuroprotective effect of dietary selenium enrichment and agrees with 
current literature in which certain selenoproteins have recently been characterized as 
a redox regulator specific to mitochondria37.  
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5.2 Selenium in Traumatic Brain Injury 
The results from dietary enrichment with selenium prior to SCI were interesting and 
led to further investigation of other models of neurotrauma. In order to eliminate any 
potential confounding neuroprotective effects of estrogen, only male rats were 
contused using the controlled cortical impact (CCI) device133. Following 16 weeks of 
supplementation, selenium provided modest neuroprotection following TBI as 
measured by mitochondrial respiration and behavioral assessment. Selenium 
enrichment improved mitochondrial respiration 24 hours post-injury in testing ADP 
phosphorylation and during maximal electron transport (complex I and II driven) 
respiration, as well as improved spatial memory. Due to the extended 
supplementation period, we wanted to investigate the time course and dosage needed 
to see neuroprotective effects. Selenium levels in the CNS were increased with 
enrichment at 4 weeks following injury. Different dosages of selenium in the diets 
showed changes in selenium levels within the CNS relative to the dose present in the 
diet. Shortening the supplementation period to 4 weeks increased storage of selenium 
in the CNS, however, the modest neuroprotection seen after 16 weeks of 
supplementation did not recapitulate with the shorter time frame of supplementation. 
While the diet deficient in selenium appeared to be detrimental to mitochondrial 
respiration, the neuroprotective effect on injured mitochondria seen after 16 weeks 
with selenium enrichment was not evident after only 4 weeks of supplementation. 
When examining behavioral pathologies at a more chronic time point the deficient 
diet continued to exacerbate the injury effect, but selenium enrichment did not 
provide any improvements in spatial memory as compared to the control injured 
animals.  
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5.3 Future Directions 
These studies indicate that while 16 weeks of selenium supplementation improves 
mitochondrial function and behavioral outcomes in TBI by providing modest 
improvements in SCI models, but 4 weeks may not be long enough to induce 
noticeable neuroprotective effects in animal models of neurotrauma. Transcriptional 
changes can occur quickly within different cellular systems, depending on the 
stimulus driving the change. Supplementation studies indicated increased tissue levels 
of selenium at early time points suggesting potential downstream effects of enriched 
selenium tissue levels may require longer periods of increased tissue levels. It is not 
surprising that SCI induces a vast response of expressional changes soon after injury. 
CNS trauma triggers a host of cellular responses, including influx of different 
inflammatory molecules. The presence of these different cell types is solitarily 
sufficient to create substantial changes in gene expression. Selenium, however, builds 
up in the tissues as short as 2 weeks after supplementation and may require an even 
longer to change enzyme levels or trigger downstream signaling cascades.  
Selenium is typically stored in tissues in the form of selenomethionine and can be 
broken down into the intermediate compound, selenide, for selenoprotein synthesis. 
Uniquely beneficial selenoproteins may take longer to build up within tissues. Exact 
speciation of selenoproteins that are increased within the CNS following dietary 
enrichment may provide critical information in further elucidating this mechanism. 
Further testing is required to determine whether shorter time frames, such as 8 or 12 
weeks of supplementation prior to injury, are sufficient to provide neuroprotective 
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benefits. Other models using various treatments for CNS disorders, such as anti-
depressants, require long-term treatment before patients experience any noticeable 
changes in symptoms. Much like the proposed mechanism for these drugs, selenium 
could be inducing transcriptional changes, but the translational modifications and 
alterations in protein levels within the CNS may take longer to reach levels sufficient 
to confer neuroprotection. 
An alternative hypothesis for the mechanism of action of selenium within the CNS is 
through modulation of gene expression pathways associated with DNA repair. One of 
the significantly upregulated pathways from our microarray analysis indicated that 
selenium enrichment increased expression of DNA repair pathways following injury. 
This data is interesting in light of other experiments that support the role of selenium 
in DNA oxidation. McKelvey and colleagues showed that organic selenium 
compounds (including selenized yeast as used for these studies) protected against 
DNA damage as well as altered expression patterns in DNA damage functional 
pathways40. Additionally, studies using AD mouse models also showed in vvio 
decreases in DNA and RNA oxidation in animals supplemented with increased levels 
of dietary selenium34. Barger and colleagues detected improvements in DNA damage 
gene pathways39. Specifically, selenized yeast reduced the expression of the DNA 
damage inducing gene, Gadd45b. The current study supports these previous findings 
and suggests that selenium may play a role in modulating transcriptional changes in 
gene involved with DNA repair following traumatic SCI. Up regulation of specific 
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genes within this pathway prior to injury could lead to an improved response in the 
secondary injury cascade that follows CNS trauma. 
Long term dietary selenium enrichment provided modest neuroprotection following 
CNS injury, supporting our original hypothesis. However, a shorter supplementation 
time frame did not recapitulate these findings. While it appeared that the presence of 
selenium was beneficial for mitochondrial health in comparison to deficient 
conditions, there was no additional protective effect with increased levels of 
selenium. In shorter time frames, increased levels of selenium may not confer 
additional neuroprotection when compared to normal dietary selenium. Further 
investigation into treatment time frames for use in neurodegenerative disorders may 
still be warranted.  
While the rationale for these studies was well supported by current literature, dietary 
selenium enrichment did not provide overwhelming support for the use of selenium as 
a prophylactic against CNS trauma. The acute nature of a CNS insult may overwhelm 
the potential protective effects gained from selenium supplementation. However, the 
modest neuroprotective role of selenium may be beneficial for chronic models of 
neurodegeneration. Alzheimer’s disease, which is characterized by a slow onset, has 
shown that selenium provides protective effects in preclinical trials34, 57. Currently, a 
clinical trial is underway examining the potential neuroprotective role of selenium 
and vitamin E for Alzheimer’s disease (clinicaltrials.gov: NCT00040378). The 
presence of critical nutrients, such as selenium, is known to be crucial for maintaining 
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normal health and may alter the neurodegenerative pathologies that ultimately lead to 
disease.  
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APPENDICES 
Appendix A: List of acronyms and abbreviations 
3’ UTR 3’	  untranslated	  region	  
AD Alzheimer’s	  Disease	  
ANOVA 	  analysis	  of	  variance	  
ApoE2 apolipoprotein	  E	  receptor	  2	  
BBB Basso,	  Beattie,	  Bresnahan	  locomotor	  score	  
CCI controlled	  cortical	  impact	  injury	  
CNS central	  nervous	  system	  
CVB3 coxsackie	  virus	  
ETC electron	  transport	  chain	  
EtOH ethanol	  
GFAP glial	  fibrillary	  acidic	  protein	  
GPx glutathione	  peroxidase	  
LC-MS liquid	  chromatography	  mass	  spectrometry	  
LD50 average	  lethal	  dose	  
MPTP mitochondrial	  permeability	  transition	  pore	  
MWM Morris	  Water	  Maze	  
NOAEL No	  observed	  adverse	  effect	  level	  
OCR oxygen	  consumption	  rate	  
PUFA polyunsaturated	  fatty	  acids	  
RDA Recommended	  Dietary	  Allowance	  
RfD Reference	  dose	  
ROS reactive	  oxygen	  species	  
SBP2 SECIS	  binding	  protein	  
SCI spinal	  cord	  injury	  
Sec selenocysteine	  
SECIS selenocysteine	  insertion	  sequence	  
SeCys selenocysteine	  (amino	  acid)	  
SeDef selenium	  deficient	  
SelO selenoprotein	  O	  
SelP selenoprotein	  P	  
SelS selenoprotein	  S	  
SEM standard	  error	  of	  the	  mean	  
SeMet selenomethionine	  
SP1 control	  diet	  +	  1ppm	  selenized	  yeast	  
SP2 control	  diet	  +	  2ppm	  selenized	  yeast	  
TBI traumatic	  brain	  injury	  
tRNAMet transfer	  RNA	  for	  methionine	  
UL tolerable	  upper	  intake	  level	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Appendix B: Genes increased in expression in injured animals on selenium 
enriched diets 
Affymetrix 
probe set ID Gene ID Description 
1390124_at Fam98b family with sequence similarity 98, member B 
1379254_at Tmem183a transmembrane protein 183A 
1373745_at Gtf2h4 general transcription factor II H, polypeptide 4 
1370225_at Cited4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 
1369327_at Pdzd2 PDZ domain containing 2 
1382751_at Wfdc10 WAP four-disulfide core domain 10 
1392719_at Mthfs 5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclo-ligase) 
1372942_at Exosc5 exosome component 5 
1392351_at Fpgt fucose-1-phosphate guanylyltransferase 
1389604_at Hspa12b heat shock protein 12B 
1376145_at Eif2b5 eukaryotic translation initiation factor 2B, subunit 5 epsilon 
1379015_at Foxj2 forkhead box J2 
1396674_at Gpr44 G protein-coupled receptor 44 
1399007_at Cog2 component of oligomeric golgi complex 2 
1395406_at Sbno1 Strawberry notch homolog 1 (Drosophila) 
1399108_at Dis3l DIS3 mitotic control homolog (S. cerevisiae)-like 
1370087_at Rab2a RAB2A, member RAS oncogene family 
1374715_at Wdr70 WD repeat domain 70 
1399092_at LOC100361208 transmembrane protein 39b 
1388506_at Dsp desmoplakin 
1383729_at LOC303566 E2F1-inducible gene 
1392828_at Med12 mediator complex subunit 12 
1388156_at Plcb3 phospholipase C, beta 3 (phosphatidylinositol-specific) 
1373429_at Atf6b activating transcription factor 6 beta 
1377532_at Phf20 PHD finger protein 20 
1377383_at Efs embryonal Fyn-associated substrate 
1369969_at Parp1 poly (ADP-ribose) polymerase 1 
1382151_at Trub1 TruB pseudouridine (psi) synthase homolog 1 (E. coli) 
1369685_at Twist2 twist homolog 2 (Drosophila) 
1371015_at Mx1 myxovirus (influenza virus) resistance 1 
1381816_at Rnls renalase, FAD-dependent amine oxidase 
1398943_at Lage3 L antigen family, member 3 
1368379_at Scarb2 scavenger receptor class B, member 2 
1372494_a_at Hmg20b high mobility group 20 B 
1387605_at Casp12 caspase 12 
1382175_at Wtap Wilms tumor 1 associated protein 
1373138_at Nudt5 nudix (nucleoside diphosphate linked moiety X)-type motif 5 
1368441_at Msln mesothelin 
1378079_at Golga3 golgi autoantigen, golgin subfamily a, 3 
1398944_at Acin1 apoptotic chromatin condensation inducer 1 
1377801_at Btbd12 BTB (POZ) domain containing 12 
1370005_at Cyb5b cytochrome b5 type B (outer mitochondrial membrane) 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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1372152_at Alg14 asparagine-linked glycosylation 14 homolog (S. cerevisiae) 
1368355_at Myo5b myosin Vb 
1389061_at Nsun5 NOL1/NOP2/Sun domain family, member 5 
1382083_at Coch coagulation factor C homolog, cochlin (Limulus polyphemus) 
1393745_at Orc3l origin recognition complex, subunit 3-like (yeast) 
1372305_at Copz2 coatomer protein complex, subunit zeta 2 
1387037_at Cubn cubilin (intrinsic factor-cobalamin receptor) 
1393017_at Rhpn1 rhophilin, Rho GTPase binding protein 1 
1385189_at Duoxa1 dual oxidase maturation factor 1 
1374704_at Kdelc2 KDEL (Lys-Asp-Glu-Leu) containing 2 
1372431_at Mrpl12 mitochondrial ribosomal protein L12 
1395325_s_at Mmgt1 membrane magnesium transporter 1 
1390933_a_at Rg9mtd3 RNA (guanine-9-) methyltransferase domain containing 3 
1395881_at Dap Death-associated protein 
1369714_at Dnajc14 DnaJ (Hsp40) homolog, subfamily C, member 14 
1371611_at Ext2 exostoses (multiple) 2 
1387531_at Msra methionine sulfoxide reductase A 
1379949_at Tfb1m transcription factor B1, mitochondrial 
1390105_at B4galt2 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 
1371442_at Hyou1 hypoxia up-regulated 1 
1388141_at Cetn3 centrin, EF-hand protein, 3 (CDC31 homolog, yeast) 
1370651_a_at Inppl1 inositol polyphosphate phosphatase-like 1 
1375439_at Wdr18 WD repeat domain 18 
1392116_at Sike suppressor of IKK epsilon 
1380360_at Oma1 OMA1 homolog, zinc metallopeptidase (S. cerevisiae) 
1372323_at Sardh sarcosine dehydrogenase 
1388959_at Ttll12 Tubulin tyrosine ligase-like family, member 12 
1390385_at Glce glucuronic acid epimerase 
1383692_at Prelid2 PRELI domain containing 2 
1374555_at Acbd6 acyl-Coenzyme A binding domain containing 6 
1393317_at Thumpd3 THUMP domain containing 3 
1389089_at Slc39a7 solute carrier family 39 (zinc transporter), member 7 
1391768_at Psmc4 proteasome (prosome, macropain) 26S subunit, ATPase, 4 
1390141_at Mthfd1l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
1370941_at Pdgfra platelet derived growth factor receptor, alpha polypeptide 
1374517_at Recql RecQ protein-like (DNA helicase Q1-like) 
1368341_at Polb polymerase (DNA directed), beta 
1394403_at Spata20 spermatogenesis associated 20 
1375042_at Alg8 asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog 
1376493_at Commd7 COMM domain containing 7 
1383391_a_at C2 complement component 2 
1378178_at Smc6 structural maintenance of chromosomes 6 
1374767_at Npepo aminopeptidase O 
1392033_a_at Pank2 pantothenate kinase 2 (Hallervorden-Spatz syndrome) 
1376192_at Nat9 N-acetyltransferase 9 (GCN5-related, putative) 
1372320_at Msl3 male-specific lethal 3 homolog (Drosophila) 
1388913_at Ppap2c phosphatidic acid phosphatase type 2c 
1372127_at Ubap2 ubiquitin-associated protein 2 
1377787_at Rbm6 RNA binding motif protein 6 
1370835_at Tox4 TOX high mobility group box family member 4 
1373239_at Snx33 sorting nexin 33 
1378150_at LOC100363332 caspase recruitment domain family, member 11 
1383107_at Snrpd1 small nuclear ribonucleoprotein D1 
1367859_at Tgfb3 transforming growth factor, beta 3 
1387233_at Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 
1391455_at Zc3h18 zinc finger CCCH-type containing 18 
1386006_at Larp7 La ribonucleoprotein domain family, member 7 
1391004_at Svil Supervillin 
1373000_at Srpx2 sushi-repeat-containing protein, X-linked 2 
1382396_at Ubfd1 ubiquitin family domain containing 1 
1378165_at Twist1 twist homolog 1 (Drosophila) 
1369412_a_at Slc19a1 solute carrier family 19 (folate transporter), member 1 
1370374_at Steap3 STEAP family member 3 
1367974_at Anxa3 annexin A3 
1368571_at Clip2 CAP-GLY domain containing linker protein 2 
1399114_at Gtf2e2 general transcription factor IIE, polypeptide 2, beta 
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Appendix C: Genes down regulated in injury and restored to sham levels with 
selenium supplementation 
Affymetrix 
Probeset ID Gene Description 
1398660_at Slc35f2 solute carrier family 35, member F2 
1387209_at Sec16b SEC16 homolog B (S. cerevisiae) 
1392162_at Pspc1 Paraspeckle component 1 
1370202_at Pla2g16 phospholipase A2, group XVI 
1387083_at Ctf1 cardiotrophin 1 
1382462_at L2hgdh L-2-hydroxyglutarate dehydrogenase 
1369508_at Kcnj15 potassium inwardly-rectifying channel, subfamily J, member 15 
1371590_s_at Ubl5 ubiquitin-like 5 
1374604_at Mfsd9 major facilitator superfamily domain containing 9 
1374328_at C2cd3 C2 calcium-dependent domain containing 3 
1368069_at Sharpin SHANK-associated RH domain interactor 
1390926_at Zswim3 zinc finger, SWIM-type containing 3 
1387105_at Zfp422 zinc finger protein 422 
1386346_at Tmem19 transmembrane protein 19 
1385296_at Trmt12 tRNA methyltransferase 12 homolog (S. cerevisiae) 
1380118_at Fdxacb1 ferredoxin-fold anticodon binding domain containing 1 
1389452_at Zdhhc8 zinc finger, DHHC-type containing 8 
1397284_at Zfp444 zinc finger protein 444 
1374115_at Mzf1 myeloid zinc finger 1 
1385899_at Trim16 tripartite motif-containing 16 
1378092_at Mdp1 magnesium-dependent phosphatase 1 
1373308_at Sgsm3 small G protein signaling modulator 3 
1395820_at Rnf150 Ring finger protein 150 
1384324_at Rbm4 RNA binding motif protein 4 
1369233_at Kcnk10 potassium channel, subfamily K, member 10 
1387137_at Comp cartilage oligomeric matrix protein 
1375666_at Dmtf1 cyclin D binding myb-like transcription factor 1 
1393632_at C1qtnf7 C1q and tumor necrosis factor related protein 7 
1387232_at Bmp4 bone morphogenetic protein 4 
1389433_at Mkks McKusick-Kaufman syndrome 
1394842_at Tmem19 transmembrane protein 19 
1384217_at Zhx2 Zinc fingers and homeoboxes 2 
1388660_at Mcts1 malignant T cell amplified sequence 1 
1376088_at Slc25a19 solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 
1374309_at Radil Ras association and DIL domains 
1388760_at Slc35b4 solute carrier family 35, member B4 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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1367797_at Men1 multiple endocrine neoplasia 1 
1368159_at Abcb6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
1376106_at Tmem178 transmembrane protein 178 
1367953_at Tyro3 TYRO3 protein tyrosine kinase 
1371645_at Sdf2 stromal cell derived factor 2 
1374658_at Iqsec2 IQ motif and Sec7 domain 2 
1383668_at Mmp15 matrix metallopeptidase 15 
1373020_at Magmas 
mitochondria-associated protein involved in granulocyte-macrophage colony-
stimulating factor signal transduction 
1369113_at Grem1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 
1396022_at Zfp322a Zinc finger protein 322a 
1372105_at Efha1 EF-hand domain family, member A1 
1390098_at N6amt2 N-6 adenine-specific DNA methyltransferase 2 (putative) 
1367550_a_at Tm2d1 TM2 domain containing 1 
1368891_at Gnpat glyceronephosphate O-acyltransferase 
1372819_at Cog4 component of oligomeric golgi complex 4 
1371548_at Mrps25 mitochondrial ribosomal protein S25 
1372927_at Mrpl50 mitochondrial ribosomal protein L50 
1374020_at Lrrc38 leucine rich repeat containing 38 
1370540_at Nr1d2 nuclear receptor subfamily 1, group D, member 2 
1374188_at Sec62 SEC62 homolog (S. cerevisiae) 
1392189_at Rfx4 Regulatory factor X, 4 (influences HLA class II expression) 
1371586_at Mrpl48 mitochondrial ribosomal protein L48 
1367815_at Slc5a6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 
1373952_at Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
1389792_at Solh small optic lobes homolog (Drosophila) 
1385810_at Lrtomt leucine rich transmembrane and 0-methyltransferase domain containing 
1397541_at Twsg1 twisted gastrulation homolog 1 (Drosophila) 
1379484_at Aven apoptosis, caspase activation inhibitor 
1389662_at Wnk4 WNK lysine deficient protein kinase 4 
1399125_at Inpp1 inositol polyphosphate-1-phosphatase 
1376909_at Rasl10a RAS-like, family 10, member A 
1383049_at Klhl8 kelch-like 8 (Drosophila) 
1377961_at Zfhx3 zinc finger homeobox 3 
1389703_at Zzef1 zinc finger, ZZ-type with EF hand domain 1 
1389044_at Gbf1 golgi-specific brefeldin A resistant guanine nucleotide exchange factor 1 
1378158_at Brms1 breast cancer metastasis-suppressor 1 
1371979_at Srebf2 sterol regulatory element binding transcription factor 2 
1385473_x_at Tomm40b translocase of outer mitochondrial membrane 40 homolog B (yeast) 
1380641_at Pcdhb6 protocadherin beta 6 
1381783_at Akap3 A kinase (PRKA) anchor protein 3 
1391775_at Zpbp2 zona pellucida binding protein 2 
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Appendix D: Genes increased with injury and restored to sham levels with 
selenium supplementation  
Affymetrix 
Probeset 
ID Gene Description 
1394731_at Csnk1g3 casein kinase 1, gamma 3 
1368866_at Eif2c2 eukaryotic translation initiation factor 2C, 2 
1382523_at Dpm1 dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit 
1384957_at Atf6 activating transcription factor 6 
1393822_at Tmcc3 transmembrane and coiled-coil domain family 3 
1370485_a_at Bcl2l1 Bcl2-like 1 
1393738_s_at Mfhas1 malignant fibrous histiocytoma amplified sequence 1 
1398648_at Mfhas1 malignant fibrous histiocytoma amplified sequence 1 
1397302_at Zmynd11 zinc finger, MYND domain containing 11 
1382103_at Pgm3 phosphoglucomutase 3 
1379409_at Atxn7 Ataxin 7 
1375121_at Smad6 SMAD family member 6 
1395261_at Snrnp70 small nuclear ribonucleoprotein 70 (U1) 
1368961_at Mmp23 matrix metallopeptidase 23 
1375085_at Slc25a35 solute carrier family 25, member 35 
1396078_at Krit1 KRIT1, ankyrin repeat containing 
1384348_at Tcf23 transcription factor 23 
1369347_s_at Prom2 prominin 2 
1391303_at Purb purine rich element binding protein B 
1392542_at Cdc42se2 CDC42 small effector 2 
1389364_at Ndfip2 Nedd4 family interacting protein 2 
1387484_at Tgfbr3 transforming growth factor, beta receptor III 
1377919_at Arhgap10 Rho GTPase activating protein 10 
1395441_at Pcbp4 poly(rC) binding protein 4 
1391787_at Traf3ip3 TRAF3 interacting protein 3 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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1395015_at F8 coagulation factor VIII, procoagulant component 
1374021_at Wipi1 WD repeat domain, phosphoinositide interacting 1 
1384050_at Bub3 budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) 
1371103_at Rab6a RAB6A, member RAS oncogene family 
1387638_a_at Ctla4 cytotoxic T-lymphocyte-associated protein 4 
1387410_at Nr4a2 nuclear receptor subfamily 4, group A, member 2 
1387533_at Pspn persephin 
1394518_at Adamts9 
A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin 
type 1 motif, 9 
1370974_at Vps54 vacuolar protein sorting 54 homolog (S. cerevisiae) 
1389088_at Adnp activity-dependent neuroprotector homeobox 
1393593_at Mar6 membrane-associated ring finger (C3HC4) 6 
1381804_at Bcl6b B-cell CLL/lymphoma 6, member B (zinc finger protein) 
1369912_at Crk v-crk sarcoma virus CT10 oncogene homolog (avian) 
1386721_at Znf503 zinc finger protein 503 
1385502_at Trim21 Tripartite motif-containing 21 
1391128_at Bcl9l B-cell CLL/lymphoma 9-like 
1375228_at Brd2 bromodomain containing 2 
1397473_at Dtnbp1 distrobrevin binding protein 1 
1393843_at Fem1b fem-1 homolog b (C. elegans) 
1382203_at Gdf1 growth differentiation factor 1 
1390531_at Pric285 peroxisomal proliferator-activated receptor A interacting complex 285 
1384773_at Ubtd2 ubiquitin domain containing 2 
1367770_at Degs1 degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) 
1389184_at Rpp30 ribonuclease P/MRP 30 subunit (human) 
1376294_at Smcr7 Smith-Magenis syndrome chromosome region, candidate 7 homolog (human) 
1379668_at Alg11 
asparagine-linked glycosylation 11, alpha-1,2-mannosyltransferase homolog 
(yeast) 
1369571_at Golph3 golgi phosphoprotein 3 (coat-protein) 
1369862_at Pim1 pim-1 oncogene 
1394749_at Atg7 ATG7 autophagy related 7 homolog (S. cerevisiae) 
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Appendix E: Genes increased in sham animals on selenium enriched diets 
Affymetrix 
Probeset 
ID Gene Description 
1372243_at Cab39 calcium binding protein 39 
1369179_a_at Pparg peroxisome proliferator-activated receptor gamma 
1388058_at Taf6 TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor 
1394838_at Aoc3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 
1389037_at Rit1 Ras-like without CAAX 1 
1369634_at Slc4a1 solute carrier family 4 (anion exchanger), member 1 
1387043_at Lypd3 Ly6/Plaur domain containing 3 
1378435_at Art4 ADP-ribosyltransferase 4 
1368755_at Clec4f C-type lectin domain family 4, member f 
1368102_at Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 
1371066_at Snrk SNF related kinase 
1384890_at Ezh1 enhancer of zeste homolog 1 (Drosophila) 
1369192_at Cdkn1b cyclin-dependent kinase inhibitor 1B 
1368879_a_at Gnao1 
guanine nucleotide binding protein (G protein), alpha activating activity 
polypeptide O 
1368144_at Rgs2 regulator of G-protein signaling 2 
1396749_at Cabp1 calcium binding protein 1 
1369232_at Kcnk10 potassium channel, subfamily K, member 10 
1398948_at Tax1bp1 Tax1 (human T-cell leukemia virus type I) binding protein 1 
1369510_at Gapdhs glyceraldehyde-3-phosphate dehydrogenase, spermatogenic 
1376953_at Unc5cl unc-5 homolog C (C. elegans)-like 
1372036_at Cd2bp2 Cd2 (cytoplasmic tail) binding protein 2 
1386883_at Gsk3a glycogen synthase kinase 3 alpha 
1370983_at Pou6f1 POU class 6 homeobox 1 
1396711_at Obsl1 Obscurin-like 1 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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1368859_at Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 
1397866_at Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, member 6b 
1369809_at Htr1a 5-hydroxytryptamine (serotonin) receptor 1A 
1394764_at Lmtk2 lemur tyrosine kinase 2 
1391075_at Rgs17 regulator of G-protein signaling 17 
1395232_at Dcaf6 DDB1 and CUL4 associated factor 6 
1384645_at Toag1 tolerance-associated gene 1 
1398614_at Ptch1 patched homolog 1 (Drosophila) 
1376992_a_at Ccdc84 coiled-coil domain containing 84 
1369660_at Defb1 defensin beta 1 
1370268_at Kcna5 potassium voltage-gated channel, shaker-related subfamily, member 5 
1398289_a_at Crhr1 corticotropin releasing hormone receptor 1 
1369016_at Cdon Cdon homolog (mouse) 
1393337_at Tcfcp2l1 transcription factor CP2-like 1 
1395990_at Srcap Snf2-related CREBBP activator protein 
1370753_at Olr1078 olfactory receptor 1078 
1386280_at Mettl7b methyltransferase like 7B 
1379550_a_at Gtf2ird1 GTF2I repeat domain containing 1 
1384975_at Ermp1 endoplasmic reticulum metallopeptidase 1 
1384933_at Slc18a2 Solute carrier family 18 (vesicular monoamine), member 2 
1393436_at Scgb1c1 secretoglobin, family 1C, member 1 
1375494_a_at Nlgn3 neuroligin 3 
1392340_at Klhl3 kelch-like 3 (Drosophila) 
1397211_at Grb10 growth factor receptor bound protein 10 
1387828_at Agap2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 
1382024_at Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6 
1397716_at Klhdc2 Kelch domain containing 2 
1369359_at Il9r interleukin 9 receptor 
1369188_at Fbxo32 F-box protein 32 
1369864_a_at Sds serine dehydratase 
1389834_at Nudt8 Nudix (nucleoside diphosphate linked moiety X)-type motif 8 
1398267_at Slc22a7 solute carrier family 22 (organic anion transporter), member 7 
1388613_at Isca1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae) 
1369287_at Syt9 synaptotagmin IX 
1396158_at Rem1 RAS (RAD and GEM)-like GTP-binding 1 
1398314_at Hoxd3 homeo box D3 
1387672_at Gnmt glycine N-methyltransferase 
1379456_at Mcart1 mitochondrial carrier triple repeat 1 
1379203_at Tfdp2 transcription factor Dp-2 (E2F dimerization partner 2) 
1379264_at Znrf2 zinc and ring finger 2 
1392079_at Akap7 A kinase (PRKA) anchor protein 7 
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1392976_at Tpm2 tropomyosin 2, beta 
1368077_at Fbp1 fructose-1,6-bisphosphatase 1 
1387322_at Sema6b 
sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6B 
1368788_at Chad chondroadherin 
1368334_at Grb7 growth factor receptor bound protein 7 
1369017_at Kcnh6 potassium voltage-gated channel, subfamily H (eag-related), member 6 
1384978_at Klk1c10 T-kininogenase 
1388238_at Defa24 defensin, alpha, 24 
1393474_at Sult2b1 sulfotransferase family, cytosolic, 2B, member 1 
1376274_at Btbd10 BTB (POZ) domain containing 10 
1387267_at Ntf3 neurotrophin 3 
1393390_at Shd Src homology 2 domain-containing transforming protein D 
1389496_at Akap7 A kinase (PRKA) anchor protein 7 
1387999_at Slc18a1 solute carrier family 18 (vesicular monoamine), member 1 
1372280_at Asb2 ankyrin repeat and SOCS box-containing 2 
1392474_at Ulk2 Unc-51 like kinase 2 (C. elegans) 
1380453_at Zswim5 zinc finger, SWIM domain containing 5 
1371165_a_at Atp2a3 ATPase, Ca++ transporting, ubiquitous 
1368837_at Arid4b AT rich interactive domain 4B (Rbp1 like) 
1385130_at Fezf2 Fez family zinc finger 2 
1387215_at Agxt alanine-glyoxylate aminotransferase 
1370129_at Mgea5 meningioma expressed antigen 5 (hyaluronidase) 
1387512_at Zfp238 zinc finger protein 238 
1387388_at Chp calcium binding protein p22 
1385740_at Lrrc27 leucine rich repeat containing 27 
1384397_x_at Crb3 crumbs homolog 3 (Drosophila) 
1378278_at Pou2f2 POU class 2 homeobox 2 
1369446_at Cry2 cryptochrome 2 (photolyase-like) 
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Appendix F: Genes increased with selenium supplementation, regardless of 
injury  
Affymetrix 
Probeset 
ID Gene Description 
1379197_at Cacna1h Calcium channel, voltage-dependent, T type, alpha 1H subunit 
1369011_at Apoa5 apolipoprotein A-V 
1395026_at Fmo4 flavin containing monooxygenase 4 
1389884_at Ccdc88b coiled-coil domain containing 88B 
1393689_at Ndufaf1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 1 
1395579_at Dhx32 DEAH (Asp-Glu-Ala-His) box polypeptide 32 
1373313_at Sel1l Sel-1 suppressor of lin-12-like (C. elegans) 
1368205_at Cfi complement factor I 
1368317_at Aqp7 aquaporin 7 
1387250_at Pla2g10 phospholipase A2, group X 
1388478_at Tbl1x transducin (beta)-like 1 X-linked 
1389115_at Evpl envoplakin 
1369385_at Afap1 actin filament associated protein 1 
1374119_at Elf3 E74-like factor 3 
1393651_at Galnt10 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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Appendix G: Genes decreased with selenium supplementation, regardless of 
injury  
Affymetrix 
Probeset 
ID Gene Description 
1384133_at Kif1a kinesin family member 1A 
1391625_at Wasl Wiskott-Aldrich syndrome-like 
1399132_at Cul3 cullin 3 
1387117_at Zranb2 zinc finger, RAN-binding domain containing 2 
1388064_a_at Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 
1375641_at Arpc5l actin related protein 2/3 complex, subunit 5-like 
1369095_at Ppp1r9a protein phosphatase 1, regulatory (inhibitor) subunit 9A 
1389912_at Ensa endosulfine alpha 
1377798_at Tchp trichoplein, keratin filament binding 
1380121_at Nek7 NIMA (never in mitosis gene a)-related kinase 7 
1369046_at Syt6 synaptotagmin VI 
1391820_at Tanc2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 
1369177_at Pi4k2a phosphatidylinositol 4-kinase type 2 alpha 
1368450_at Myo5a myosin VA 
1386547_at Tanc2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 
1393324_at Jam2 junctional adhesion molecule 2 
1398533_at Cyfip2 cytoplasmic FMR1 interacting protein 2 
1382981_at Ahi1 Abelson helper integration site 1 
1389874_at Zrsr1 zinc finger (CCCH type), RNA binding motif and serine/arginine rich 1 
1391285_at Zfyve9 zinc finger, FYVE domain containing 9 
1368750_a_at Pde4d 
phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce 
homolog, Drosophila) 
1376347_at Kdm5b lysine (K)-specific demethylase 5B 
1394626_at Hmbox1 homeobox containing 1 
1376843_at Bmpr2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
-­‐1.5	  
-­‐1.0	  
-­‐0.5	  
0.0	  
0.5	  
1.0	  
1.5	  
CS	   CI	   SS	   SI	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1384376_at Dnajb14 DnaJ (Hsp40) homolog, subfamily B, member 14 
1385970_at Ctr9 Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 
1376739_at Ddx24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 
1369310_at Basp1 brain abundant, membrane attached signal protein 1 
1369008_a_at Olfm1 olfactomedin 1 
1395399_at Zcchc17 zinc finger, CCHC domain containing 17 
126 
Appendix H: Dietary nutrient information 
Diet	  
Nutrient	   Selenium	  Deficient	   Control	  	   SP1	   SP2	  
Kcal/g	   4.3	   3.1	   3.1	   3.1	  
Protein	  (%	  by	  weight)	   15.3	   16.2	   16.2	   16.2	  
CHO	  (%	  by	  weight)	   57.9	   52.8	   52.8	   52.8	  
Fat	  (%	  by	  weight)	   14.9	   3.6	   3.6	   3.6	  
Selenium	  (ppm)	   0	   0.3	   1.3	   2.3	  
	  Micronutrients	  
(g/kg)	  
Choline	   2.8	   1.03	   1.03	   1.03	  
Niacin	   0.03	   0.075	   0.075	   0.075	  
Pantothenic	  Acid	   0.016	   33	   33	   33	  
Vitamin	  B6	   0.007	   0.018	   0.018	   0.018	  
Vitamin	  B1	   0.006	   0.017	   0.017	   0.017	  
Vitamin	  B2	   0.006	   0.015	   0.015	   0.015	  
Folate	   0.002	   0.004	   0.004	   0.004	  
Biotin	   0.0002	   0.0004	   0.0004	   0.0004	  
Vitamin	  B12	   0.025	   0.00008	   0.00008	   0.00008	  
Vitamin	  E	   0.1	   0.11	   0.11	   0.11	  
Vitamin	  K	   0.003	   0.05	   0.05	   0.05	  
Additional	  additives	   Selenium	  Deficient	  
Sucrose	  (g/kg)	   537	  
Corn	  oil	  (g/kg)	   140	  
Torula	  yeast	  (g/kg)	   300	  
127 
REFERENCES 
1. Fairweather-­‐Tait	  SJ,	  Bao	  Y,	  Broadley	  MR,	  et	  al.	  Selenium	  in	  human	  health
and	  disease.	  Antioxidants	  &	  redox	  signaling	  2011;14:1337-­‐1383.	  
2. Kryukov	  GV,	  Castellano	  S,	  Novoselov	  SV,	  et	  al.	  Characterization	  of
mammalian	  selenoproteomes.	  Science	  2003;300:1439-­‐1443.	  
3. Reeves	  WC,	  Marcuard	  SP,	  Willis	  SE,	  Movahed	  A.	  Reversible
cardiomyopathy	  due	  to	  selenium	  deficiency.	  JPEN	  Journal	  of	  parenteral	  and	  
enteral	  nutrition	  1989;13:663-­‐665.	  
4. Li	  Q,	  Liu	  M,	  Hou	  J,	  Jiang	  C,	  Li	  S,	  Wang	  T.	  The	  prevalence	  of	  Keshan	  disease
in	  China.	  International	  journal	  of	  cardiology	  2013;168:1121-­‐1126.	  
5. Thomson	  CD.	  Assessment	  of	  requirements	  for	  selenium	  and	  adequacy	  of
selenium	  status:	  a	  review.	  European	  journal	  of	  clinical	  nutrition	  2004;58:391-­‐
402.	  
6. Combs	  GF,	  Jr.,	  Clark	  LC,	  Turnbull	  BW.	  An	  analysis	  of	  cancer	  prevention	  by
selenium.	  BioFactors	  2001;14:153-­‐159.	  
7. Burk	  RF,	  Brown	  DG,	  Seely	  RJ,	  Scaief	  CC,	  3rd.	  Influence	  of	  dietary	  and
injected	  selenium	  on	  whole-­‐blody	  retention,	  route	  of	  excretion,	  and	  tissue	  
retention	  of	  75SeO3	  2-­‐	  in	  the	  rat.	  The	  Journal	  of	  nutrition	  1972;102:1049-­‐1055.	  
8. Dietary	  Reference	  Intakes	  for	  Vitamin	  C,	  Vitamin	  E,	  Selenium,	  and
Carotenoids.	  Washington	  (DC)2000.	  
9. Patterson	  BH,	  Levander	  OA.	  Naturally	  occurring	  selenium	  compounds	  in
cancer	  chemoprevention	  trials:	  a	  workshop	  summary.	  Cancer	  epidemiology,	  
biomarkers	  &	  prevention	  :	  a	  publication	  of	  the	  American	  Association	  for	  Cancer	  
Research,	  cosponsored	  by	  the	  American	  Society	  of	  Preventive	  Oncology	  
1997;6:63-­‐69.	  
10. Beck	  MA,	  Nelson	  HK,	  Shi	  Q,	  et	  al.	  Selenium	  deficiency	  increases	  the
pathology	  of	  an	  influenza	  virus	  infection.	  FASEB	  journal	  :	  official	  publication	  of	  
the	  Federation	  of	  American	  Societies	  for	  Experimental	  Biology	  2001;15:1481-­‐
1483.	  
11. Hurwitz	  BE,	  Klaus	  JR,	  Llabre	  MM,	  et	  al.	  Suppression	  of	  human
immunodeficiency	  virus	  type	  1	  viral	  load	  with	  selenium	  supplementation:	  a	  
randomized	  controlled	  trial.	  Archives	  of	  internal	  medicine	  2007;167:148-­‐154.	  
12. Yang	  GQ,	  Wang	  SZ,	  Zhou	  RH,	  Sun	  SZ.	  Endemic	  selenium	  intoxication	  of
humans	  in	  China.	  The	  American	  journal	  of	  clinical	  nutrition	  1983;37:872-­‐881.	  
13. Longnecker	  MP,	  Taylor	  PR,	  Levander	  OA,	  et	  al.	  Selenium	  in	  diet,	  blood,
and	  toenails	  in	  relation	  to	  human	  health	  in	  a	  seleniferous	  area.	  The	  American	  
journal	  of	  clinical	  nutrition	  1991;53:1288-­‐1294.	  
14. Cummins	  LM,	  Kimura	  ET.	  Safety	  evaluation	  of	  selenium	  sulfide
antidandruff	  shampoos.	  Toxicology	  and	  applied	  pharmacology	  1971;20:89-­‐96.	  
15. Salbe	  AD,	  Levander	  OA.	  Comparative	  toxicity	  and	  tissue	  retention	  of
selenium	  in	  methionine-­‐deficient	  rats	  fed	  sodium	  selenate	  or	  L-­‐
selenomethionine.	  The	  Journal	  of	  nutrition	  1990;120:207-­‐212.	  
16. Griffiths	  JC,	  Matulka	  RA,	  Power	  R.	  Acute	  and	  subchronic	  toxicity	  studies
on	  Sel-­‐Plex,	  a	  standardized,	  registered	  high-­‐selenium	  yeast.	  International	  journal	  
of	  toxicology	  2006;25:465-­‐476.	  
128 
17. Bierla	  K,	  Bianga	  J,	  Ouerdane	  L,	  Szpunar	  J,	  Yiannikouris	  A,	  Lobinski	  R.	  A
comparative	  study	  of	  the	  Se/S	  substitution	  in	  methionine	  and	  cysteine	  in	  Se-­‐
enriched	  yeast	  using	  an	  inductively	  coupled	  plasma	  mass	  spectrometry	  (ICP	  
MS)-­‐assisted	  proteomics	  approach.	  Journal	  of	  proteomics	  2013;87:26-­‐39.	  
18. Bierla	  K,	  Szpunar	  J,	  Yiannikouris	  A,	  Lobinski	  R.	  Comprehensive	  speciation
of	  selenium	  in	  selenium-­‐rich	  yeast.	  Trends	  in	  Analytical	  Chemistry	  2012;41:122-­‐
132.	  
19. Schrauzer	  GN.	  Selenomethionine:	  a	  review	  of	  its	  nutritional	  significance,
metabolism	  and	  toxicity.	  The	  Journal	  of	  nutrition	  2000;130:1653-­‐1656.	  
20. Vendeland	  SC,	  Deagen	  JT,	  Butler	  JA,	  Whanger	  PD.	  Uptake	  of	  selenite,
selenomethionine	  and	  selenate	  by	  brush	  border	  membrane	  vesicles	  isolated	  
from	  rat	  small	  intestine.	  Biometals	  :	  an	  international	  journal	  on	  the	  role	  of	  metal	  
ions	  in	  biology,	  biochemistry,	  and	  medicine	  1994;7:305-­‐312.	  
21. Burk	  RF,	  Hill	  KE.	  Selenoprotein	  P:	  an	  extracellular	  protein	  with	  unique
physical	  characteristics	  and	  a	  role	  in	  selenium	  homeostasis.	  Annual	  review	  of	  
nutrition	  2005;25:215-­‐235.	  
22. Gronbaek	  H,	  Thorlacius-­‐Ussing	  O.	  Selenium	  in	  the	  central	  nervous	  system
of	  rats	  exposed	  to	  75-­‐Se	  L-­‐selenomethionine	  and	  sodium	  selenite.	  Biological	  
trace	  element	  research	  1992;35:119-­‐127.	  
23. Drake	  EN.	  Cancer	  chemoprevention:	  selenium	  as	  a	  prooxidant,	  not	  an
antioxidant.	  Medical	  hypotheses	  2006;67:318-­‐322.	  
24. Copeland	  PR,	  Fletcher	  JE,	  Carlson	  BA,	  Hatfield	  DL,	  Driscoll	  DM.	  A	  novel
RNA	  binding	  protein,	  SBP2,	  is	  required	  for	  the	  translation	  of	  mammalian	  
selenoprotein	  mRNAs.	  The	  EMBO	  journal	  2000;19:306-­‐314.	  
25. Hatfield	  DL,	  Gladyshev	  VN.	  How	  selenium	  has	  altered	  our	  understanding
of	  the	  genetic	  code.	  Molecular	  and	  cellular	  biology	  2002;22:3565-­‐3576.	  
26. Zhong	  L,	  Holmgren	  A.	  Essential	  role	  of	  selenium	  in	  the	  catalytic	  activities
of	  mammalian	  thioredoxin	  reductase	  revealed	  by	  characterization	  of	  
recombinant	  enzymes	  with	  selenocysteine	  mutations.	  The	  Journal	  of	  biological	  
chemistry	  2000;275:18121-­‐18128.	  
27. Papp	  LV,	  Lu	  J,	  Holmgren	  A,	  Khanna	  KK.	  From	  selenium	  to	  selenoproteins:
synthesis,	  identity,	  and	  their	  role	  in	  human	  health.	  Antioxidants	  &	  redox	  
signaling	  2007;9:775-­‐806.	  
28. Flohe	  L,	  Gunzler	  WA,	  Schock	  HH.	  Glutathione	  peroxidase:	  a
selenoenzyme.	  FEBS	  letters	  1973;32:132-­‐134.	  
29. Brigelius-­‐Flohe	  R.	  Tissue-­‐specific	  functions	  of	  individual	  glutathione
peroxidases.	  Free	  radical	  biology	  &	  medicine	  1999;27:951-­‐965.	  
30. Renko	  K,	  Werner	  M,	  Renner-­‐Muller	  I,	  et	  al.	  Hepatic	  selenoprotein	  P
(SePP)	  expression	  restores	  selenium	  transport	  and	  prevents	  infertility	  and	  
motor-­‐incoordination	  in	  Sepp-­‐knockout	  mice.	  The	  Biochemical	  journal	  
2008;409:741-­‐749.	  
31. Arteel	  GE,	  Mostert	  V,	  Oubrahim	  H,	  Briviba	  K,	  Abel	  J,	  Sies	  H.	  Protection	  by
selenoprotein	  P	  in	  human	  plasma	  against	  peroxynitrite-­‐mediated	  oxidation	  and	  
nitration.	  Biological	  chemistry	  1998;379:1201-­‐1205.	  
 129 
32.	   Peters	  MM,	  Hill	  KE,	  Burk	  RF,	  Weeber	  EJ.	  Altered	  hippocampus	  synaptic	  
function	  in	  selenoprotein	  P	  deficient	  mice.	  Molecular	  neurodegeneration	  
2006;1:12.	  
33.	   Valentine	  WM,	  Hill	  KE,	  Austin	  LM,	  Valentine	  HL,	  Goldowitz	  D,	  Burk	  RF.	  
Brainstem	  axonal	  degeneration	  in	  mice	  with	  deletion	  of	  selenoprotein	  p.	  
Toxicologic	  pathology	  2005;33:570-­‐576.	  
34.	   Lovell	  MA,	  Xiong	  S,	  Lyubartseva	  G,	  Markesbery	  WR.	  Organoselenium	  (Sel-­‐
Plex	  diet)	  decreases	  amyloid	  burden	  and	  RNA	  and	  DNA	  oxidative	  damage	  in	  
APP/PS1	  mice.	  Free	  radical	  biology	  &	  medicine	  2009;46:1527-­‐1533.	  
35.	   Curran	  JE,	  Jowett	  JB,	  Elliott	  KS,	  et	  al.	  Genetic	  variation	  in	  selenoprotein	  S	  
influences	  inflammatory	  response.	  Nature	  genetics	  2005;37:1234-­‐1241.	  
36.	   Fradejas	  N,	  Serrano-­‐Perez	  Mdel	  C,	  Tranque	  P,	  Calvo	  S.	  Selenoprotein	  S	  
expression	  in	  reactive	  astrocytes	  following	  brain	  injury.	  Glia	  2011;59:959-­‐972.	  
37.	   Han	  SJ,	  Lee	  BC,	  Yim	  SH,	  Gladyshev	  VN,	  Lee	  SR.	  Characterization	  of	  
mammalian	  selenoprotein	  o:	  a	  redox-­‐active	  mitochondrial	  protein.	  PloS	  one	  
2014;9:e95518.	  
38.	   Hill	  KE,	  Lyons	  PR,	  Burk	  RF.	  Differential	  regulation	  of	  rat	  liver	  
selenoprotein	  mRNAs	  in	  selenium	  deficiency.	  Biochemical	  and	  biophysical	  
research	  communications	  1992;185:260-­‐263.	  
39.	   Barger	  JL,	  Kayo	  T,	  Pugh	  TD,	  et	  al.	  Gene	  expression	  profiling	  reveals	  
differential	  effects	  of	  sodium	  selenite,	  selenomethionine,	  and	  yeast-­‐derived	  
selenium	  in	  the	  mouse.	  Genes	  &	  nutrition	  2012;7:155-­‐165.	  
40.	   McKelvey	  SM,	  Horgan	  KA,	  Murphy	  RA.	  Chemical	  form	  of	  selenium	  
differentially	  influences	  DNA	  repair	  pathways	  following	  exposure	  to	  lead	  nitrate.	  
Journal	  of	  trace	  elements	  in	  medicine	  and	  biology	  :	  organ	  of	  the	  Society	  for	  
Minerals	  and	  Trace	  Elements	  2015;29:151-­‐169.	  
41.	   Narayan	  V,	  Ravindra	  KC,	  Liao	  C,	  Kaushal	  N,	  Carlson	  BA,	  Prabhu	  KS.	  
Epigenetic	  regulation	  of	  inflammatory	  gene	  expression	  in	  macrophages	  by	  
selenium.	  The	  Journal	  of	  nutritional	  biochemistry	  2015;26:138-­‐145.	  
42.	   Wu	  RT,	  Cao	  L,	  Chen	  BP,	  Cheng	  WH.	  Selenoprotein	  H	  suppresses	  cellular	  
senescence	  through	  genome	  maintenance	  and	  redox	  regulation.	  The	  Journal	  of	  
biological	  chemistry	  2014;289:34378-­‐34388.	  
43.	   Nagy	  E,	  Maquat	  LE.	  A	  rule	  for	  termination-­‐codon	  position	  within	  intron-­‐
containing	  genes:	  when	  nonsense	  affects	  RNA	  abundance.	  Trends	  in	  biochemical	  
sciences	  1998;23:198-­‐199.	  
44.	   Berry	  MJ,	  Banu	  L,	  Chen	  YY,	  et	  al.	  Recognition	  of	  UGA	  as	  a	  selenocysteine	  
codon	  in	  type	  I	  deiodinase	  requires	  sequences	  in	  the	  3'	  untranslated	  region.	  
Nature	  1991;353:273-­‐276.	  
45.	   Lillig	  CH,	  Holmgren	  A.	  Thioredoxin	  and	  related	  molecules-­‐-­‐from	  biology	  
to	  health	  and	  disease.	  Antioxidants	  &	  redox	  signaling	  2007;9:25-­‐47.	  
46.	   Wrobel	  JK,	  Choi	  JJ,	  Xiao	  R,	  et	  al.	  Selenoglycoproteins	  attenuate	  adhesion	  of	  
tumor	  cells	  to	  the	  brain	  microvascular	  endothelium	  via	  a	  process	  involving	  NF-­‐
kappaB	  activation.	  The	  Journal	  of	  nutritional	  biochemistry	  2015;26:120-­‐129.	  
47.	   Hoffmann	  PR,	  Berry	  MJ.	  The	  influence	  of	  selenium	  on	  immune	  responses.	  
Molecular	  nutrition	  &	  food	  research	  2008;52:1273-­‐1280.	  
130 
48. Hawkes	  WC,	  Kelley	  DS,	  Taylor	  PC.	  The	  effects	  of	  dietary	  selenium	  on	  the
immune	  system	  in	  healthy	  men.	  Biological	  trace	  element	  research	  2001;81:189-­‐
213.	  
49. Broome	  CS,	  McArdle	  F,	  Kyle	  JA,	  et	  al.	  An	  increase	  in	  selenium	  intake
improves	  immune	  function	  and	  poliovirus	  handling	  in	  adults	  with	  marginal	  
selenium	  status.	  The	  American	  journal	  of	  clinical	  nutrition	  2004;80:154-­‐162.	  
50. Clark	  LC,	  Combs	  GF,	  Jr.,	  Turnbull	  BW,	  et	  al.	  Effects	  of	  selenium
supplementation	  for	  cancer	  prevention	  in	  patients	  with	  carcinoma	  of	  the	  skin.	  A	  
randomized	  controlled	  trial.	  Nutritional	  Prevention	  of	  Cancer	  Study	  Group.	  Jama	  
1996;276:1957-­‐1963.	  
51. Baliga	  MS,	  Wang	  H,	  Zhuo	  P,	  Schwartz	  JL,	  Diamond	  AM.	  Selenium	  and	  GPx-­‐
1	  overexpression	  protect	  mammalian	  cells	  against	  UV-­‐induced	  DNA	  damage.	  
Biological	  trace	  element	  research	  2007;115:227-­‐242.	  
52. Meuillet	  E,	  Stratton	  S,	  Prasad	  Cherukuri	  D,	  et	  al.	  Chemoprevention	  of
prostate	  cancer	  with	  selenium:	  an	  update	  on	  current	  clinical	  trials	  and	  
preclinical	  findings.	  Journal	  of	  cellular	  biochemistry	  2004;91:443-­‐458.	  
53. Arthur	  JR,	  McKenzie	  RC,	  Beckett	  GJ.	  Selenium	  in	  the	  immune	  system.	  The
Journal	  of	  nutrition	  2003;133:1457S-­‐1459S.	  
54. Bains	  M,	  Hall	  ED.	  Antioxidant	  therapies	  in	  traumatic	  brain	  and	  spinal	  cord
injury.	  Biochimica	  et	  biophysica	  acta	  2012;1822:675-­‐684.	  
55. Dawson	  DA,	  Masayasu	  H,	  Graham	  DI,	  Macrae	  IM.	  The	  neuroprotective
efficacy	  of	  ebselen	  (a	  glutathione	  peroxidase	  mimic)	  on	  brain	  damage	  induced	  by	  
transient	  focal	  cerebral	  ischaemia	  in	  the	  rat.	  Neuroscience	  letters	  1995;185:65-­‐
69.	  
56. Imai	  H,	  Graham	  DI,	  Masayasu	  H,	  Macrae	  IM.	  Antioxidant	  ebselen	  reduces
oxidative	  damage	  in	  focal	  cerebral	  ischemia.	  Free	  radical	  biology	  &	  medicine	  
2003;34:56-­‐63.	  
57. Luo	  Z,	  Liang	  L,	  Sheng	  J,	  et	  al.	  Synthesis	  and	  biological	  evaluation	  of	  a	  new
series	  of	  ebselen	  derivatives	  as	  glutathione	  peroxidase	  (GPx)	  mimics	  and	  
cholinesterase	  inhibitors	  against	  Alzheimer's	  disease.	  Bioorganic	  &	  medicinal	  
chemistry	  2014;22:1355-­‐1361.	  
58. Yeo	  JE,	  Kang	  SK.	  Selenium	  effectively	  inhibits	  ROS-­‐mediated	  apoptotic
neural	  precursor	  cell	  death	  in	  vitro	  and	  in	  vivo	  in	  traumatic	  brain	  injury.	  
Biochimica	  et	  biophysica	  acta	  2007;1772:1199-­‐1210.	  
59. Yeo	  JE,	  Kim	  JH,	  Kang	  SK.	  Selenium	  attenuates	  ROS-­‐mediated	  apoptotic	  cell
death	  of	  injured	  spinal	  cord	  through	  prevention	  of	  mitochondria	  dysfunction;	  in	  
vitro	  and	  in	  vivo	  study.	  Cellular	  physiology	  and	  biochemistry	  :	  international	  
journal	  of	  experimental	  cellular	  physiology,	  biochemistry,	  and	  pharmacology	  
2008;21:225-­‐238.	  
60. Wenstrup	  D,	  Ehmann	  WD,	  Markesbery	  WR.	  Trace	  element	  imbalances	  in
isolated	  subcellular	  fractions	  of	  Alzheimer's	  disease	  brains.	  Brain	  research	  
1990;533:125-­‐131.	  
61. Bellinger	  FP,	  Raman	  AV,	  Rueli	  RH,	  et	  al.	  Changes	  in	  selenoprotein	  P	  in
substantia	  nigra	  and	  putamen	  in	  Parkinson's	  disease.	  Journal	  of	  Parkinson's	  
disease	  2012;2:115-­‐126.	  
131 
62. Burk	  RF,	  Hill	  KE,	  Motley	  AK,	  et	  al.	  Selenoprotein	  P	  and	  apolipoprotein	  E
receptor-­‐2	  interact	  at	  the	  blood-­‐brain	  barrier	  and	  also	  within	  the	  brain	  to	  
maintain	  an	  essential	  selenium	  pool	  that	  protects	  against	  neurodegeneration.	  
FASEB	  journal	  :	  official	  publication	  of	  the	  Federation	  of	  American	  Societies	  for	  
Experimental	  Biology	  2014;28:3579-­‐3588.	  
63. Ellwanger	  JH,	  Molz	  P,	  Dallemole	  DR,	  et	  al.	  Selenium	  reduces	  bradykinesia
and	  DNA	  damage	  in	  a	  rat	  model	  of	  Parkinson's	  disease.	  Nutrition	  2015;31:359-­‐
365.	  
64. Ran	  Q,	  Gu	  M,	  Van	  Remmen	  H,	  Strong	  R,	  Roberts	  JL,	  Richardson	  A.
Glutathione	  peroxidase	  4	  protects	  cortical	  neurons	  from	  oxidative	  injury	  and	  
amyloid	  toxicity.	  Journal	  of	  neuroscience	  research	  2006;84:202-­‐208.	  
65. Burk	  RF,	  Hill	  KE,	  Olson	  GE,	  et	  al.	  Deletion	  of	  apolipoprotein	  E	  receptor-­‐2
in	  mice	  lowers	  brain	  selenium	  and	  causes	  severe	  neurological	  dysfunction	  and	  
death	  when	  a	  low-­‐selenium	  diet	  is	  fed.	  The	  Journal	  of	  neuroscience	  :	  the	  official	  
journal	  of	  the	  Society	  for	  Neuroscience	  2007;27:6207-­‐6211.	  
66. Summers	  CR,	  Ivins	  B,	  Schwab	  KA.	  Traumatic	  brain	  injury	  in	  the	  United
States:	  an	  epidemiologic	  overview.	  The	  Mount	  Sinai	  journal	  of	  medicine,	  New	  
York	  2009;76:105-­‐110.	  
67. Royo	  NC,	  Shimizu	  S,	  Schouten	  JW,	  Stover	  JF,	  McIntosh	  TK.	  Pharmacology
of	  traumatic	  brain	  injury.	  Current	  opinion	  in	  pharmacology	  2003;3:27-­‐32.	  
68. Hall	  ED,	  Vaishnav	  RA,	  Mustafa	  AG.	  Antioxidant	  therapies	  for	  traumatic
brain	  injury.	  Neurotherapeutics	  2010;7:51-­‐61.	  
69. Ankarcrona	  M,	  Dypbukt	  JM,	  Orrenius	  S,	  Nicotera	  P.	  Calcineurin	  and
mitochondrial	  function	  in	  glutamate-­‐induced	  neuronal	  cell	  death.	  FEBS	  letters	  
1996;394:321-­‐324.	  
70. Pandya	  JD,	  Pauly	  JR,	  Nukala	  VN,	  et	  al.	  Post-­‐Injury	  Administration	  of
Mitochondrial	  Uncouplers	  Increases	  Tissue	  Sparing	  and	  Improves	  Behavioral	  
Outcome	  following	  Traumatic	  Brain	  Injury	  in	  Rodents.	  Journal	  of	  neurotrauma	  
2007;24:798-­‐811.	  
71. Brown	  MR,	  Sullivan	  PG,	  Dorenbos	  KA,	  Modafferi	  EA,	  Geddes	  JW,	  Steward
O.	  Nitrogen	  disruption	  of	  synaptoneurosomes:	  an	  alternative	  method	  to	  isolate	  
brain	  mitochondria.	  Journal	  of	  neuroscience	  methods	  2004;137:299-­‐303.	  
72. Sullivan	  PG,	  Krishnamurthy	  S,	  Patel	  SP,	  Pandya	  JD,	  Rabchevsky	  AG.
Temporal	  characterization	  of	  mitochondrial	  bioenergetics	  after	  spinal	  cord	  
injury.	  Journal	  of	  neurotrauma	  2007;24:991-­‐999.	  
73. Spinal	  cord	  injury	  facts	  and	  figures	  at	  a	  glance.	  The	  journal	  of	  spinal	  cord
medicine	  2013;36:394-­‐395.	  
74. Singh	  IN,	  Sullivan	  PG,	  Hall	  ED.	  Peroxynitrite-­‐mediated	  oxidative	  damage
to	  brain	  mitochondria:	  Protective	  effects	  of	  peroxynitrite	  scavengers.	  Journal	  of	  
neuroscience	  research	  2007;85:2216-­‐2223.	  
75. Ansari	  MA,	  Roberts	  KN,	  Scheff	  SW.	  Oxidative	  stress	  and	  modification	  of
synaptic	  proteins	  in	  hippocampus	  after	  traumatic	  brain	  injury.	  Free	  radical	  
biology	  &	  medicine	  2008;45:443-­‐452.	  
76. Xiong	  Y,	  Rabchevsky	  AG,	  Hall	  ED.	  Role	  of	  peroxynitrite	  in	  secondary
oxidative	  damage	  after	  spinal	  cord	  injury.	  Journal	  of	  neurochemistry	  
2007;100:639-­‐649.	  
 132 
77.	   Hall	  ED,	  Detloff	  MR,	  Johnson	  K,	  Kupina	  NC.	  Peroxynitrite-­‐mediated	  
protein	  nitration	  and	  lipid	  peroxidation	  in	  a	  mouse	  model	  of	  traumatic	  brain	  
injury.	  Journal	  of	  neurotrauma	  2004;21:9-­‐20.	  
78.	   Bistrian	  BR,	  Askew	  W,	  Erdman	  JW,	  Jr.,	  Oria	  MP.	  Nutrition	  and	  traumatic	  
brain	  injury:	  a	  perspective	  from	  the	  Institute	  of	  Medicine	  report.	  JPEN	  Journal	  of	  
parenteral	  and	  enteral	  nutrition	  2011;35:556-­‐559.	  
79.	   Sullivan	  PG,	  Geiger	  JD,	  Mattson	  MP,	  Scheff	  SW.	  Dietary	  supplement	  
creatine	  protects	  against	  traumatic	  brain	  injury.	  Annals	  of	  neurology	  
2000;48:723-­‐729.	  
80.	   Senol	  N,	  Naziroglu	  M,	  Yuruker	  V.	  N-­‐acetylcysteine	  and	  selenium	  modulate	  
oxidative	  stress,	  antioxidant	  vitamin	  and	  cytokine	  values	  in	  traumatic	  brain	  
injury-­‐induced	  rats.	  Neurochemical	  research	  2014;39:685-­‐692.	  
81.	   Song	  E,	  Su	  C,	  Fu	  J,	  et	  al.	  Selenium	  supplementation	  shows	  protective	  
effects	  against	  patulin-­‐induced	  brain	  damage	  in	  mice	  via	  increases	  in	  GSH-­‐
related	  enzyme	  activity	  and	  expression.	  Life	  sciences	  2014;109:37-­‐43.	  
82.	   Nuttall	  KL.	  Evaluating	  selenium	  poisoning.	  Ann	  Clin	  Lab	  Sci	  2006;36:409-­‐
420.	  
83.	   Song	  KD,	  Dowd	  SE,	  Lee	  HK,	  Kim	  SW.	  Long-­‐term	  dietary	  supplementation	  
of	  organic	  selenium	  modulates	  gene	  expression	  profiles	  in	  leukocytes	  of	  adult	  
pigs.	  Animal	  science	  journal	  =	  Nihon	  chikusan	  Gakkaiho	  2013;84:238-­‐246.	  
84.	   Salbe	  AD,	  Levander	  OA.	  Comparative	  toxicity	  and	  tissue	  retention	  of	  
selenium	  in	  methionine-­‐deficient	  rats	  fed	  sodium	  selenate	  or	  L-­‐
selenomethionine.	  The	  Journal	  of	  nutrition	  1990;120:207-­‐212.	  
85.	   Spallholz	  JE.	  Free	  radical	  generation	  by	  selenium	  compounds	  and	  their	  
prooxidant	  toxicity.	  Biomedical	  and	  environmental	  sciences	  :	  BES	  1997;10:260-­‐
270.	  
86.	   Spallholz	  JE.	  On	  the	  nature	  of	  selenium	  toxicity	  and	  carcinostatic	  activity.	  
Free	  Radic	  Biol	  Med	  1994;17:45-­‐64.	  
87.	   Burk	  RF,	  Brown	  DG,	  Seely	  RJ,	  Scaief	  CC,	  3rd.	  Influence	  of	  dietary	  and	  
injected	  selenium	  on	  whole-­‐blody	  retention,	  route	  of	  excretion,	  and	  tissue	  
retention	  of	  75SeO3	  2-­‐	  in	  the	  rat.	  The	  Journal	  of	  nutrition	  1972;102:1049-­‐1055.	  
88.	   Burk	  RF,	  Hill	  KE.	  Selenoprotein	  P-­‐expression,	  functions,	  and	  roles	  in	  
mammals.	  Biochim	  Biophys	  Acta	  2009;1790:1441-­‐1447.	  
89.	   Hill	  KE,	  Zhou	  J,	  Austin	  LM,	  et	  al.	  The	  selenium-­‐rich	  C-­‐terminal	  domain	  of	  
mouse	  selenoprotein	  P	  is	  necessary	  for	  the	  supply	  of	  selenium	  to	  brain	  and	  testis	  
but	  not	  for	  the	  maintenance	  of	  whole	  body	  selenium.	  The	  Journal	  of	  biological	  
chemistry	  2007;282:10972-­‐10980.	  
90.	   Papp	  LV,	  Lu	  J,	  Holmgren	  A,	  Khanna	  KK.	  From	  selenium	  to	  selenoproteins:	  
synthesis,	  identity,	  and	  their	  role	  in	  human	  health.	  Antioxidants	  &	  redox	  
signaling	  2007;9:775-­‐806.	  
91.	   Steinbrenner	  H,	  Sies	  H.	  Protection	  against	  reactive	  oxygen	  species	  by	  
selenoproteins.	  Biochim	  Biophys	  Acta	  2009;1790:1478-­‐1485.	  
92.	   Anderson	  DK,	  Saunders	  RD,	  Demediuk	  P,	  et	  al.	  Lipid	  hydrolysis	  and	  
peroxidation	  in	  injured	  spinal	  cord:	  partial	  protection	  with	  methylprednisolone	  
or	  vitamin	  E	  and	  selenium.	  Central	  nervous	  system	  trauma	  :	  journal	  of	  the	  
American	  Paralysis	  Association	  1985;2:257-­‐267.	  
133 
93. Parnham	  MJ,	  Leyck	  S,	  Kuhl	  P,	  Schalkwijk	  J,	  van	  den	  Berg	  WB.	  Ebselen:	  a
new	  approach	  to	  the	  inhibition	  of	  peroxide-­‐dependent	  inflammation.	  Int	  J	  Tissue	  
React	  1987;9:45-­‐50.	  
94. Xiong	  Y,	  Rabchevsky	  AG,	  Hall	  ED.	  Role	  of	  peroxynitrite	  in	  secondary
oxidative	  damage	  after	  spinal	  cord	  injury.	  J	  Neurochem	  2007;100:639-­‐649.	  
95. Scheff	  SW,	  Rabchevsky	  AG,	  Fugaccia	  I,	  Main	  JA,	  Lumpp	  JE,	  Jr.
Experimental	  modeling	  of	  spinal	  cord	  injury:	  characterization	  of	  a	  force-­‐defined	  
injury	  device.	  J	  Neurotrauma	  2003;20:179-­‐193.	  
96. Ferrero	  SL,	  Brady	  TD,	  Dugan	  VP,	  Armstrong	  JE,	  Hubscher	  CH,	  Johnson	  RD.
Effects	  of	  lateral	  funiculus	  sparing,	  spinal	  lesion	  level,	  and	  gender	  on	  recovery	  of	  
bladder	  voiding	  reflexes	  and	  hematuria	  in	  rats.	  J	  Neurotrauma	  2014.	  
97. Liebscher	  T,	  Schnell	  L,	  Schnell	  D,	  et	  al.	  Nogo-­‐A	  antibody	  improves
regeneration	  and	  locomotion	  of	  spinal	  cord-­‐injured	  rats.	  Ann	  Neurol	  
2005;58:706-­‐719.	  
98. Basso	  DM,	  Beattie	  MS,	  Bresnahan	  JC.	  A	  sensitive	  and	  reliable	  locomotor
rating	  scale	  for	  open	  field	  testing	  in	  rats.	  J	  Neurotrauma	  1995;12:1-­‐21.	  
99. Rabchevsky	  AG,	  Fugaccia	  I,	  Sullivan	  PG,	  Blades	  DA,	  Scheff	  SW.	  Efficacy	  of
methylprednisolone	  therapy	  for	  the	  injured	  rat	  spinal	  cord.	  J	  Neurosci	  Res	  
2002;68:7-­‐18.	  
100.	   Rabchevsky	  AG,	  Sullivan	  PG,	  Scheff	  SW.	  Temporal-­‐spatial	  dynamics	  in	  
oligodendrocyte	  and	  glial	  progenitor	  cell	  numbers	  throughout	  ventrolateral	  
white	  matter	  following	  contusion	  spinal	  cord	  injury.	  Glia	  2007;55:831-­‐843.	  
101.	   Michel	  RP,	  Cruz-­‐Orive	  LM.	  Application	  of	  the	  Cavalieri	  principle	  and	  
vertical	  sections	  method	  to	  lung:	  estimation	  of	  volume	  and	  pleural	  surface	  area.	  J	  
Microsc	  1988;150:117-­‐136.	  
102.	   Behne	  D,	  Hilmert	  H,	  Scheid	  S,	  Gessner	  H,	  Elger	  W.	  Evidence	  for	  specific	  
selenium	  target	  tissues	  and	  new	  biologically	  important	  selenoproteins.	  Biochim	  
Biophys	  Acta	  1988;966:12-­‐21.	  
103.	   Prohaska	  JR,	  Ganther	  HE.	  Glutathione	  peroxidase	  activity	  of	  glutathione-­‐
s-­‐transferases	  purified	  from	  rat	  liver.	  Biochem	  Biophys	  Res	  Commun	  
1976;76:437-­‐445.	  
104.	   Prohaska	  JR,	  Ganther	  HE.	  Selenium	  and	  glutathione	  peroxidase	  in	  
developing	  rat	  brain.	  Journal	  of	  neurochemistry	  1976;27:1379-­‐1387.	  
105.	   Wrobel	  JK,	  Seelbach	  MJ,	  Chen	  L,	  Power	  RF,	  Toborek	  M.	  Supplementation	  
with	  selenium-­‐enriched	  yeast	  attenuates	  brain	  metastatic	  growth.	  Nutr	  Cancer	  
2013;65:563-­‐570.	  
106.	   Lovell	  MA,	  Xiong	  S,	  Lyubartseva	  G,	  Markesbery	  WR.	  Organoselenium	  (Sel-­‐
Plex	  diet)	  decreases	  amyloid	  burden	  and	  RNA	  and	  DNA	  oxidative	  damage	  in	  
APP/PS1	  mice.	  Free	  Radic	  Biol	  Med	  2009;46:1527-­‐1533.	  
107.	   Ogawa	  A,	  Yoshimoto	  T,	  Kikuchi	  H,	  et	  al.	  Ebselen	  in	  acute	  middle	  cerebral	  
artery	  occlusion:	  a	  placebo-­‐controlled,	  double-­‐blind	  clinical	  trial.	  Cerebrovasc	  
Dis	  1999;9:112-­‐118.	  
108.	   Bellinger	  FP,	  Raman	  AV,	  Rueli	  RH,	  et	  al.	  Changes	  in	  selenoprotein	  p	  in	  
substantia	  nigra	  and	  putamen	  in	  Parkinson's	  disease.	  J	  Parkinsons	  Dis	  
2012;2:115-­‐126.	  
134 
109.	   Yeo	  JE,	  Kang	  SK.	  Selenium	  effectively	  inhibits	  ROS-­‐mediated	  apoptotic	  
neural	  precursor	  cell	  death	  in	  vitro	  and	  in	  vivo	  in	  traumatic	  brain	  injury.	  
Biochim	  Biophys	  Acta	  2007;1772:1199-­‐1210.	  
110.	   Grulova	  I,	  Slovinska	  L,	  Nagyova	  M,	  Cizek	  M,	  Cizkova	  D.	  The	  effect	  of	  
hypothermia	  on	  sensory-­‐motor	  function	  and	  tissue	  sparing	  after	  spinal	  cord	  
injury.	  The	  spine	  journal	  :	  official	  journal	  of	  the	  North	  American	  Spine	  Society	  
2013.	  
111.	   Ozsoy	  O,	  Ozsoy	  U,	  Stein	  G,	  et	  al.	  Functional	  deficits	  and	  morphological	  
changes	  in	  the	  neurogenic	  bladder	  match	  the	  severity	  of	  spinal	  cord	  
compression.	  Restor	  Neurol	  Neurosci	  2012;30:363-­‐381.	  
112.	   Sharp	  KG,	  Yee	  KM,	  Steward	  O.	  A	  re-­‐assessment	  of	  treatment	  with	  a	  
tyrosine	  kinase	  inhibitor	  (imatinib)	  on	  tissue	  sparing	  and	  functional	  recovery	  
after	  spinal	  cord	  injury.	  Exp	  Neurol	  2014;254:1-­‐11.	  
113.	   Kjell	  J,	  Pernold	  K,	  Olson	  L,	  Abrams	  MB.	  Oral	  erlotinib,	  but	  not	  rapamycin,	  
causes	  modest	  acceleration	  of	  bladder	  and	  hindlimb	  recovery	  from	  spinal	  cord	  
injury	  in	  rats.	  Spinal	  Cord	  2014;52:186-­‐190.	  
114.	   Shunmugavel	  A,	  Khan	  M,	  Hughes	  FM,	  Jr.,	  Purves	  JT,	  Singh	  A,	  Singh	  I.	  S-­‐
Nitrosoglutathione	  protects	  the	  spinal	  bladder:	  Novel	  therapeutic	  approach	  to	  
post-­‐spinal	  cord	  injury	  bladder	  remodeling.	  Neurourol	  Urodyn	  2014.	  
115.	   Anderson	  DK,	  Saunders	  RD,	  Demediuk	  P,	  et	  al.	  Lipid	  hydrolysis	  and	  
peroxidation	  in	  injured	  spinal	  cord:	  partial	  protection	  with	  methylprednisolone	  
or	  vitamin	  E	  and	  selenium.	  Central	  nervous	  system	  trauma	  :	  journal	  of	  the	  
American	  Paralysis	  Association	  1985;2:257-­‐267.	  
116.	   Vaishnav	  RA,	  Singh	  IN,	  Miller	  DM,	  Hall	  ED.	  Lipid	  peroxidation-­‐derived	  
reactive	  aldehydes	  directly	  and	  differentially	  impair	  spinal	  cord	  and	  brain	  
mitochondrial	  function.	  Journal	  of	  neurotrauma	  2010;27:1311-­‐1320.	  
117.	   De	  Biase	  A,	  Knoblach	  SM,	  Di	  Giovanni	  S,	  et	  al.	  Gene	  expression	  profiling	  of	  
experimental	  traumatic	  spinal	  cord	  injury	  as	  a	  function	  of	  distance	  from	  impact	  
site	  and	  injury	  severity.	  Physiological	  genomics	  2005;22:368-­‐381.	  
118.	   Carmel	  JB,	  Galante	  A,	  Soteropoulos	  P,	  et	  al.	  Gene	  expression	  profiling	  of	  
acute	  spinal	  cord	  injury	  reveals	  spreading	  inflammatory	  signals	  and	  neuron	  loss.	  
Physiological	  genomics	  2001;7:201-­‐213.	  
119.	   Aimone	  JB,	  Leasure	  JL,	  Perreau	  VM,	  Thallmair	  M,	  Christopher	  Reeve	  
Paralysis	  Foundation	  Research	  C.	  Spatial	  and	  temporal	  gene	  expression	  profiling	  
of	  the	  contused	  rat	  spinal	  cord.	  Experimental	  neurology	  2004;189:204-­‐221.	  
120.	   Chamankhah	  M,	  Eftekharpour	  E,	  Karimi-­‐Abdolrezaee	  S,	  Boutros	  PC,	  San-­‐
Marina	  S,	  Fehlings	  MG.	  Genome-­‐wide	  gene	  expression	  profiling	  of	  stress	  
response	  in	  a	  spinal	  cord	  clip	  compression	  injury	  model.	  BMC	  genomics	  
2013;14:583.	  
121.	   Spinal	  cord	  injury	  facts	  and	  figures	  at	  a	  glance.	  The	  journal	  of	  spinal	  cord	  
medicine	  2014;37:659-­‐660.	  
122.	   Trivedi	  A,	  Olivas	  AD,	  Noble-­‐Haeusslein	  LJ.	  Inflammation	  and	  Spinal	  Cord	  
Injury:	  Infiltrating	  Leukocytes	  as	  Determinants	  of	  Injury	  and	  Repair	  Processes.	  
Clinical	  neuroscience	  research	  2006;6:283-­‐292.	  
135 
123.	   Zaloshnja	  E,	  Miller	  T,	  Langlois	  JA,	  Selassie	  AW.	  Prevalence	  of	  long-­‐term	  
disability	  from	  traumatic	  brain	  injury	  in	  the	  civilian	  population	  of	  the	  United	  
States,	  2005.	  The	  Journal	  of	  head	  trauma	  rehabilitation	  2008;23:394-­‐400.	  
124.	   Harmon	  KG,	  Drezner	  J,	  Gammons	  M,	  et	  al.	  American	  Medical	  Society	  for	  
Sports	  Medicine	  position	  statement:	  concussion	  in	  sport.	  Clinical	  journal	  of	  sport	  
medicine	  :	  official	  journal	  of	  the	  Canadian	  Academy	  of	  Sport	  Medicine	  2013;23:1-­‐
18.	  
125.	   Bird	  SM,	  Ge	  H,	  Uden	  PC,	  Tyson	  JF,	  Block	  E,	  Denoyer	  E.	  High-­‐performance	  
liquid	  chromatography	  of	  selenoamino	  acids	  and	  organo	  selenium	  compounds.	  
Speciation	  by	  inductively	  coupled	  plasma	  mass	  spectrometry.	  Journal	  of	  
chromatography	  A	  1997;789:349-­‐359.	  
126.	   Ip	  C.	  Lessons	  from	  basic	  research	  in	  selenium	  and	  cancer	  prevention.	  The	  
Journal	  of	  nutrition	  1998;128:1845-­‐1854.	  
127.	   Fiskum	  G.	  Mitochondrial	  participation	  in	  ischemic	  and	  traumatic	  neural	  
cell	  death.	  Journal	  of	  neurotrauma	  2000;17:843-­‐855.	  
128.	   Azbill	  RD,	  Mu	  X,	  Bruce-­‐Keller	  AJ,	  Mattson	  MP,	  Springer	  JE.	  Impaired	  
mitochondrial	  function,	  oxidative	  stress	  and	  altered	  antioxidant	  enzyme	  
activities	  following	  traumatic	  spinal	  cord	  injury.	  Brain	  research	  1997;765:283-­‐
290.	  
129.	   Sullivan	  PG,	  Keller	  JN,	  Mattson	  MP,	  Scheff	  SW.	  Traumatic	  brain	  injury	  
alters	  synaptic	  homeostasis:	  implications	  for	  impaired	  mitochondrial	  and	  
transport	  function.	  Journal	  of	  neurotrauma	  1998;15:789-­‐798.	  
130.	   Dash	  PK,	  Hylin	  MJ,	  Hood	  KN,	  et	  al.	  Inhibition	  of	  eIF2alpha	  phosphatase	  
reduces	  tissue	  damage	  and	  improves	  learning	  and	  memory	  following	  
experimental	  traumatic	  brain	  injury.	  Journal	  of	  neurotrauma	  2015.	  
131.	   Eakin	  K,	  Baratz-­‐Goldstein	  R,	  Pick	  CG,	  et	  al.	  Efficacy	  of	  N-­‐acetyl	  cysteine	  in	  
traumatic	  brain	  injury.	  PloS	  one	  2014;9:e90617.	  
132.	   Morris	  R.	  Developments	  of	  a	  water-­‐maze	  procedure	  for	  studying	  spatial	  
learning	  in	  the	  rat.	  Journal	  of	  neuroscience	  methods	  1984;11:47-­‐60.	  
133.	   Lighthall	  JW.	  Controlled	  cortical	  impact:	  a	  new	  experimental	  brain	  injury	  
model.	  Journal	  of	  neurotrauma	  1988;5:1-­‐15.	  
134.	   Patel	  SP,	  Sullivan	  PG,	  Pandya	  JD,	  et	  al.	  N-­‐acetylcysteine	  amide	  preserves	  
mitochondrial	  bioenergetics	  and	  improves	  functional	  recovery	  following	  spinal	  
trauma.	  Experimental	  neurology	  2014;257:95-­‐105.	  
136 
VITA 
Carolyn Anne (Crowdus) Meyer 
CITIZENSHIP 
United States of America 
EDUCATION 
University of Kentucky College of Medicine, Lexington, KY 
- Doctor of Philosophy, Anatomy and Neurobiology, August 2015. 
- Graduate Certificate in Anatomical Sciences Instruction, August 2015. 
University of Kentucky College of Agriculture, Lexington, KY 
- Bachelor of Science, Agricultural Biotechnology, May 2008 
RESEARCH EXPERIENCE 
Research Assistant/Graduate Student 
University of Kentucky College of Medicine, Department of Anatomy and 
Neurobiology and Spinal Cord and Brain Injury Research Center (SCoBIRC) 
Mentor: James W. Geddes, PhD 
Dates: August 2010 – August 2015 
Research Laboratory Technician 
Center for Animal Nutrigenomics and Applied Animal Nutrition, Alltech, 
Nicholasville, KY 
Supervisor: Ronan F. Power, Ph.D. 
Dates: July 2008 – July 2010 
Research Intern 
Center for Animal Nutrigenomics and Applied Animal Nutrition, Alltech, 
Nicholasville, KY 
Supervisor: Ronan F. Power, Ph.D. 
Dates: May 2008 – July 2008 
Undergraduate Research Assistant 
Gluck Equine Research Center, University of Kentucky 
Mentor: Daniel K. Howe, Ph.D. 
Dates: August 2004 – May 2008 
137 
TEACHING EXPERIENCE 
Teaching Assistant 
University of Kentucky, College of Medicine, Department of Anatomy and 
Neurobiology 
Supervisor: April Hatcher, Ph.D. 
Dates: January 2015 to May 2015 
Course: Physician Assistant (ANA611) and Physical Therapy (ANA811) 
Regional Human Gross Anatomy  
Instructor 
Area Health Education Center’s (AHEC) Summer Enrichment Program, University of 
Kentucky Outreach Program 
Supervisor: Carlos Marin 
Dates: June – July (2012, 2013, 2014, 2015) 
Course: Anatomy and Physiology Instructor 
Teaching Assistant 
University of Kentucky, College of Medicine, Department of Anatomy and 
Neurobiology 
Supervisor: Magdalena Muchilinski, Ph.D. 
Dates: 2011, 2012, 2013, 2014 
Course: Anatomy and Physiology (ANA 109/110) 
Private tutor  
Anatomy and Physiology (ANA 109/110) – 2014, 2015 
AWARDS AND HONORS 
BGSFN Poster Presentation Award – 2015  
University of Kentucky 3 Minute Thesis® Competition, Second place – 2014  
Seahorse Bioscience Travel Award – 2013  
University of Kentucky Graduate School Travel Award – 2013  
BGSFN Chapter Travel Award for Society for Neuroscience meeting – 2013 
BGSFN Poster Presentation Award – April 2013 
Neurobiology of CNS Injury and Repair Training Grant (T32 NS077889) – April 
2013 – April 2015 
Alltech Graduate Student Fellowship – August 2010 – April 2013 
ACTIVITIES 
American Heart Association Heart Walk Volunteer Coordinator – 2013, 2014, 2015  
Women in Neurotrauma Research (WiNTR) Newsletter Editor – 2013, 2014, 2015  
Committee for Center-Wide Initiatives, SCoBIRC – Member – 2011, 2012 
Integrated Biomedical Sciences Student Advisory Committee – 2011, 2012 
138 
BGSFN Graduate Student Representative – fall 2013 – spring 2014 
OUTREACH 
Fayette County Public Schools Science Fair Judge – 2015 
Wheelchair for a Day Fundraiser, organizer and participant – 2013  
STEM Camp Neuroscience Instructor, University of Kentucky – 2013  
Fayette County Public Schools Science Fair, BGSFN representative – 2013 
Science Explorers with the Living Arts and Sciences Center – 2011, 2012 
Athens-Chilesburg Elementary Arts and Sciences Day – 2012 
PROFESSIONAL MEMBERSHIPS 
Society for Neuroscience – 2013  
National Neurotrauma Society – 2012, 2014 
Bluegrass Society for Neuroscience (BGSFN) – 2011, 2012, 2013, 2014, 2015 
ORAL PRESENTATIONS 
Kentucky Spine and Head Injury Research Trust (KSHIRT) Symposium. May 2015. 
Selenium Deficiency is Detrimental Following Traumatic Brain Injury. 
PEER-REVIEWED PUBLICATIONS 
1. Reneer DV, Crowdus CA, Ghoshal S, Corkins J, Hisel RD, Lusk BT, Geddes
JW. 2014. Extent of cerebrovascular disruption following blast exposure is
influenced by the duration of the positive phase in addition to peak
overpressure. J Neurol Neurophysiol. 5:188.
2. Yu CG, Singh R, Crowdus C, Raza K, Kincer J, Geddes JW. 2014.
Fenbendazole improves pathological and functional recovery following
traumatic spinal cord injury. Neuroscience. Jan 3;256:163-9.
3. Brennan KM, Crowdus CA, Cantor AH, Pescatore AJ, Barger JL, Horgan K,
Xiao R, Power RF, Dawson KA.  2011.  Effects of organic and inorganic
dietary selenium supplementation on gene expression profiles in oviduct
tissue from broiler-breeder hens.  Anim Reprod Sci. 125(1-4): 180-8.
4. Xiao R, Power RF, Mallonee D, Crowdus C, Brennan KM, Ao T, Pierce JL,
Dawson KA.  2011.  A comparative transcriptomic study of vitamin E and an
algae-based antioxidant as antioxidative agents: investigation of replacing
vitamin E with the algae-based antioxidant in broiler diets. Poult Sci.
90(1):136-46.
5. Mallonee DH, Crowdus CA, Barger JL, Dawson KA, Power RF.  2010.  Use
of stringent selection parameters for the identification of possible selenium-
responsive marker genes in mouse liver and gastrocnemius.  Biol Trace Elem
Res.  2010 Nov 16.
6. Crowdus CA, Marsh AE, Saville WJ, Lindsay DS, Dubey JP, Granstrom DE,
Howe DK. 2008.  SnSAG5 is an alternative surface antigen of Sarcocystis
neurona strains that is mutually exclusive to SnSAG1.  Vet Parasitol. 158(1-
2): 36-43.
139 
ABSTRACTS – POSTER PRESENTATIONS 
1. Meyer CA, Power RF, Geddes JW. 2015. Selenium deficiency is detrimental
following traumatic brain injury. Bluegrass Society for Neuroscience, Spring
Neuroscience Day.
2. Crowdus CA, Blalock EM, Yu CG, Power RF, Geddes JW. 2014. Gene
expression changes in response to selenium diet in spinal cord injured rats.
National Neurotrauma Symposium.
3. Crowdus CA, Pandya JD, Power LM, Sebastian AH, Yonutas HM, Hopkins
DM, Jones J, Pauly JR, Sullivan PG, Power RF, Geddes JW. 2013. Dietary
selenium supplementation improves behavioral and mitochondrial function
following traumatic brain injury. Society for Neuroscience Annual Meeting.
4. Crowdus CA, Pandya JD, Power LM, Sebastian AH, Yonutas HM, Hopkins
DM, Jones J, Pauly JR, Sullivan PG, Power RF, Geddes JW. 2013. Selenium
for the treatment of traumatic brain injury. Kentucky Spine and Head Injury
Research Trust (KSHIRT) Symposium.
5. Crowdus CA, Pandya JD, Power LM, Sebastian AH, Yonutas HM, Hopkins
DM, Jones J, Pauly JR, Sullivan PG, Power RF, Geddes JW. 2013. Selenium
for the treatment of traumatic brain injury. Bluegrass Society for
Neuroscience, Spring Neuroscience Day.
6. Crowdus CA, Yu CG, Singh R, Pandya JD, Patel SP, Sullivan PG,
Rabchevsky AG, Power RF, Geddes JW. 2012. Enhancing endogenous
protective mechanisms following spinal cord injury. National Neurotrauma
Symposium.
7. Yu CG, Crowdus CA, Raza K, Geddes JW. 2012. Fenbendazole improves
locomotor recovery after spinal cord injury in mice. National Neurotrauma
Symposium.
8. Crowdus CA, Yu CG, Singh R, Power RF, Geddes JW. 2012. Enhancing
endogenous protective mechanisms following spinal cord injury. University of
Kentucky Department of Physical Medicine and Rehabilitation Annual
Resident Research Day, Cardinal Hill Rehabilitation Hospital.
9. Crowdus CA, Power L, Chishti A, Geddes JW, Yu CG.  2011. Calpain 1
knockout is not protective for spinal cord injury. Bluegrass Neuroscience Day,
University of Kentucky.
10. Xiao, R., Power RF, Mallonee D, Crowdus CA, Ao T, Pierce JL, Dawson
KA. 2009. Gene expression profiles provide evidence of reduced vitamin E
needed by feeding EconomasETM in broiler diets. International Poultry
Scientific Forum.
11. Xiao, R., Power RF, Mallonee D, Crowdus CA, Ao T, Pierce JL, and
Dawson KA. 2009.  Transcriptional signatures associated with biological
functions of Bio-Mos® and ActigenTM in broilers. International Poultry
Scientific Forum.
12. Crowdus CA and Mallonee D. 2009. Nutrigenomics Methods: Using DNA
Microarrays.  Alltech 25th International Symposium. Lexington, KY.
140 
13. Crowdus CA, Marsh AE, and Howe DK. 2008. Characterization of the
Sarcocystis neurona merozoite surface antigen SnSAG5. Annual Midwestern
Conference of Parasitologists.
14. Crowdus CA and Howe DK. 2008. Characterization of a Sarcocystis neurona
Surface Antigen (SnSAG5). University of Kentucky Showcase of
Undergraduate Scholars.
15. Crowdus CA and Howe DK. 2008. Characterization of a Sarcocystis neurona
Surface Antigen (SnSAG5). National Conference for Undergraduate
Research.
